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Thesis Abstract 
The association between the vaginal microbiota and recurrent early 
spontaneous preterm birth 
Laura Goodfellow 
Preterm birth is the leading cause of death of children under 5 worldwide. Despite over 30 years 
investment in basic science and clinical research the rate has remained relatively static. This has 
been attributed to the multifactorial nature of preterm birth.  
 
Infection and/or inflammation are estimated to contributing to approximately a third of preterm 
births, however the exact organism(s) frequently remain elusive and are often attributed to bacteria 
that are not cultured using standard laboratory techniques. Vaginal bacteria are a presumed source 
of inflammatory organisms due to the close anatomical relationship with the uterus and cervix.  The 
advent of culture-independent methods of assessment of the microbiota has enabled new 
interrogation of this theory. In the past seven years over 2000 women have undergone assessment 
of the vaginal microbiota (VMB) in pregnancy. Most studies have identified components of the VMB 
that relate to preterm birth. However, poor understanding of the distribution of VMB characteristics 
in healthy pregnancies, differences in almost every aspect of study design, and reliance on 
proportional data rather than quantification have hampered efforts to translate these findings into 
clinically meaningful information.  
 
This project advances the field of VMB in preterm birth work in two ways. Firstly we summarised 
VMB characteristics that have previously been associated with preterm birth and assessed whether 
these are associated with recurrence of preterm birth under 34 weeks gestation, contextualised by 
reference to the expected distribution of the VMB characteristics in our locality.  
 
Secondly, a criticism of the initial next-generation sequencing studies was over-reliance on data 
solely describing the proportions of bacteria present in a given sample, without consideration of the 
overall bacterial load. We were able to address this by complementing our analysis with semi-
quantitative analysis using quantitative PCR of the 16S rRNA gene. 
 
We found that four VMB characteristics (out of 29 assessed) showed trends towards reproduction of 
previous work. These associations did not meet traditional statistical significance (<0.05%), most 
likely because we could only evaluate 22 preterm births.  
 
The most striking finding of our analysis was that vaginal bacterial load in the second trimester, 
irrespective of the bacterial composition, was associated with early spontaneous preterm birth or 
preterm prelabour rupture of membranes recurrence. Women with a recurrence, compared to those 
without, had a fivefold higher median vaginal bacterial load. There was a gradient effect of bacterial 
load on risk of recurrence of preterm birth. Interestingly, domination by lactobacilli other than L. 
iners protected women from developing high bacterial loads. This could explain the inconsistent 
association between L. iners and preterm birth in previous studies; if L. iners dominance is only 
associated with PTB when there is a concurrent high bacterial load, then women with L. iners 
domination and a normal bacterial load would not show this association. We also found that the 
women who have high bacterial loads and a preterm birth have a higher rate of early onset 
chorioamnionitis, strengthening the evidence that the bacterial load is clinically important. 
 
This study provides a strong foundation on which to base further studies incorporating assessment 
of bacterial load alongside traditional 16S rRNA analysis to fully elucidate the contribution of the 
VMB to preterm birth. Once fully understood the VMB is potentially modifiable and could provide a 
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1 Introduction 
1.1 Definitions 
1.1.1 Microbiota and microbiome 
A microbiota describes the microorganisms that colonize a biological niche, in this case the 
vagina. The term microorganism refers to taxa that can be viewed down a microscope as 
discrete organisms and includes bacteria, fungi, archaea and protists. Bacteria form the 
most abundant part of the human microbiome and are the focus of most work assessing 
the vaginal microbiota in pregnancy.  
The term ‘microbiome’ refers to an ‘entire habitat’ including the microorganisms, their 
genomes, and the surrounding environmental conditions, whereas the ‘microbiota’ consists 
of only ‘microorganisms present in a defined environment’.1 Therefore the vaginal 
microbiota shall be the focus of this thesis. 
1.1.2 Spontaneous early preterm birth 
The World Health Organisation (WHO) defines preterm birth as birth less than 37 
completed weeks of gestation.2  This is subclassified into extremely preterm (<28+0 weeks), 
early preterm (28+0 to 33+6 weeks), and late preterm (34+0 to 36+6 weeks).  
This thesis will focus on births between 16+0 and 33+6 weeks (inclusive). This will include 
births of spontaneous onset and those preceded by preterm prelabour rupture of 
membranes (PPROM), but not medically indicated preterm births. 
1.1.3 Preterm prelabour rupture of membranes 
PPROM refers to the rupture of the amniotic membranes prior to the onset of labour and 
prior to 37+0 weeks gestation. In some cases the rupture of membranes is the first symptom 
a woman will notice of the labour process; in other cases it occurs remotely from the labour 
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process. PPROM can also precipitate spontaneous preterm labour. In order to achieve a 
differentiation of membranes rupturing early in the labour process (which was actually 
preterm labour), and isolated PPROM we used a definition of rupture of membranes at 
least 12 hours prior to the onset of uterine activity.  This was in keeping with previous 
research from our group.3 A small number of cases of PPROM are preceded by 
instrumentation of the uterus, mostly for the purposes of amniocentesis or chorionic villous 
sampling. Only cases of spontaneous PPROM were eligible for this study. 
1.2 Impact of preterm birth 
Worldwide, approximately 10.6% of births are preterm,4 with a rate ranging from 5% to 
18% by country.5 Preterm birth complications are the leading cause of death in children 
under 5 years old globally, and were responsible for approximately 1 million deaths of 
children in 2015.6 Despite improvements in neonatal care the mortality attributed to 
preterm birth between 2000 and 2015 remained static, due to the increases in the 
incidence of preterm birth.5,7 
Preterm birth is recognised as an important public health problem and national and 
international bodies have committed to reducing this burden. The WHO set a goal of a 50% 
reduction in mortality related to preterm birth in resource poor countries from 2010-2025 8 
and this is seen as crucial to the Sustainable Development Goal of ending preventable 
newborn and child deaths by 2030.9,10 In the UK the Department of Health has committed 
to reducing the preterm birth rate from 8% to 6% by 2025.11 
The morbidity and mortality associated with preterm birth are inversely proportional to 
gestational age at birth,12 as shown in Figure 1.1. The EPICure 2 study found that babies 
born at 24 weeks gestation in 2006 in England had only a 40% chance of survival to hospital 
discharge, and these infants had a 48% chance of major morbidity.13 At the other end of the 
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scale later preterm births have very good neonatal survival rates (Figure 1.114). However, 
infants born in the late preterm period do have a higher risk of long term health sequelae 
compared to babies born at term: the risk of cerebral palsy for infants born at 32-36 weeks 
is 0.7%, compared to 0.1% in term infants.15 Later preterm birth is more common than 
earlier preterm birth, therefore more children with cerebral palsy are survivors of later 
preterm births than early preterm births.12 Ultimately a reduction in all preterm births is 
needed at both ends of this scale to make a significant impact on the related morbidity and 
mortality.  
 
Figure 1.1:Percentage of infant deaths and number of live births by week gestation, 2013, in England and Wales. 
From Office of National Statistics, 201714 
The reasons for the rising incidence of preterm births are more complex than it initially 
appears for several reasons. Firstly, the rate of preterm birth attributed to multiple birth is 
increasing globally, driven by the increase in assisted reproductive technologies. Twin 
pregnancies have approximately a 50% chance of preterm birth,16 and almost all higher 
order multiple pregnancies deliver preterm.17 Secondly, with the improvements in neonatal 
medicine the lower limit of viability is reducing, and so pregnancies that may have 
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previously been classified as miscarriages are now being classified as extremely preterm 
births.18 Finally, interventions to reduce stillbirth can lead to an apparent increase in 
preterm live birth rate.19 Preterm birth as a pregnancy outcome can be seen as a success 
when it replaces pregnancy loss, or an adverse outcome preventing further developmental 
time in utero. 20 Either way, it is desirable to understand the pathophysiology related to 
preterm birth in order to understand how to optimise gestational length.  
The ill-health consequences of preterm birth mean that a strategy to reduce the burden 
even by a small amount could potentially equate to great improvements in healthcare 
costs, wellbeing of families, and most importantly improved health for the next generation. 
1.3 The multifactorial nature of preterm birth 
Preterm labour is a pathological condition with multiple aetiologies.21 Figure 1.2 visualises 
some possible underlying aetiologies, and the concept that, individually, these could be 
contributing in varying amounts. 
 
Figure 1.2: Possible mechanisms of preterm birth22 
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When a woman presents with symptoms of preterm labour the process of birth may have 
already started. Tocolytics have only shown benefit in delaying birth to allow time for 
administration of corticosteroids and in-utero transfer; in the best cases they only delay 
birth by an average of 4 days.23,24 
In order to prevent preterm birth the current clinical strategy focuses on an attempt to 
identify women destined to have preterm labour antenatally and initiate preterm birth 
prevention treatment, psychological support and optimisation of the fetal condition. In 
2019 NHS England published the Saving Babies Lives Version II Care Bundle recommending 
that every maternity provider has a designated clinician with an interest in preterm birth 
prevention and access to transvaginal ultrasound assessment of cervix.25 Preterm birth 
prevention treatment is then initiated based on obstetric history and/ or a short cervix.26 
The primary preterm birth prevention treatment options available in the UK are cervical 
cerclage, vaginal progesterone and cervical pessary. Cervical cerclage and pessary are 
viewed as ‘mechanical’ therapies to strengthen a cervix and keep the cervix closed enabling 
the pregnancy to continue. These may also improve the ‘barrier’ between the vagina and 
the uterus thereby protecting the pregnancy from ascending microorganisms. The 
mechanism by which progesterone works has been suggested as a combination of averting 
a functional progesterone withdrawal27 (which would have otherwise led to labour) and 
reducing inflammation.28 Progesterone is also the treatment with the strongest evidence 
for preterm birth prevention in women with a short cervix.29 
Clinically, these treatments are primarily targeted towards treating or preventing cervical 
shortening. However, in our hospital 9% of women with a previous spontaneous preterm 
birth under 34 weeks and a cervical length that would be considered adequate, ≥25mm in 
the midtrimester, still have a recurrent early preterm birth.30 This suggests that a fair 
proportion of recurrent early preterm births are mediated by other pathologies that we 
 
 
   
   17 
currently do not target.  In support of this sentiment an individual patient data analysis of 
4.1 million singleton births in 5 high income countries concluded that “a strong emphasis 
on new basic research is ultimately more likely to mitigate the problem of preterm birth 
than either policy or public health actions or more widespread use of currently available 
clinical interventions and medications”.31 
This thesis describes the conduct and findings of a cohort study which aimed to identify and 
understand putative causes of recurrent preterm birth that are not currently targeted by 
preterm birth prevention treatments. The study was designed to target two cohorts of 
women: a ‘high-risk’ cohort with a history of preterm prelabour rupture of membranes 
(PPROM) or spontaneous preterm birth (sPTB) under 34 weeks gestation and a ‘low-risk’ 
cohort who were parous women with all previous births at term (≥ 37 weeks gestation). 
The high-risk cohort was used to understand the contribution of the vaginal microbiota and 
clinically available data to recurrent early spontaneous preterm birth. The low-risk cohort 
provided reference ranges for the expected distribution of the variables studied.  
1.4 Infection and preterm birth 
It has been recognised for over 30 years that infection contributes to the causation of some 
preterm births.32 Evidence for infection causing preterm birth includes: 
• In animal experiments the introduction of both systemic and intrauterine microbes 
results in preterm birth.33  
• Extra uterine infections, such as pyelonephritis are associated with preterm birth.34 
• Antibiotics for asymptomatic bacteriuria may reduce the chance of preterm birth 
(95% CI 0.13-0.88). 35 
• Bacterial vaginosis is associated with preterm birth, independent of other risk 
factors of preterm birth.36 
 
 
   
   18 
• Women delivering by Caesarean section after spontaneous preterm labour with 
intact membranes are much more likely to have positive chorioamniotic fluid 
cultures than either women who had a Caesarean section ≤30 weeks without 
preterm labour, or a Caesarean section after 37 weeks with labour.37 
However, the relationship between infection and preterm birth is at times unclear. As 
detailed in Table 1.1 treatment of infection does not necessarily confer a reduction in 
preterm birth risk.  Also, it is not understood how infection outside of the genital tract, for 
example in the dental cavity, travels to the intrauterine cavity and initiates preterm birth. It 
had been postulated that this was mediated via the placental microbiome,38,39 however more 
recent research refutes the description of the placental microbiome and appears to 
comprehensively demonstrate that most placentas are sterile.40 It is still possible that a 
placental microbiota may exist in some women; with a potential contribution to preterm 
birth in these women. Recent commentaries call for a consensus on a careful technique for 
further analysis of this field.41 
The true picture of the vaginal microbiota in a given woman is likely to be much more 
complex than the result that can be obtained from a single swab culture. For example there 
will be a range of species that are not amenable to laboratory culture, and the ‘load’ of a 
particular species maybe as important as the presence or absence, but this detail is lost 
with culture alone. The advent of large scale,  affordable culture independent techniques to 
assess the human microbiota was hoped to address this. 
Table 1.1: Infection related risk factors for preterm birth and effects of intervention.42 
Risk factor for 
preterm birth 
OR or RR of preterm birth 
(under 37 weeks) 
Risk reducing interventions  Effect of intervention 
Bacterial vaginosis Bacterial vaginosis OR of 
preterm birth 2.19 (95%CI 
1.54-3.12)43 
a) Screening and treatment for 
bacterial vaginosis within a 
programme of screening for infections 
in pregnancy 
b) Screening and treatment only for 
bacterial vaginosis 
a) RR of 0.55 for preterm birth (95% CI 0.41-0.75; 2058 participants, 
moderate quality evidence) 44 No evidence of benefit in low income 
settings45                                                                                                                             
. 
b) RCT in low risk pregnancies showed no difference in PTB risk with 
treatment of bacterial vaginosis RR 1.10 (95%CI 0.53-2.32)46  
Chlamydia 
trachomatis 
OR 2.28 (95% CI:1.64–
3.16)47 
Screening and treatment for 
Chlamydia trachomatis 
Treatment under 20 weeks gestation associated with lower risk of preterm 
birth compared to after 20 weeks, RR 0.54 (95 % CI 0.37–0.80).48 Risk of 
PTB with infection in Australia 2001-12 similar to background rate, 




OR 2.10 (95%CI 1.56-
2.85)51  
Antibiotics for asymptomatic 
bacteriuria 
May be associated with a reduction in preterm birth RR of 0.34 for 
preterm birth (95% CI 0.13-0.88; two studies, 327 women, low certainty 
evidence) 52 
Single study in low risk women showed no benefit in treatment for birth 
<34 weeks (risk 2.5% in treated vs 1.0% in untreated, risk difference -1.5% 




OR from 2.04 to 4.19 54 Periodontal treatment during 
pregnancy 
Reduction in risk of preterm birth OR 0.65 (95% CI 0.45-0.93)55 but 
uncertain 56    
 
     
   20 
Table 1.2 (continued): Infection related risk factors for preterm birth and effects of intervention.42 
Risk factor for 
preterm birth 
OR or RR of preterm birth 
(under 37 weeks) 
Risk reducing interventions  Effect of intervention 
Trichomonas 
vaginalis 
RR 1.42 (95% CI, 1.15-1.75) 
57 
Screening and treatment for 
Trichomonas vaginalis 
RCT found increased risk of PTB with metronidazole treatment in USA (RR 
1.8; 95%CI 1.2 - 2.7)58, subsequent Cochrane review found no benefit of 
treatment 59   
Vaginal 
candidiasis 
No increased risk in cohort 
studies60,61  
a) Screening and treatment for vaginal 
candidiasis within a programme of 
screening for infections in pregnancy 
b) Screening and treatment only for 
vaginal candidiasis 
a) RR of 0.55 for preterm birth (95% CI 0.41-0.75; 2058 participants, 
moderate quality evidence) 44                                                                                    
. 
b) Pilot study showed non-significant trend towards prevention of preterm 
birth (RR = 0.33, 95%CI 0.04-3.03) 62 
 
 
1.4.1 The human microbiota 
The human body is a complex ecosystem and hosts taxa from the entire phlogenic tree of 
life including eukarya, bacteria, archaea and viruses.63–65 The human body has roughly the 
same number  of bacterial cells as human cells,66 and these are the component of the 
human microbiota that have had the most scientific interest. 
The study of the human microbiota has been revolutionised by the application of culture 
independent sequencing technologies over the past 20 years. This project used 16S rRNA 
gene sequencing, which is possible because bacteria have areas of the 16S rRNA gene that 
have been conserved for long periods of evolution.67 The 16S rRNA gene can be used as a 
target site for application of primers to amplify the number of reads using polymerase chain 
reaction (PCR), and then sequenced using high throughput technologies. In between the 
primer target sites are ‘hypervariable’ regions that are unique to each bacterial taxon. The 
16S rRNA gene sequencing result can then cross referenced to libraries to identify the taxa 
present.68  
16S rRNA sequencing was developed and initially applied to environmental samples,68 but 
by the early 2000s the technique had been developed enough for application to human 
health and disease.69 With a reduction in price and increase in capacity, the use of gene 
sequencing for microbial identification has vastly increased over the past decade. In 
parallel, complementary culture-independent ways of assessing the human microbiota 
have also been developed, such as metagenomic shotgun sequencing and 
metatranscriptomic sequencing. These are collectively referred to as ‘next generation 
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Table 1.3: Techniques for assessing the human microbiota 










Sequences only DNA with 16S rRNA 
gene (bacteria and archaea) 
 
Works with very small number of 
copies of gene in initial sample (as 
low as 10 copies) 
 
More widely used and so better 
reference libraries available 
 
Lower risk of false positives 
 
Lower cost  
 
Can be combined with quantitative 
PCR (qPCR) to estimate 
concentration/absolute abundance 
In isolation can only be used for taxa 
identification and relative abundance 
 
By sequencing only a limited 
component of the DNA potential to 
miss differences in strain 
 
Not possible to sequence other 
microbes (for example fungi) 
 
Reliance on reference databases for 
taxonomy, which may be inaccurate 
or not optimised for use in the vaginal 
microbiome 
 
Poor negative predictive value of 
rarer members of the microbiome 
(due to preferential PCR expansion of 
more abundant species) 
 
Dependent on DNA extraction 

















Sequences all genetic information in 
the sample 
 
Possible to use for additional genetic 
analysis such as metabolic function 
profiling or antibiotic resistance 
profiling 
 
Able to achieve better resolution 
because it sequences all genetic 
variations 
Higher risk of false positives 
 
Sequences host DNA too, so need for 
host DNA depletion if this is not 
desired, with potential to deplete 
DNA of interest too 
 
Higher bacterial load needed in initial 
sample 
 
Less widely used and so reference 
libraries are less complete 
 


















Sequences all actively transcribed 
genes from microbes and host 
 
Lower host fraction means that is can 
be more cost effective than 
metagenomic sequencing  
 
Provides stronger evidence for 
functional activity than 16S rRNA 
sequencing or metagenomic 
sequencing 
Unable to capture those microbes 
that are insufficiently 
transcriptionally active at the time of 
sampling 
 
Higher cost than 16S rRNA 
sequencing 
 
Reliance on reference databases 
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Over the past two decades next generation sequencing has been utilised in both large 
projects and specialised niches to characterise the human microbiota in health and disease. 
The largest of these was the US National Institute for Health(NIH) project ‘The Human 
Microbiome Project’. 65,70  These projects have now generated a wealth of information, as 
well as ‘more questions than answers’,71 which are beginning to be applied to human 
diseases. 
An initial finding from the Human Microbiome Project was that each person appears to 
have a largely unique gut microbiota,72 which appears to be influenced by geographical 
location, age and lifestyle.73,74 There appears to be characteristics of the gut microbiota that 
are associated with conditions as diverse as inflammatory bowel disease,75 autism,76 and 
obesity.77 Intriguingly, there is increasing evidence of a ‘microbiota–gut–brain 
communication’78 which links neurological conditions to microbiota ‘signatures’. Features 
of the microbiota have been described for psychiatric conditions such as depression79 and 
even neurosurgical pathology such as vascular malformations (cavernous angiomas).80 
These findings have prompted trials of gut microbiota transplants, with as yet mixed 
results.81 Outside of the gut, different microbiological niches have been studied in specific 
diseases, for example, lung microbiota correlate with disease severity in cystic fibrosis.82 
However, we are still  searching for the best method to characterise a microbiota, and how 
to understand the interaction between a microbiota, host and environment. The NIH 
funded Human Microbiome Project finished in 2019 and their concluding summary 
recommended that more work is needed to understand these interactions before related 
therapeutics are likely to be developed.71,83 The legacy of these initial projects is that we 
now have access to robust libraries to characterise individual taxa, an initial framework for 
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1.4.2 The vaginal microbiota 
The vaginal microbiota of most women of reproductive age has low diversity and is 
dominated by a single species of Lactobacillus.84 In the non-pregnant state the microbiota of 
healthy women changes with the menstrual cycle85 and sexual activity. 85–87 The vaginal 
microbiota also differs with ethnicity88 and influences from external sources, such as vitamin D 
have been suggested recently.89  
Vaginal dysbiosis is characterised by a deviation from the low diversity, Lactobacillus dominated 
state. Bacterial vaginosis (BV) is the most common form of vaginal dysbiosis, in which there is an 
increase in a range of anaerobic bacteria. There is a highly diverse bacterial community in BV, 
which is why the bacterial richness (total number of species observed in a given sample) and the 
alpha diversity index (a measure to quantify the diversity of the vaginal community in a given 
sample) of the vaginal microbiota in these women is higher than in Lactobacillus-dominated 
women.  
Vaginal dysbiosis is associated with increasing inflammation, irrespective of whether the woman 
experiences symptoms such as itching or pain.90 Women with BV have an increased chance of 
acquiring  human immunodeficiency virus (HIV) and other sexually transmitted infections, with 
a correspondingly increased risk of pelvic inflammatory disease. 91,92  
The more complete understanding of the vaginal microbiota afforded by next generation 
sequencing has prompted a renewed interest in the opportunity to modify the vaginal 
microbiota away from a dysbiotic state using probiotics. However, probiotics have struggled to 
achieve sustained modifications of the vaginal microbiota, suggesting that colonisation of the 
vagina has not been achieved.93 As a consequence, antibiotics remain the mainstay of 
treatment of bacterial vaginosis, both in the pregnant and non-pregnant state.94 
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1.4.3 The vaginal microbiota in pregnancy 
The vaginal microbiota in healthy pregnancy was first characterised by 16S rRNA 
sequencing in the United States in 2014,95 and shortly afterwards in the European 
population.96 Both of these studies described Lactobacillus dominance in the majority of 
pregnant women, which increases as pregnancy progresses with a corresponding reduction 
in diversity at later gestations. The dominant species of Lactobacillus appears relatively 
stable on an individual level throughout pregnancy but appears to differ by ethnicity. In 
2019 similar findings were replicated on a larger scale (n=613) in the pregnancy component 
of the US Human Microbiome Project.97 
1.4.4 The vaginal microbiota and preterm birth 
Given the long standing association between infection, inflammation and preterm birth the 
application of 16S rRNA sequencing to pregnancy was swiftly applied to the field of preterm 
birth research.98 Over the past 7 years over 2000 women have been involved in studies 
assessing the relationship between the VMB and PTB.99,100 The majority of these studies 
have suggested a contribution of the VMB to PTB, but the particular relationship remains 
contentious.  As described above the vaginal microbiota of healthy pregnancies differs by 
ethnicity and gestation, and so this needs to be considered within descriptors and 
comparisons. 
The optimal way of describing and analysing VMB compositions is yet to be determined for 
the PTB field. The difficulty with this is understandable; the healthy vagina in pregnancy has 
up to 80 different bacterial taxa,97 and between 10,000,000 and 100,000,000 bacterial cells 
are expected on a high vaginal swab.101   
Initial work assessing the association between the vaginal microbiome and preterm birth 
classified the vaginal microbiome into five community state types (CST) according to the 
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Ward hierarchical clustering. This suggested an association between community state type 
II (Lactobacillus iners dominance) and preterm birth.102 However, the primers used in this 
work were not optimised to differentiate the different species of Lactobacillus. More recent 
work has moved to grouping participants based on the relative abundance of Lactobacillus, 
and attempting to identify other species or global assessments of the microbiome such as 
‘richness’ and ‘diversity’ that can be used to quantify the whole microbiome and attempt to 
predict adverse outcome. 103  
The ‘relative abundance’ of a particular microbial species within a particular participant is 
calculated as the percentage of the 16S rRNA gene that corresponds to that species in a 
particular participant. This masks the differences in the numbers of 16S rRNA genes that a 
particular species has (range 1-9 copies), and differences in the ‘density’ of the bacterial 
load between participants. This means that one participant with 10% relative abundance of 
a given species and a ‘bacterial load’ of 109 microbial species in her vagina could have 10x 
more copies of this species in her microbiota than a participant with a total bacterial load of 
108, but this would be masked by only assessing relative abundance. The studies of lung and 
gut microbiota suggest that the ‘bacterial load’ may be a significant part of the assessment 
of the microbiome.104 
It is possible to semi-quantify 16S rRNA sequencing data by combining sequencing with a 
quantitative PCR (qPCR) of the 16S rRNA gene.105 Assuming that sampling techniques are 
similar between participants, and using published data about the number of copies of 16S 
rDNA that a particular species has, it is then possible to estimate the quantity of a particular 
species for each participant. This technique has not been as widely used in pregnancy, but 
is mentioned as an important next step in a number of recent publications. 103,106,107 This 
technique has the additional benefit of avoiding compositional statistics, which strictly 
should avoid traditional regression analyses, although they are commonly applied.108 
 
 
   
   27 
The BactQuant assay is a commonly used qPCR assay of the 16S rRNA gene that can be used 
to semi quantify the amount of bacterial DNA in a sample, and in turn the bacterial load 
within that sample.105 In order to assess reproducibility of the assay the developers used 
plasmid standards and reported a coefficient of variance below 15% their intra-run 
analysis.105 However, a logical concern with regard to estimation of bacterial load in the 
vagina is the effect of variance in sampling technique on the result. It would be logical to 
suppose that a sample obtained with more rotations, or more pressure may obtain a higher 
bacterial load. To my knowledge only one published paper has assessed the reproducibility 
of the BactQuant assay of cervico-vaginal swabs (and no studies of specifically high vaginal 
swabs). This study found no difference in bacterial load between two swabs in 30 
women with a histologically-proven diagnosis of high-grade squamous intra-epithelial 
lesions of the cervix, once the volume of carrier fluid was accounted for.109 This study was 
primarily designed to compare Cytobrush and swab sampling of the VMB, and therefore the 
amount of pressure applied/method of sampling of each participant was likely to be similar 
for each swab. Therefore, whilst the reproducibility between two swabs from the same 
participant is reassuring, the uncertainty with regard to the potential for variation in result 
by sample collection method should be borne in mind as a potential limitation of this assay. 
1.4.5 Meta-analysis of the vaginal microbiota in preterm birth studies 
Two recent attempts to perform a metanalysis of VMB in PTB studies were abandoned due 
to ‘differences in every technical aspect of study design’.99,110  The PREBIC preterm birth 
collaborative recently published recommendations for a minimum dataset for future 
research as a first step to address these issues.99 However, until a universal method of 
performing the laboratory analysis and characterisation of the vaginal microbiota is 
adopted, individual patient data meta-analyses will not be feasible.  
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We are now entering the ‘next era’ of VMB and PTB analysis, whereby in order to advance 
the field it is necessary to be informed by the initial work and use this to focus the next 
steps to assess which initial findings are reproducible  and clinically important. 
2 Justification for project 
The aetiology of preterm birth is still poorly understood. Women with recurrent early 
preterm birth/PPROM may have an underlying tendency to infection, low level 
inflammation, or consistent environmental influences that alter the VMB and in turn 
contribute to the recurrent early PTB. This project was performed to assess the 
contribution of the vaginal microbiota to this medley.  
2.1 Rationale for components of the study 
2.1.1 Rationale for focus on early spontaneous preterm birth 
The focus on extremely preterm and early preterm births (<34+0 weeks) was chosen for two 
reasons. Firstly, this is the cohort with the highest morbidity and mortality, and so there is 
the strongest desire to understand, and ideally prevent, these events. Secondly, although 
preterm birth is normally defined by an arbitrary timepoint that birth occurs, the 
relationship between the gestation at birth and neonatal outcome may be best understood 
as a continuum.111 Pregnancies with a late preterm birth are more likely to include not only 
pregnancies with pathology relating to preterm birth, but also ‘normal’ pregnancies in 
which the normal occurrence of labour happened to start on the earlier side of the normal 
distribution of spontaneous labour for that population. Therefore, we postulated that by 
focusing on births under 34 weeks gestation there would be  a better chance of identifying 
pregnancies affected by pathology(ies) causing  preterm birth. 
The lower gestational limit of preterm birth is contentious. The WHO definition of preterm 
birth does not include a lower limit, and individual countries report variably from all live 
births or gestations between 20 and 28 weeks.5 In the UK if a birth occurs at less than 24+0 
completed weeks of pregnancy, and the infant shows no signs of life at birth, then the 
pregnancy is classified as a ‘miscarriage’; and correspondingly will not be included in birth 
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data. However, in 2019 the British Association of Perinatal Medicine (BAPM) published a 
framework advocating active management for appropriately selected cases of birth from 
22+0 weeks gestation onwards.112 Therefore, UK classifications of preterm birth will 
fluctuate dependent on resuscitation practices of births between 22+0 and 23+6 weeks 
gestation. Risk factors and outcomes of subsequent pregnancies, are similar in women with 
pregnancy losses at 14+0 -23+6 weeks and women with spontaneous preterm birth after 24 
weeks gestation.113–115 In 2012 an expert working group suggested that second trimester 
births could be included within the analysis of preterm birth.111 Correspondingly this thesis 
will focus on early preterm birth and use the gestational range 16+0 to 33+6 weeks.  
The prospective nature of the cohort study meant that some participants did have late 
spontaneous preterm birth or PPROM. These samples were analysed and the results 
assessed, to help understand the complete picture, but they were not the primary focus of 
the project. 
2.1.2 Rationale for including early PPROM 
Once the membranes are ruptured at early gestations, any ongoing pregnancy remains 
vulnerable to serious complications including chorioamnionitis, cord prolapse and placental 
abruption. A genetic pathway analysis performed by our group prior to the study suggested 
that sPTB and PPROM have some common causes, and also some unique pathways116 and 
so analysis was planned individually and combined. 
2.1.3 Rationale for exclusion of medically indicated preterm births 
Approximately two thirds of preterm births are either of spontaneous onset or following 
preterm prelabour rupture of membranes (PPROM).117 The remaining third are medically 
indicated, and often related to pregnancy pathologies such as hypertensive disorders, 
diabetes or small for gestational age.118–120 There is considerable overlap between these 
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pregnancy pathologies and preterm birth, indeed having had a previous pregnancy 
pathology is a risk factor for preterm birth in a subsequent pregnancy.121 However, these 
pathologies are studied separately and this work will focus on preterm birth of spontaneous 
onset, or following PPROM.  
2.1.4 Rationale for study of recurrent preterm births 
Previous PTB is the strongest risk factor for spontaneous PTB.122  This has commonly been 
quoted as an example of the genetic contribution to preterm birth.123 However, this does 
not rule out other possible reasons for recurrence such as a microbial contribution due to 
low level inflammation, a susceptibility to infection as demonstrated in the first 
pregnancy.124 Alternatively environmental contributions that are relatively constant 
between pregnancies, such as maternal nutritional state may in turn impact upon her 
microbiota.125 
We targeted recruitment at women who had had a sPTB or PPROM under 34 weeks (high-
risk cohort), expecting a reoccurrence rate between 10% and 20% based on our previous 
internal audit and external cohorts.126  
Previous preterm birth research has been criticised for heterogeneous phenotypes 
contributing to heterogeneity in outcomes.127 Focusing on this group with a high 
reoccurrence rate a had several advantages. Firstly, a narrower inclusion criteria reduced 
the heterogeneity in our population. Secondly, the high reoccurrence rate meant we 
needed to recruit less participants to achieve enough preterm births for analysis, and so we 
had the resources to focus on carefully characterising all preterm births in the cohort. This 
meant we were able to include only those with carefully phenotyped  sPTB or PPROM. 
Finally the risk factor of a previous preterm birth means that that any positive findings of 
the research could potentially be considered as contributing to the primary preterm birth 
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too and lead to targeted further work looking at preterm births in primiparous women. 
Primiparous women make up the group with the largest amount of preterm babies born, 
but on an individual level without specific risk factors have a low chance of preterm birth.117 
If a targeted test and treatment could be applied in this group then large population 
benefits could be achieved in preterm birth reduction.  
The focus on recurrent early preterm birth does have a drawback; in this study the low risk 
cohort was recruited only to describe the expected distribution of the variables in the local 
population and was not expected to provide enough participants with early sPTB or PPROM 
to analyse the contribution of the variables to preterm birth in this group. As such, our 
findings can only directly be related to recurrent early sPTB or PPROM, and these might 
differ from contributions to preterm birth in the population as a whole found in other 
literature. 
2.1.5 Rationale for reference to low-risk cohort 
The ‘healthy’ VMB in pregnancy is well described as varying by location and ethnicity,97 but 
had not previously been characterised in the Liverpool population. In order to place our 
VMB findings within the local context we therefore characterised the VMB of parous 
women who delivered at term as our normal reference group. 
Since our high risk cohort were, by definition of having a previous preterm birth, parous 
women, we chose to recruit only parous women to the low risk cohort too. There is some 
evidence that having had a previous pregnancy, whether or not this resulted in a livebirth, 
is associated with an alteration in the VMB,128 so it was desirable to overcome this 
confounder. In order to identify parous women at low risk of preterm birth we recruited 
only those who had had all previous births at term (≥ 37+0 weeks gestation).  
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The analysis was restricted to only those low-risk women who gave birth ≥ 39+0 weeks 
gestation. This was because of previous work suggesting that this should be considered the 
gestation of absolute ‘normality’.129 This is because the risk of more subtle 
neurodevelopmental adverse outcomes actually extends into the ‘early term’ gestational 
period. Figure 2.1 illustrates that in a study of Scottish school children aged 4 to 19 years, 
gestation at birth has a dose-dependent relationship across the whole range of gestation.130 
This scale is exaggerated by the log function on the y axis and as an observational 
population study could not completely control for the current obstetric practice of 
recommending early term birth to women with complex pregnancies (for example diabetes, 
preeclampsia, growth restriction). Nevertheless it is consistent with other studies 
demonstrating higher mortality and morbidity amongst infants born at 37 to 38 weeks 
gestation compared to 39 to 40 weeks.113,131,132   
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Figure 2.1:  Gestational age at delivery and special educational need (SEN): retrospective cohort study of 407,503 
school children130 
 
2.2 Justification for reference to previous vaginal microbiota studies 
This project is submitted seven years after the first assessment of the contribution of the 
VMB to PTB.133 At present, most VMB in PTB studies suggest an association between a 
particular VMB component and PTB. However, differences in almost every technical aspect 
of study design make comparability effectively impossible. In order to advance this field, 
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2.3 Aims 
1) Identify and develop methods of VMB characterisation in the second trimester that 
are potentially associated with sPTB/PPROM based on previous literature 
2) Describe the distribution of the VMB in ‘healthy’ pregnancies in the second 
trimester in our local population, using the VMB characteristics described in (1) 
3) Assess the contribution of the vaginal microbiota in the second trimester to 
recurrent early sPTB/PPROM, with reference to the expected distribution of VMB 
characteristics in ‘healthy’ pregnancies 
4) Assess whether any VMB characteristics associated with recurrent early 
sPTB/PPROM identified in (3) are also associated with late sPTB/PPROM, in high-
risk women 
2.4 Objectives 
1) To review published studies that have assessed the association between the VMB 
and PTB, alongside studies of the VMB in non-pregnant women that have 
characterised pathologies known to be associated with PTB. This body of literature 
will be used to select previously used VMB characteristics for inclusion in this 
project, and develop new VMB characteristics for analysis 
2) Vaginal swab samples in the second trimester from parous women with all previous 
births at term, and birth ≥39+0 weeks in the index pregnancy, will be analysed by 
16S rRNA gene sequencing and qPCR of the 16S gene. These samples will be used to 
determine the distribution of the VMB characteristics identified in (1) in the 
‘healthy’ pregnancies 
3) Vaginal swab samples will be collected in the second trimester from women with a 
history of sPTB or PPROM at 16+0 to 33+6 weeks gestation. Those women who go on 
to have a recurrent sPTB or PPROM at 16+0 to 33+6 weeks gestation will form our 
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‘cases’. Participants who go on to give birth at ≥37+0 weeks without PPROM will 
form our ‘controls’. These two groups will be used to perform a nested case-control 
study, with aetiological modelling, to assess the contribution of the VMB (using the 
characteristics identified in (1)) to recurrent early sPTB/PPROM. These results will 
be compared to the expected distribution of the VMB characteristics in the low-risk 
reference group. 
4) Any VMB characteristics that are identified as having an association with recurrent 
early sPTB or PPROM in (3) will also be assessed for within high-risk participants 
who have a late sPTB or PPROM. Aetiological modelling will then be used to assess 
the association between these characteristics and late sPTB or PPROM, in 
comparison to high-risk women who give birth at ≥37+0 weeks without PPROM, in 
the high-risk group.  
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3 Participants and Methods 
3.1 Introduction 
The Harris-Wellbeing Preterm Birth Research Centre team conducted a prospective 
observational study entitled “The development of novel biomarkers for prediction of 
preterm labour in a high-risk population” study. Recruitment to the first stage of the study 
started on 1 April 2012. The vaginal microbiota and clinically available data components 
were added on 19th October 2015 with an ethical amendment that approved the collection 
of vaginal swabs and the recruitment of the low-risk cohort. I joined the study team on 1st 
February 2016. Recruitment was completed on 31 December 2017 and all participants had 
given birth by the end of June 2018.  
This thesis describes a nested case-control study to assess the relationship between the 
vaginal microbiota and recurrent early preterm birth in women at high-risk of sPTB, with 
reference to the expected distribution of the vaginal microbiota in women at low-risk of 
sPTB. 
3.2 Ethical approval  
The study was approved by North West Research Ethics Committee - Liverpool Central, 
reference 11/NW/0720, on 4th November 2011. The amendment in October 2015 retained 
the original reference code. All participants gave written informed consent.  
3.3 Funding 
The prospective cohort study was funded as part of a charitable donation from Lord and 
Lady Harris, gained in an open competition that was facilitated by the charity Wellbeing of 
Women. This donation founded the Harris-Wellbeing PTB Research Centre, University of 
Liverpool. This covered administrative costs, laboratory analysis, and study support costs 
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for myself.  
3.4 Study design 
Pregnant women were recruited from Liverpool Women’s Hospital, UK, in two groups:  
• Healthy parous women with no risk factors for preterm birth. These women formed 
our low-risk reference group. 
• Women with a history of at least one previous sPTB or PPROM at 16+0-33+6 weeks 
gestation. These women formed our high-risk group. 
3.4.1 Whole study inclusion criteria 
Inclusion criteria for both groups of the study were: 
• Singleton pregnancy 
• Having had early pregnancy ‘dating’ scan134 before 14+0 weeks gestation showing no 
fetal abnormalities 
• Between 15+1 and 23+0 weeks gestation at first study visit 
• Standard antenatal care in the UK includes offering all women HIV and hepatitis B 
testing at their ‘booking’ appointment with a midwife.134 Potential participants 
were required to have taken part in this programme, and the results to have been 
negative.  
• Participants were only eligible for study participation for one pregnancy, so they 
could not be recruited a second time during a subsequent pregnancy.  
• Not having had vaginal sex within 48 hours prior to the first study visit 
The early pregnancy ‘dating’ scan was used to calculate gestational age at sampling and 
birth. The HIV and hepatitis testing was stipulated as part of the laboratory risk assessment 
for the parallel analysis of biomarkers present in the blood that were also assessed in this 
project (separate manuscripts in preparation). The uptake of HIV testing in UK antenatal 
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services in 2015 was 98.2%, with only 0.15% of women testing positive135 so this is unlikely 
to have had a substantial impact upon recruitment. 
3.4.2 Low-risk group recruitment 
These participants were women who were planning to give birth at Liverpool Women’s 
Hospital, or with the hospital’s linked homebirth team. 
In the UK all pregnant women are encouraged to ‘book’ with an antenatal care provider in 
the first trimester, and it is anticipated that the majority of women will receive antenatal 
and intrapartum care from the same provider.134 Liverpool Women’s Hospital136 is one such 
care provider, with the largest stand-alone maternity unit in the UK and a dedicated 
midwifery led birthing suite. As such it provides care for many women who have ‘low-risk’ 
pregnancies and ‘midwifery led antenatal care’134 (as well as being a tertiary referral centre 
for complex pregnancies). 
Low-risk participants were selected to reflect the ‘healthy pregnant’ population as much as 
possible. Additional inclusion criteria for this group were: 
• Having had at least 1 previous pregnancy that progressed to at least 37+0 weeks 
gestation 
Exclusion criteria for this group were: 
• Previous late miscarriage (≥ 16+0 weeks gestation) 
• Previous preterm birth (<37+0 weeks gestation), including medically induced 
preterm birth 
• Previous PPROM (<37+0 weeks gestation) 
• History of significant cervical surgery* 
• Medical condition considerably affecting health† 
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• Previous pregnancy affected by an obstetric complication with an increased chance 
of reoccurrence# 
* Significant cervical surgery was defined as either: 1 large loop excision of the 
transformation zone (LLETZ) over 10mm; 2 or more LLETZ; or a knife cone biopsy 
† A medical condition considerably affecting health was defined as women who had been 
referred to a specialist antenatal clinic for a medical condition by the ‘booking midwife’ 
(first healthcare professional who met woman in pregnancy and took a detailed medical 
history). For example (not limited to): epilepsy, inflammatory bowel disease, or renal 
impairment. 
# A previous pregnancy affected by an obstetric complication with an increased chance of 
reoccurrence was defined as previous gestational diabetes, preeclampsia requiring 
magnesium sulphate, or gestational hypertension requiring antihypertensives. 
The low-risk participants were recruited as follows: 
1. Study clinicians used hospital electronic records to identify women who had 
‘booked’ for antenatal care134 to be provided by Liverpool Women’s Hospital and 
fitted the eligibility criteria as described above.   
2. Study staff then telephoned or sent a text message to potential participants to offer 
them involvement in the study. The offer of involvement was given between the 
early pregnancy ‘dating’ scan (described above) and 15+0 weeks gestation. Each 
potential participant was only contacted once, with an answerphone message left if 
possible. A smaller number of the low-risk cohort were recruited by self-
identification from study leaflets (Appendix A) distributed by the community 
midwives or the same information from the leaflet that was posted on social media 
by the research group and Liverpool Women’s Hospital. Potential participants were 
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invited to telephone or send a text message to a dedicated research number and 
then eligibility was confirmed by the research team. 
3. Potential participants were spoken to on the telephone and the research study was 
briefly explained, including the rationale and need for speculum examination with 
vaginal swabs and cervical length scan. Participants were offered a 3D ultrasound 
scan of the pregnancy at each study visit. 
4. Potential participants who wanted to proceed with study recruitment were then 
scheduled for their first study visit at approximately 16 weeks gestation (15+1-18+6 
weeks). Study visits then proceeded as described below. 
 
The process for identification and approach of the both groups of pregnant women was 
approved by the ethics committee with input from the Harris-Wellbeing patient and public 
involvement group. The use of electronic case notes for participant identification predated 
the changes to UK general data protection legislation.137 
3.4.3 High-risk group recruitment 
Additional eligibility criteria to this group were: 
• Having had at least one previous preterm spontaneous preterm birth (sPTB), 
preterm prelabour rupture of membranes (PPROM) or spontaneous late 
miscarriage at 16+0-33+6 weeks gestation. 
• Not using preterm birth preventative treatment (cervical cerclage/vaginal 
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There were no additional exclusion criteria for the high risk cohort, and in particular women 
could take part in this group if they had had significant cervical surgery, previous obstetric 
or medical problems. 
These participants were prospectively recruited from the Liverpool Women’s Hospital 
Preterm Labour Prevention Clinic. Study visits were timed to coincide with the participant’s 
scheduled visits to the preterm birth prevention clinic (within the study schedule).   
3.4.4 Study schedule 
Participants for were invited to two study visits at approximately 16 weeks gestation (15+1-
18+6 weeks) and approximately 20 weeks gestation (19+0-23+0 weeks). Participants who 
were recruited after 19+0 weeks gestation only had a single study visit. 
Participants who had a second study visit were asked to abstain from sex for 48 hours prior 
to the study visit. 
3.4.5 Procedure for study visits 
 First visit 
At the first study visit an obstetric doctor confirmed eligibility and provided a participant 
information leaflet (Appendix B low-risk and Appendix C high-risk). The doctor and 
participant then completed a written consent form (Appendix D) and a study number was 
allocated. 
The doctor then completed a data collection form (Appendix E low risk and Appendix F 
high-risk) detailing the following: 
• Age in years (at time of first study visit) 
• Height and weight (these were used to calculate the body mass index) 
• Home postcode 
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• Smoking history 
• Self-reported ethnicity 
• Current gestation and estimated due date 
• Method used to estimate due date 
• Number of previous pregnancies affected by sPTB or PPROM between 16+0 and 33+6 
weeks gestation (only relevant for the high-risk cohort) 
• Whether the participant had previous cervical surgery, and if so, this was classified 
into one of three groups: (1) nil significant (for example no cervical surgery or 
punch biopsy); (2) single LLETZ <10mm (large loop excision of the transformation 
zone); or (3) a single LLETZ ≥10mm, multiple LLETZ or at least one knife cone biopsy 
• Medication that the participant had taken in the previous 72 hours (including 
vitamin supplements) 
• Whether antimicrobials had been used in the pregnancy, and if so the name, 
indication and dates of administration  
• Whether the participant had had vaginal sex in the previous 48 hours (if so the 
participant was not recruited to this part of the study) 
The participant then had blood taken for additional components of the study. Next, the 
participant had a speculum examination, with a chaperone present, and five vaginal swabs 
were taken as below. A cervical length scan was performed after the speculum 
examination.  
The 3D ultrasound scan was then performed, and photographs provided to the participant. 
Any questions were addressed as necessary, and the second clinic visit was scheduled. 
High-risk participants were managed in the standard manner for the preterm birth 
prevention clinic. Preterm birth prevention therapy (cerclage, vaginal pessary or vaginal 
progesterone) was offered if cervical length was ≤ 25mm or based on clinician and patient 
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preference if there was considered to be a large change in cervical length between 
measurements. 
 Collection and storage of cervico-vaginal swabs 
Firstly, a sample of cervico-vaginal fluid was taken from the posterior fornix (10 seconds of 
rotation) for quantitative fetal fibronectin (qfFN) assessment using Rapid fFN 10Q System 
(HOLOGIC, Marlborough, MA, USA). Secondly, three high vaginal swab samples were 
collected using HydraFlock standard tapered swabs (Medical Wire and Equipment, 
Corsham, England). Two of these were frozen dry and the other was placed in 1ml of 
‘RNAlater’ (Merck Life Science UK Ltd, Dorset, UK). Thirdly a high vaginal swab was used to 
collect a sample of fluid from the posterior fornix and sent to the NHS laboratory for 
standard culture and sensitivity.  
The qfFN swab was processed by laboratory technicians and the result recorded. Obstetric 
doctors were blind to the qfFN result until all participants in the study had given birth. The 
HydraFlock standard tapered swabs were stored in 1.2ml cryogenic tubes (Fisher scientific, 
Loughborogh, UK)  at -80°C within an hour of sampling.  
 Second study visit 
At the second study visit the obstetric doctor verbally confirmed ongoing willingness to 
participate in the study, then completed the second section of the data collection form 
(Appendix E low-risk and Appendix F high-risk).  
Information gathered at the second visit included: 
• Whether any new concerns or pathologies had been identified with the pregnancy 
• Whether preterm birth prevention treatment was currently being used (if so what, 
and when started) 
• Medication usage within the previous 72 hours (including vitamins) 
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• Use of antimicrobials since the previous study visit, and if so the name, indication 
and dates of administration  
• Whether the participant had had vaginal sex in the previous 48 hours 
The blood sampling, speculum examination with vaginal swabs, cervical length scan and 
fetal scan were then repeated in the same way as the first visit.  At the end of the second 
visit patient contact details were confirmed and verbal consent was re-iterated to contact 
the patient for pregnancy outcome data if this wasn’t possible on the hospital electronic 
system. 
 Further data collection 
Preterm birth clinic records were reviewed to ascertain whether preterm birth prevention 
treatment (cervical cerclage, pessary or vaginal progesterone) was used after enrolment in 
the study. No low-risk participants required preterm birth prevention therapy, so this was 
only relevant to the high-risk group.  
Hospital records were used to ascertain delivery details for all women delivering at our unit. 
If participants gave birth elsewhere then clinicians at the delivering unit were contacted 
and asked to provide delivery details. Where this wasn’t possible the participants were 
contacted directly by telephone. The GROW birthweight centile138 was calculated using the 
mother’s height, weight, ethnicity, parity and the infant’s birthweight to facilitate 
comparison of birthweights across the groups despite differences in gestation at birth. 
 Data handling 
Study data was inputted into a Microsoft Excel spreadsheet, stored on the University of 
Liverpool’s secure server. The Index of Multiple Deprivation (IMD) was obtained using the 
woman’s home postcode on the UK government website.139 The IMD ranks every 
neighbourhood in England from 1 (most deprived) to 32844 (least deprived).140 The IMD is a 
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collective score summarising income deprivation, employment deprivation, health 
deprivation and disability, education skills and training deprivation, barriers to housing and 
services, living environment deprivation, and crime.  
3.5 Classification of birth outcome 
3.5.1 Low-risk group 
When a participant in the low-risk group gave birth ≥39+0 weeks gestation, the hospital 
electronic records were reviewed to confirm there was no evidence of PPROM <37 weeks 
gestation (or if the woman delivered elsewhere this was confirmed with the unit where she 
gave birth). If no PPROM <37+0 weeks was confirmed, then the participant was allocated to 
the low-risk reference group. 
The remainder of participants within the low-risk group were excluded from the analysis. 
However, their births were still classified in the same way as the high risk women for 
completeness and to facilitate later analysis, as described in Figure 3.1. In cases of birth or 
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Figure 3.1:Workflow for classification of births in the low-risk group. Only those low-risk participants who gave 
birth ≥39+0 weeks gestation formed the ‘low risk reference group’ and were included in the primary analysis. 
The remainder of the low-risk births were still classified for pregnancy outcome purposes but not included in the 
primary analysis. 
 
3.5.2 Term births in the high-risk group 
When a participant in the high-risk group gave birth ≥37+0 weeks gestation the hospital 
electronic records were reviewed to confirm there was no evidence of PPROM <37+0 weeks 
gestation (or if the woman gave birth elsewhere this was confirmed with the unit where 
birth occured). If no PPROM <37+0 weeks was confirmed, then the participant was allocated 
to the high-risk reference group. 
3.5.3 Preterm births and PPROM  
Dr Angharad Care, Harris Wellbeing clinical research fellow, and I, independently reviewed 
all available data relating to all births or PPROM <37+0 weeks gestation, including hospital 
records and supplementary reports from other hospitals if participants had care elsewhere. 
In the cases of discrepancy the case was reviewed by Professor Alfirevic until the team 
reached a consensus on classification of the birth. 
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Figure 3.2 shows the workflow for the classification of births, and Table 3.1 shows how 
clinical diagnoses were defined. The judgement of the contemporaneously recorded 
treating clinicians was used to record diagnoses unless further information became 
available at a later time that refuted this. For example, if a diagnosis of PPROM was made 
by the treating clinicians based on history and examination, then this diagnosis was kept 
unless further information later refuted this. Further information that could refute this 
would be ultrasound scans showing normal amniotic fluid levels and the absence of 
ongoing vaginal leakage of fluid. In order to achieve as homogeneous population of 
sPTB/PPROM as possible participants where the diagnosis of sPTB or PPROM was uncertain 
were excluded. High-risk participants with obstetric complications, for example 
preeclampsia or gestational diabetes were included if they also clearly had sPTB or PPROM. 
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Figure 3.2: Workflow for classification of births in the high-risk group 
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Table 3.1: Definitions used for classification of birth outcomes 
Classification Description 
Spontaneous labour Regular uterine activity with cervical shortening or dilation such that 
the treating clinicians judged labour to be present 
Prelabour rupture of 
membranes 
Rupture of membranes confirmed either by speculum examination or 
the AmniSure ROM test (QIAGEN, UK) without onset of spontaneous 
labour in the following 12 hours 
Caregiver initiated 
preterm birth 
Induction of labour or Caesarean section ≤36+6 weeks gestation 
without evidence of PPROM or spontaneous preterm labour 
 
3.5.4 Additional classification for cases of PPROM 
In cases of PPROM we were particularly interested to ascertain whether chorioamnionitis 
was thought to be present at the time of PPROM (and so could have been implicated in the 
pathway to PPROM), or whether PPROM occurred in the absence of chorioamnionitis. We 
therefore further classified cases of PPROM according to whether there was evidence of 
chorioamnionitis within 7 days of PPROM, or not (Figure 3.3, Table 3.2).  
 
Figure 3.3: Additional classification for women with PPROM 
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Table 3.2: Definition of chorioamnionitis developed for this study 
Term Description 
Chorioamnionitis 
Contemporaneous clinical notes documenting concern about 
chorioamnionitis due to one or more of: raised white cell count; 
raised C-reactive protein (CRP); maternal pyrexia; or the use of broad 
spectrum antibiotics to treat chorioamnionitis based on the clinical 
situation. 
Not histologic evidence of chorioamnionitis on placental histology 
alone (subclinical chorioamnionitis) 
 
3.5.5 Conclusion of major classification of birth outcomes 
The review of all births culminated in all participants being classified into one of 15 
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16+0- 33+6 weeks 
gestation 
Term Birth ≥37+0 weeks gestation A 
Caregiver initiated 
preterm birth 
Caregiver initiated preterm birth B 
Early PPROM 
PPROM ≤33+6 weeks gestation with 
early chorioamnionitis 
C 




PPROM 34+0-≤36+6 weeks gestation with 
early chorioamnionitis 
E 
PPROM 34+0-≤36+6 weeks gestation 
without early chorioamnionitis 
F 
Early sPTB sPTB ≤33+6 G 
Late sPTB sPTB 34+0-≤36+6 H 
Unknown Unable to ascertain birth details I 
Low-risk 
Parous women 
with all previous 
births ≥37+0 
weeks gestation 
Term Birth ≥39+0 weeks gestation LA 
Caregiver initiated 
preterm birth 
Caregiver initiated preterm birth LB 
Early PPROM 
PPROM ≤33+6 weeks gestation with 
early chorioamnionitis 
LC 




PPROM 34+0-≤36+6 weeks gestation with 
early chorioamnionitis 
LE 
PPROM 34+0-≤36+6 weeks gestation 
without early chorioamnionitis 
LF 
Early sPTB sPTB ≤33+6 LG 
Late sPTB sPTB 34+0-≤36+6 LH 
Unknown Unable to ascertain birth details LI 
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3.5.6 Contributing factors to preterm birth 
In addition to the major classification of birth Dr Care and I reviewed the medical 
information and attributed ‘contributing factors’ to the women with sPTB and PPROM 
(classification codes C-H and LC-LH). This was based on the Clinical Phenotyping Tool 
developed by Villar et al (2012).141 Of note the contributing factors are not mutually 
exclusive, and some women had no discernible contributing factors to preterm birth. The 
tool developed by Villar et al also included maternal stress and family history in the 
classification system. We did not measure maternal stress around the time of delivery, and 
the project includes a genetic component, and so these were excluded from our 
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Table 3.4: Potential contributing factors to sPTB/PPROM that were assessed for within the medical records and 
recorded if present 
Contributing factors to 
preterm birth 
Description 
Chorioamnionitis Contemporaneous clinical notes documenting concern about 
chorioamnionitis due to one or more of; raised white cell 
count, raised C-reactive protein (CRP), maternal pyrexia, or the 
use of broad spectrum antibiotics to treat chorioamnionitis. 
Not histologic evidence of chorioamnionitis on placental 
histology alone (subclinical chorioamnionitis) 
Placental dysfunction Evidence of placental dysfunction contributing to preterm 
labour. Defined as evidence of placental abruption at time of 
delivery or on placental histology report, birthweight under 5th 
customised centile, or severe preeclampsia 
Extra amniotic 
infection  
Contemporaneous clinical notes documenting concern about 
major systemic infection due to one or more of; raised white 
cell count, raised CRP, maternal pyrexia, microbiological 
culture of pathological organism from a normally sterile site, or 
the use of broad spectrum antibiotics for presumed extra 
amniotic infection. 
Polyhydramnios  Maximum pool depth ≥10cm on ultrasound assessment 
Uterine anomaly  Documented uterine anomaly 
Maternal 
comorbidities 
Maternal medical condition that affects a major organ system 
(for example chronic hypertension, chronic renal failure, 
epilepsy, pre-existing and gestational diabetes) 
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3.6 Final study inclusion and exclusion criteria 
This nested case-control study retained six groups of participants for analysis. These were: 
1) Low-risk reference group: Low-risk participants (as described in 3.4.2) who gave 
birth ≥39+0 weeks gestation (LA classification code, Table 3.3) 
2) High-risk reference group: High-risk participants (as described in 3.4.3) who gave 
birth ≥37+0 weeks gestation, without PPROM (A classification code, Table 3.3) 
3) High-risk late sPTB group: High-risk participants (as described in 3.4.3) who had an 
sPTB 34+0-36+6 weeks gestation, (H classification code, Table 3.3) 
4) High-risk late PPROM group: High-risk participants (as described in 3.4.3) who had 
PPROM 34+0-36+6 weeks gestation (E and F classification codes, Table 3.3) 
5) High-risk early sPTB group: High-risk participants (as described in 3.4.3) who had an 
sPTB 16+0-33+6 weeks gestation, (G classification code, Table 3.3) 
6) High-risk early PPROM group: High-risk participants (as described in 3.4.3) who had 
PPROM 16+0-33+6 weeks gestation (C and D classification codes, Table 3.3) 
In addition to the global inclusion criteria (section 3.4.1) and low and high risk group 
specific criteria (sections 3.4.2 and 3.4.3) the final study had the additional inclusion 
criteria:  
A vaginal microbiota sample result available for analysis (having passed the quality 
control process) with: 
o The participant having abstained from vaginal intercourse in the 48 hours 
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o The participant not using preterm birth prevention therapy at the time of 
study visit 
We only used the first set of valid sequencing results for each participant for the majority of 
analyses because of the short time period between the two study visits, with one 
exception. In the subset of participants with valid sequencing results for both visits we used 
data from both visits for the stability analyses. 
3.7 Laboratory process for assessment of the vaginal microbiota 
3.7.1 DNA extraction 
DNA extraction and sequencing were performed at the University of Liverpool Centre for 
Genomic Research. DNA was extracted from one sample per participant per visit. Birth 
outcomes were not known at the time of DNA extraction. A total of n=706 swabs from 364 
participants underwent DNA extraction, PCR amplification and 16S rRNA sequencing and 
rarefaction. After this the analysis was restricted to only the participants eligible for the 
case-control study as described in section 3.6.  
The samples were thawed, and DNA was extracted by adding 180 μl of enzymatic lysis 
buffer containing lysozyme to the sample (Sigma-Aldrich, Dorset, UK); incubation for 30 
minutes at 37 0C; 25 μl of proteinase K and 200 μl of buffer AL were added from the Qiagen 
DNeasy Blood and Tissue kit (Qiagen, Manchester, UK); incubation for 30 minutes at 560 C; 
addition of 200 mg of 0.1 mm zirconia/silica beads (Thistle Scientific, Glasgow, UK) then 
bead-beating for 5 minutes at 25 Hz on a Qiagen TissueLyser II (Qiagen, Manchester, UK). 
Next 200 μl of 100% ethanol was added to the sample and it was centrifuged. After 
centrifugation the swab head was discarded, and the pellet was purified in four subsequent 
centrifugation steps after adding one-by-one 200 μl 100% ethanol, 500 μl buffer AW1, 500 
μl buffer AW2 and 75 μl buffer AE as per manufacturer’s instructions (Qiagen, Manchester, 
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UK). In order to facilitate detection of contaminants downstream we included one negative 
control (an empty tube) with each DNA extraction round of 23 study samples. The DNA 
concentration of all samples was measured by Qubit (Invitrogen, Thermo Scientific, Paisley, 
UK) and the DNA quality of all samples by Nanodrop (Thermo Scientific, Paisley, UK). 
Samples with a particularly low DNA concentration or quality were discarded (n=25) and 
the DNA extraction process was performed on the second sample taken during that study 
visit (these samples subsequently achieved acceptable concentration and quality 
assessments).  
3.7.2 PCR amplification and 16S rRNA gene sequencing 
Two PCR rounds were performed for each DNA sample (study samples and negative 
controls) for 16S rRNA gene amplification and barcoding. Firstly, the V3-V4 region of the 
16S rRNA gene was amplified as described previously.142 DNA was amplified using 1.25 μl of 
a 10 µM concentration of 319F 5’-ACTCCTACGGGAGGCAGCAG-3’ forward primer and 1.25 
μl of a 10 µM concentration of 806R 5’-GGACTACHVGGGTWTCTAAT-3’ reverse primer, 12.5 
μl NEB Next HF 2x PCR Master Mix (New England Biolabs, Hitchin, UK), 9 μl of nuclease-free 
water and 1 μl of DNA extraction product to make a 25 μl reaction volume. The first 
denaturation cycle was performed for 30 seconds at 98 °C, followed by 10 cycles with a 
denaturation cycle of 10 seconds (at 98 °C), an annealing cycle of 30 seconds (at 58 °C), an 
extension cycle of 30 seconds (at 72 °C), and finally an extension cycle of 5 minutes at 72 °C. 
PCR products were then purified and size-selected using Agencourt AMPure XP beads 
(Beckman Coulter, High Wycombe, UK) in a 1:1 bead-to-sample ratio. The final PCR round 
used the standard Illumina Nextera XT index kit v2 (Illumina, San Diego, CA, USA), aimed at 
V3-V4 sequences by a dual-index approach. This permits multiplexing of up to 384 samples 
at a time (two rounds were performed to accommodate all samples). The barcoding used 
2.5 μl of Index 1 primer, 2.5 μl of Index 2 primer, 12.5 μl NEB Next HF 2x PCR Master Mix 
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and 7.5 μl sample making a 25 μl reaction volume. The first denaturation cycle was 
performed for 3 minutes at 98 0C, followed by 15 cycles with a denaturation cycle of 30 
seconds (at 98 °C), an annealing cycle of 30 seconds (at 55 °C), an extension cycle of 30 
seconds (at 72 °C), and a final extension cycle of 5 minutes at 72 0C. AMPure beads were 
then used to purify PCR products as explained above, also using a 1:1 bead-to-sample ratio. 
Each PCR run also had a negative control (10 μl of nuclease-free water instead of 9 μl of 
nuclease-free water and 1 μl of DNA) to identify contaminants, and 10 μl of 0.2 ng/μl 
ZymoBiomics Microbial Community DNA standard (Zymo Research Corp, Irvine, CA, USA), a 
commercially available positive control. The PCR runs also included the DNA extraction 
negative controls. DNA collected from the same participant at different visits were included 
in the same PCR run. The Qubit Fluorometer with the dsDNA HS Assay kit (Invitrogen, 
Thermo Scientific, Paisley, UK) was used to measure PCR product DNA concentrations of 
each sample (including negative and positive controls). Two negative controls were not 
successfully amplified and so were excluded from the subsequent steps, all participants 
samples, positive controls and the remainder of the negative controls were used for 
subsequent steps. 
Amplicons from samples were evenly pooled into sequencing libraries at a mass of 0.8 ng 
DNA per amplicon. To achieve this, Qubit DNA concentrations and Fragment Analyzer 
(Agilent, Santa Clara, USA) quality control information were combined for pooling before 
size-selection using Pippin Prep (Sage Scientific, Beverly, Massachusetts, USA). Samples 
with a DNA concentration of <0.30 ng/µl (such as the negative controls) were added in a 
fixed volume of 1 µl. The two libraries were sequenced on an Illumina HiSeq instrument 
(Illumina, San Diego, CA, USA), run in rapid mode, 2x300bp using a 250PE and 50PE kit. DNA 
collected from the same participant at different visits was included in the same library. 
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3.7.3 Panbacterial 16S rRNA gene qPCR 
Extracted DNA from all participant samples (n=706 samples from n=364 participants) was 
sent to the Institute for Genome Sciences of the University of Maryland (Baltimore, MD, 
USA) for estimation of the panbacterial 16S rRNA gene copy concentration using the 
BactQuant qPCR assay. This assay is based on an analyses of 4,938 16S rRNA gene 
sequences in the Greengenes database.105,143 The analysis was performed as described 
previously.105,144 Briefly, 1.5 μl of template (1:10 diluted DNA) was added to 3.5 μl of 
reaction mix, with the final reaction containing 1.8 μM each of the forward (341F) and 
reverse (806R) primer targeting the 16S V3-V4 region, 225 nM of the TaqManW probe, 1X 
Platinum Quantitative PCR SuperMix-UDG with ROX (Invitrogen, Thermo Scientific, 
Waltham, MA, USA) and molecular-grade water. For each experiment there was an in-run 
standard curve (ranging from 10 to 108, with 102–108 in 10-fold serial linear dilutions) and 
no-template controls performed in triplicate. Amplification and real-time fluorescence 
detections were performed on the Bio-Rad CFX 384 instrument (Bio-Rad Inc., Hercules, CA, 
USA). The PCR conditions were: 3 minutes at 50 °C for UDG treatment, 10 minutes at 95 °C 
for Taq activation, 15 seconds at 95 °C for denaturation and 1 minute at 60 °C for annealing 
and extension, times 40 cycles. Cycle threshold (Ct) value for each 16S qPCR reaction were 
obtained using a manual Ct threshold of 0.05 and automatic baseline. The 16S rRNA gene 
concentration was reported in copies/μL for each sample.  
Quality control of the BactQuant assay was performed by excluding samples that did not 
amplify in two of three, or all three, of the triplicate qPCR cycles, or had skewed low 16S 
rRNA gene concentration results of <1,000 copies/μl. 
3.7.4 Molecular data processing 
A mean raw unpaired read count of 368,205 reads per study sample (95% confidence 
interval (CI): 353,388 – 383,022 reads) was obtained. Cutadapt v1.16145 was used to 
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demultiplex the reads, and remove primer sequences. All subsequent steps were 
performed DADA2 version 1.8 package for large paired end datasets in R version 3.5.1 (R 
core team, 2015).146 DADA2 was chosen because of its ability to resolve reads to a single 
nucleotide. The fastqFilter command was used for error correction with parameter settings 
aiming to maximize read retention. The minimum read lengths (truncLen) were set to 255 
for forward reads and 210 for reverse reads based on the quality plots, maxEE to a 
maximum of 5 for forward read and 8 for reverese read expected errors, maxN to zero 
ambiguous bases allowed, and truncQ to zero. Approximately 10% of reads were discarded 
after error correction. The learnErrors command was then used to determine the read error 
rates. The reads were then assigned to unique amplicon sequence variants (ASVs, 
equivalent to a taxon) using the derepFastq command, and ASVs with higher than average 
error rates were discarded (denoised) using the dada command.146,147 The mergePairs 
command was then used to merge forward and reverse reads. The removeBimeraDenovo 
command  was used to remove chimeric compositions of two separate parent ASVs 
(Bimeras) with the Silva version 132 database as the reference database;148 6.3% of ASVs 
were identified as bimeric and removed. Overall, a median of 28% of the raw reads per 
study sample were removed during these DADA2 clean-up process. 
DADA2 was used to perform taxonomic assignment in two steps. Firstly assignTaxonomy 
was used to map ASVs to taxa at genus level or above using the RDP classifier with a 
minimum bootstrap value of 50% and the Silva v132 database as the reference 
database.148,149 Secondly addSpecies was used to map ASVs to species level. Only ASVs with 
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3.7.5 Further data processing 
A spreadsheet containing the sequences, taxonomic assignments, and read counts for each 
ASV per sample was imported into Microsoft Excel for Mac version 16. ASVs with a read 
count in all samples combined of less than 100 were removed, as well as two non-bacterial 
ASVs, and one likely contaminant ASV. The likely contaminant was a Cutibacterium genus 
that was present in two negative controls at a relative abundance that was higher than in 
any study sample. The Silva v132 database148 did not include the vaginal taxa BV-associated 
bacterium 1 (BVAB1), BVAB2 and BVAB TM7 sequences, but these have been published 
elsewhere100,150 and were identified manually in our dataset. The sequences for 
Mageeibacillus indolicus (BVAB3) and Fenollaria massiliensis were also evaluated but not 
present in our dataset. The taxonomic assignment derived from the Silva database148 was 
double-checked for the 112 ASVs with a relative abundance of at least 0.05% of the read 
count of all samples combined (out of a total of 1646 ASVs) using the Microbial Nucleotide 
BLAST (BLASTn) function on the National Center for Biotechnology Information NCBI 
website.151 In cases of discrepancy the Vaginal 16S rDNA Reference Database152 was used as 
a tiebreaker. This resulted in 45 Lactobacillus genus ASVs being reassigned to various 
Lactobacillus species, two Streptococcus genus ASVs being reassigned to S. agalactiae, a 
Staphylococcus genus being reassigned to S.aureus, a Gardnerella genus ASV being 
reassigned to G. vaginalis, an Atopobium genus ASV being reassigned to A. vaginae, a 
Sneathia genus ASV being reassigned to S. amnii and a Enterococcus genus ASV being 
reassigned to E. faecalis. Read counts for ASVs assigned to the exact same taxonomy were 
then summed for each sample. The lowest total read count for any specific sample above 
1000 reads was 1101, so GuniFrac 1.1 package in R was used to rarefy to 1101 reads. The 
rarefied ASV table contained 690 samples and 290 unique ASVs. The prop.table function in 
R was then used to transform rarefied read counts into relative abundances.  
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3.8 Selection of participants and samples to retain for analysis 
3.8.1 Selection based on pregnancy outcome 
277 of the 364 participants had a pregnancy outcome as described in section 3.6 and were 
eligible for analysis in this project. These participants contributed 484 samples. 
3.8.2 Failed quality control of 16S rRNA analysis 
16 out of 706 samples (from n=364 participants) became invalid due to rarefaction, 11 of 
which were samples eligible for inclusion in this project. Ten of the participants that 
provided these samples had an alternative study visit sample suitable for analysis (i.e. study 
visit attended, not using preterm birth prevention therapy at the time of study visit and no 
sex in previous 48 hours), so only one participant for the current analysis was excluded at 
this stage. 
3.8.3 Failed quality control of the panbacterial 16S rRNA gene qPCR  
31 out of 706 samples (from n=364 participants) did not produce valid qPCR results from 
the BactQuant assay, 19 of which were samples eligible for inclusion in this project. Fifteen 
of the participants that provided these samples had an alternative study visit sample 
suitable for analysis, so four participants for the current analysis were excluded at this 
stage. 
3.8.4 Final inclusion 
Of the 484 samples from 277 participants eligible for analysis, 454 (93.8%) of samples from 
272 (98.2%) of participants had valid 16S rRNA sequencing and valid BactQuant assays. Only 
these samples and participants with valid BactQuant assays and 16S rRNA data were 
retained for further analysis.  
The rarefied ASV relative abundance table consisted of 276 ASVs in 454 samples (for 272 
individual participants), mapping to species (181; 65.6%), genus (82; 29.7%), or higher 
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taxonomic levels (13; 4.7%) (Appendix G). This was used for all methods of data reduction 
and analysis. 
3.9 Estimation of bacterial load and taxon concentration  
The ASV-specific concentrations per sample and overall bacterial load were estimated by 
combining using the sample-specific 16S rRNA gene concentration data (BactQuant assay, 
section 3.7.3) with the rarefied ASV table (16S rRNA sequencing data, section 3.7.5).  
For each of the 276 unique ASVs included within the rarefied ASV table the 16S rDNA gene 
copy number was identified within in the NCBI version of the rrn database,153 and in the 
case of missing data the Greengenes database.143 In situations where ASVs were mapped to 
multiple species at genus level, then the mean 16S gene copy number based on all potential 
species was calculated and used. If the database didn’t detail the mean 16S gene copy 
number of a species then the mean copy number of the corresponding genus was used. For 
BVAB1 and BVAB2 only ‘order’ level taxonomic information (Clostridiales order). We 
therefore used the Clostridiales order mean copy number (=4.62). The ASV-specific copy-
normalized rarefied relative abundance was multiplied by the sample-specific 16S rRNA 
gene copies concentration to estimate the concentration of each ASV in cells/μl per sample. 
This method has previously been shown correlate with species-specific quantitative PCR 
results for non-minority species.154,155 The concentrations were then log10-transformed. To 
prevent skewed negative values concentration results less than one cell/μl were set to one 
prior to log10-transformation. 
3.10 Statistical analysis 
3.10.1 Statistical packages 
Statistical analysis, bar charts, and scatter plots were made in STATA version 15.1 
(StataCorp, College Station, TX, USA). Heatmaps showing the twenty ASVs with highest 
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median relative abundance were made using the gplots package in R. The eucalan chart 
was made using a website produced by Meta-Chart.156 
3.10.2 Analysis planned 
 Early sPTB/PPROM 
Descriptive statistics were used to describe the distribution of VMB characteristics in the 
low-risk women who delivered at ≥39+0 weeks gestation without PPROM. This group 
formed the low-risk reference group.  
Our primary comparisons were between high-risk women who gave birth ≥37+0 weeks 
gestation and high-risk women who had a recurrent early sPTB or PPROM <34+0 weeks. 
Characteristics between these groups of interest were compared by student’s t test for age, 
Mann-Whitney U test for other continuous variables, and Fisher’s exact test for binary and 
categorical variables. Initially the analysis was performed for the separate outcomes of 
early PPROM and early sPTB, and then these groups were combined for more detailed 
analysis. 
The VMB variables that were selected were compared between the high-risk who delivered 
at term and the high-risk early sPTB/PPROM preterm groups using unadjusted and adjusted 
logistic regression, with adjustments for body mass index (BMI) as a quadratic term, history 
of cervical surgery, and smoking. If a significant association between a continuous VMB 
variable and early sPTB/PPROM recurrence was identified, and the variable was present in 
over 30% of participants, then quartiles of the expected distribution of that VMB variable 
were generated using data from the low-risk reference group, and high-risk participants 
were allocated to one of these quartiles. These newly created categorical variables were 
also compared between high-risk term and preterm groups by logistic regression. Finally, in 
an effort to differentiate between the effects of total vaginal bacterial load and the types of 
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bacteria that make up this load, women were stratified by VMB type, and the logistic 
regression analyses were repeated for each stratum.   
For categorical outcomes, or if the prevalence of the taxa was so low that quartiles were 
not practical (n<5 early PTB participants with the taxon present) then the low-risk 
participants are reported alongside the high-risk, in order to give a reference range for the 
expected distribution. 
Euclan diagrams (proportional Venn diagrams) were produced to visualise the co-location 
or independence of VMB features that were associated with a higher incidence of early PTB 
for the high-risk term births and high-risk early sPTB/PPROMs. This was performed to help 
understand whether our multiple analysis methods were identifying the same participants 
in multiple ways, or different participants with disparate VMB features associated with PTB. 
 High-risk late preterm births and low-risk preterm birth groups 
If VMB characteristics were identified as associated with an increased or decreased risk of 
early sPTB/PPROM then these characteristics were also assessed for within the high-risk 
late preterm birth group, and the low-risk preterm birth groups. This was a targeted 
exploratory analysis to assess whether those characteristics were replicable. The design of 
the study was such that samples were donated by participants, and VMB analysis 
performed, prior to the outcome of the pregnancy being known, therefore the VMB 
analysis had already been performed for these participants in the course of the study. 
3.10.3 Calculation of sample size 
No formal calculation of sample size was undertaken as this was primarily an exploratory 
analysis and pragmatically planned addition to the already running “The development of 
novel biomarkers for prediction of preterm labour in a high-risk population study”.  
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3.10.4 Management of multiple comparisons 
In order to comprehensively assess the relationships between the VMB and recurrent early 
PTB that had been identified in previous work this study inevitably had to perform a large 
number of comparisons. 88 primary comparisons were performed. Using the traditional 5% 
significance level this would be expected to give a positive result in 4-5 comparisons. 
However, the picture is a little more complicated because many of the classifications of the 
VMB have significant overlap (for example VMB type/CST/group according to Lactobacillus 
dominance and the interdependencies of individual taxa). Therefore, a positive or negative 
finding using one classification system would be expected to correlate to a positive or 
negative finding using another (similar) classification system.  
The statistical analysis is further complicated because this study involved a combination of 
confirmatory analysis (for methods of VMB data reduction that had previously been linked 
to risk of PTB, such as those described in Table 4.3), and exploratory analysis using the 
bacterial types, bacterial groups and the BactQuant assay to estimate concentrations of 
bacterial groups which was applied to the field of PTB research for the first time in this 
study. This means that for some components an exploratory analysis is more appropriate, 
but for others a confirmatory analysis is more appropriate.  
Given that preterm labour is best described as a pathological condition with multiple 
aetiologies,21  it would not be expected that a single VMB characteristic would have a 
strikingly strong association with PTB, and small contributions to PTB risk in limited 
numbers of participants may best explain the contribution of the VMB to PTB. Therefore, in 
order to fairly present the data, the hypothesis-driven variables that we designed (VMB 
types, and presence/absence, relative abundance and concentration of bacteria in each 
’bacterial group’) were not adjusted for multiple comparisons (16 calculations). 
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In order to account for the large number of analyses performed within the confirmatory 
analysis component of the study (75 calculations), the Benjamini-Hochberg false discovery 
rate (FDR) procedure157 was performed for associations with early sPTB/PPROM within the 
high-risk cohort, with an FDR rate of 25%. However, mindful of the propensity of this 
method to produce type II statistical errors the results were also viewed holistically and 
findings that appeared to confirm trends seen in previous studies were also highlighted, 
and a full description of the association observed described even if this did not meet the 
significance level at 0.05%, before or after correction for multiple testing. 
3.10.5 Management of missing data 
Within the high-risk group the co-variates of BMI and smoking had one and two missing 
values respectively. The adjusted bimodal logistic regression was performed both without 
these participants, and with the participants assuming they did, then didn’t, smoke and had 
a low and high BMI. The results did not materially change, and so the adjusted bimodal 
logistic regressions are presented with exclusion of participants with missing data in order 
to present the raw data. 
3.10.6 Consideration of core outcome sets 
The CROWN initiative has defined a core outcome set for PTB.158 We report on PPROM, 
birthweight, and gestational age at birth. There were no cases of maternal mortality. The 
remainder of the core outcome set is not relevant to this study.  During the course of the 
research, the PREBIC consortium159 made recommendations for a minimum dataset for 
research on the VMB in PTB.99 Despite the recommendations not having been formulated 
during data collection, 24/26 of the ‘essential’ criteria are presented, and 11/18 of the 
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Table 3.5: Essential criteria for VMB in PTB studies as defined by PREBIC consortium99  
Item required Detail or reason for absence 
Age Table 5.3  
Race/ethnicity Table 5.3 
Parity Table 5.3 
BMI Table 5.3 
Smoking status Table 5.3 
History of sexual transmitted 
infection Information not collected 
History of PTB Table 5.3 
Indication of previous PTB All previous PTB either sPTB <34 weeks or after PPROM <34 weeks. Details in Table 5.3 
Information on included 
singleton/multiple pregnancy All singleton pregnancies  
Exclusion of other complications 
in pregnancy leading to PTB 
Study team cases of PTB other than sPTB or 
PPROM. Figure 5.1  
Information on use of antibiotics 
before sampling Table 5.3 
Information on use of antibiotics 
after sampling Data not collected 
Adequate assessment of 
gestational age 
All pregnancies had ‘dating’ scan prior to 14 
weeks gestation  
Gestational age at sampling Table 5.3 
Single or longitudinal sampling Two sampling timepoints, approximately 16 and 20 weeks gestation 
Information on primary swab 
HydraFlock standard tapered swabs,  
(Medical Wire and Equipment, Corsham, 
England) 
Sample location All swabs taken and stored at Liverpool Women’s Hospital, UK 
Information on primers used ‘PCR amplification and 16S rRNA gene sequencing’ section 3.7.2 
Range of bacteria covered by 
primers 
Good coverage of vaginal microbiota, as 
described by Van der Pol et al160 
Attrition record Figure 5.1 
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Table 3.5 continued 
Item required Detail or reason for absence 
Definition of PTB Section 3.5 
Indication for PTB of index 
pregnancy Table 5.3 
Stratification of PTB by 
phenotype 
Attempted, but as described in section 7.3 no 
difference identified and data presented as a 




Not applicable because over 90% of 
population white.  
Analysis of lactobacilli to species 
level Table 6.6 and Table 7.6  
Other interventions for PTB 
excluded (eg cerclage, pessary) 
Women with interventions for PTB not 
eligible for recruitment. Participants with 
interventions after VMB analysis are 
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Table 3.6: Desirable  criteria for VMB in PTB studies as defined by PREBIC consortium99 
Item required Detail or reason for absence 
Marital status Not collected 
Socioeconomic status Table 5.3 
Alcohol use Not collected 
Substance use Not collected 
Gestational age of previous PTB All previous PTB were sPTB or PPROM 16
+0 -33+6 
weeks 
History of late miscarriage Table 5.3 
History of LLETZ Table 5.3 
Date of last sexual intercourse prior to 
sampling 
Participants asked to abstain for 48 hours prior 
to sampling  
Reported history of douching Not collected 
Self collected or physician collected 
samples Physician collected 
Measurement of cervical length Table 5.3 
Use of fetal fibronectin Table 5.3 
Measurement of pH Not collected 
Simultaneous cultivation Not performed by research team 
Objective measurement of BV by 
microscopy Not performed by research team 
Consent to use specimens Consent documented for ‘gifting’ of samples to other ethically approved research 
Other subtypes of PTB (< 34 weeks, 
<28 weeks) 
Primary outcome sPTB or PPROM <34 weeks. 
Insufficient sample size to justify further 
subtypes  
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4 Vaginal microbiota characteristics  
In order to assess whether VMB characteristics that had previously been associated with 
preterm birth were reproducible in our population we summarised VMB in PTB studies.  
Three further methods of VMB characterisation were also developed based on published 
literature on the VMB in non-pregnant women and applied to PTB research for the first 
time. 
4.1 Previous work assessing the vaginal microbiota and preterm birth 
In order to identify previously published associations between VMB characteristics and PTB 
a PubMed search was performed on 14.1.20 as shown in Table 4.1  
Table 4.1: PubMed search terms (all fields) 
Search number Search terms Number of studies identified 
1 Preterm* OR premature* 220182 
2 Vagin* AND microbiota 1491 
3 Birth OR labour 367152 
4 1 AND 2 AND 3 limit to English language 131 
 
Abstracts and/or full text papers were then reviewed to select studies using the 
following criteria: 
Inclusions: 
• Observational cohorts, case-control or cross-sectional studies that used next 
generation sequencing or 16S rRNA qPCR to primarily assess the relationship 
between vaginal microbiota and preterm birth, preterm premature rupture of 
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Exclusions: 
• Case reports and case series that analysed the effects of interventions, such as 
vaginal pessary and cervical cerclage, on the lower genital tract microbiota or on 
PTB 
• Studies that included women with symptoms of preterm labour or preterm 
premature rupture of membranes at the time of sampling 
• Studies that included first trimester miscarriage within the PTB outcome 
Studies that included women at high and low risk of preterm birth, with or without preterm 
birth prevention treatment were included. This methodology identified 14 articles from 
which data was extracted, as shown in the PRISMA flow diagram161 (Figure 4.1). 
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PRISMA 2009 Flow Diagram 
 
  
Records identified through 
MEDLINE search 
























Additional records identified 
through other sources 
(n = 1 ) 
Records after duplicates removed 
(n = 131) 
Records excluded 
(n = 97) 
Full-text articles excluded 
(n =  20) 
• Did not use Next 
Generation 
Sequencing or 16S 
qPCR to quantify 
vaginal microbiota 
(n=7) 
• Primary outcome not 
preterm 
birth/PPROM (n=6) 
• Included women with 
symptoms of 
PTB/PPROM (n=5) 
• Meta-analysis of 
previous work (n=1) 
• Review article (n=1) 
Articles from which data 
are extracted 
(n =  14) 
Figure 4.1: PRISMA flow diagram showing selection of studies used to identify VMB characteristics 
previously associated with PTB 
Full-text articles assessed 
for eligibility 
(n = 34) 
Records screened 
(n =  131) 





























































































































Number of term birth 
participants 72 34 20 27 184 85 53 37 170 356 36 432 90 100 
Number of PTB participants 18 15 20 13 44 50 24 14 46 94 60 107 45 25 
Inclusion of sPTB cases ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✘ ✓ ✓ ✓ 
Inclusion of PPROM cases ✓ ✓  ✓ ✘ ✓ ✓  ✓  ✓ ✓ ✓ ✓ 
Inclusion of medically indicated 
PTB ✘ ✓ ✘ ✘ ✘ ✓ ✓ 
 ✘ ✘ ✘ ✘ ✘ ✘ 
Percent of PTB under 34 weeks 100% 20% 100% (<35)  52% 58% 33% 
 13% 




 Gestation of sampling (weeks) 6-birth 10-birth 
21-
25+6 9-24 16-34 6-birth 6-36 6-25












16S rRNA sequencing ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✘ ✓ ✓ ✓ ✓ ✓ 
Variable region sequenced 1-3 3-5, 4 4 4 1-3 4 1-3, 3-5 4  4 1-2 3-4 1-3 
4 
qPCR of 16S rRNA gene ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✓ ✘ ✘ ✓ ✘ ✘ 
Alternate NGS of eukaryotic 







ancestry 6% 59% 50% 0% 65% 23%  24% 60% 73% 51% 21% 14% 
 
Black/African American 87% 4% 50% 100% 19% 59% 69% 76% 2% 7% 23% 75% 78%  
Asian  12% 0% 0% 17% 4%  0% 14% 4% 26%    
Other/mixed 6% 25% 0% 0% 0% 13% 31% 0% 24% 16% 0% 4% 7%  
 Control for confounders (either 





ethnicity ✘ GA at sampling Ethnicity ✘ GA at sampling Age, BMI, ethnicity Ethnicity Age, race, income Parity, ethnicity 
Relationship between VMB and PTB 
suggested ✘ ✓ ✘ ✓ ✓ ✓ ✓ ✓ 
✘ ✓ ✓ ✓ ✓ ✓ 
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Table 4.2: Characteristics of studies used to identify VMB characteristics and taxa of interest. Abbreviations: qPCR, quantitative PCR; NGS, next generation sequencing; BMI 
body mass index; GA gestational age. *Alternate NGS of eukaryotic DNA was performed by cpn60 universal target sequencing168 and Whole shotgun 
metagenomic/metatranscriptomic sequencing110. ✓=’yes’, ✘=’no’. Grey=not available/not applicable. 
 
 
4.2 Identification of vaginal microbiota characteristics of interest  
For each of the 14 included studies (Table 4.2) the main manuscript was first assessed, and 
all VMB characteristics that the authors identified within their main manuscript as showing 
a relationship with PTB were recorded. The ‘relationship with PTB’ was included if the 
authors had identified a difference in the VMB parameter between participants who had 
term and preterm births, using each individual study’s method for participant recruitment, 
PTB classification, VMB data analysis, and test of significance. The remaining 13 studies 
were then reviewed to identify whether a comparable method of VMB data reduction was 
used in the other studies, and if so whether this identified an association with PTB, or not. 
This secondary analysis utilised all available parts of the manuscripts including 
supplementary results where available. For individual taxa where it was apparent that the 
study had identified this taxon within their sequencing data (either by reviewing heatmap 
results or lists of taxa identified), and then a biomarker discovery method was used, such as 
LEfSe170 (Linear discriminant analysis effect size), if the biomarker discovery method did not 
highlighted this taxon as having a relationship with PTB then this was classified as having 
been measured and showing no affect. When there was no evidence either within the main 
document or supplementary material of a taxon having been identified then this was 
judged to be not measured. For some individual taxa testing of the association between the 
taxon and PTB was inferred within the manuscript or supplementary material and no 
association was reported, but the statistical test results are not shown, or the level of 
assessment is uncertain. This discrepancy is noted within the resultant table, but did not 
alter the decision about whether a taxon was selected for analysis, or not. 
Taxa of interest and VMB data reduction methods were retained for analysis if the method 
had shown an association with PTB in two or more previous studies, irrespective of whether 
this relationship was in the same direction, for example the opposing findings about 
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bacterial load in Freitas et al168 and Elovitz et al.101  In addition it was acknowledged that the 
sequences for BVAB1, BVAB2 and BVAB TM7 have only recently become available, and so 
despite single studies showing a relationship between these taxa they were retained 
because historical studies would not have been able to assess these. Two further taxa were 
retained as ‘taxa of interest’ despite a relationship with PTB only having been identified in 
single studies: Lactobacillus jensenii, retained to maintain assessment all of the major 
vaginal Lactobacillus species; and Bifidobacterium breve, retained because of the plausible 
relationship with a reduction in inflammation171 and its candidacy as a non-Lactobacillus 
‘protective’ taxon. This produced six VMB data reduction methods and 23 taxa of interest 
for analysis in the present study (Table 4.3)







































































































































Species richness    Û Û  ↑ ↑ Û  ↑    
Species diversity (alpha 
diversity) Û ↑ Û Û Û  ↑ ↑ Û Û Û Û ↑ 
Û 
Community State Types (CSTs) 




  Û 
 
IV ↑  IV ↑ CST I ↓ 
Û 
Group according to 
Lactobacillus relative 
abundance 
    Û Low lactos   
 
 Low lactos   Û 
Instability      ↑ ↑    ↑  Û  

















Lactobacillus species Û ¯  Û Û ¯ Û ↑   ¯   ¯ 
Lactobacillus crispatus Û    ¯ ¯ Û Û  ¯ Û Û ¯  
Lactobacillus iners Û    ↑ Û Û Û  ¯ Û ↑ Û  
Lactobacillus jensenii Û    Û ¯ Û Û  Û Û Û Û  
Lactobacillus gasseri Û    Û ¯ Û Û  ¯ Û Û Û  
Aerococcus Û   ¯ Û ↑ Û Û  Û  Û ↑  
Atopobium vaginae Û    Û ↑ Û Û  Û Û ↑ Û  
Bifidobacterium breve     Û Û Û Û Û  ¯ Û Û   
Clostridiales BVAB2 Û     Û Û     Û ↑  
Dialister Û   Û Û ↑ Û ↑  Û ↑ Û ↑  
Gardnerella vaginalis  Û ↑  Û Û ↑ Û Û  Û Û Û Û  
Lachnospiracea BVAB1 Û     Û Û     Û ↑  
Mageeibacillus indolicus            ↑   
Megasphaera Û   Û  Û Û ↑  Û Û ↑ ↑  
Mobiluncus     Û ↑ Û ↑    ↑   
Mycoplasma     Û ↑ Û ↑    Û Û  
Parvimonas Û   Û Û  Û ↑   ↑  ↑  
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Peptoniphilus     Û ↑ Û ↑  Û ↑ Û  ↑ 
Prevotella Û   ¯ Û ↑ Û ↑  Û ↑ Û ↑  
Porphyromonas species    Û   Û ↑    ↑   
Sneathia species Û   ¯ Û Û Û   Û Û ↑ ↑  
Streptococcus species Û   Û Û ↑ Û ↑  Û ↑ Û Û  
BVAB TM7-H1 Û     Û Û      ↑  
Ureaplasma species Û ↑   Û Û Û ↑   Û Û Û  
Table 4.3: VMB characteristics and taxa of interest identified as having an association with PTB in previous literature. Abbreviations: BVAB1, BV-associated bacterium type 1; BVAB TM7, BV-
associated bacterium (phylum TM7); Lactos, Lactobacillus species; CST, community state type, as first described by Ravel et al98. CST is variably defined over the studies but in the positive 
associations CST I is characterised by dominance of L. crispatus, CST III is characterised by dominance of L. iners and CST IV is characterised by non-dominance of Lactobacillus and a VMB made 
up of mixed bacterial species. Findings associated with preterm birth in previous studies. ¯=reduced in preterm birth cases compared to term, ↑=increased in preterm birth cases compared to 
term, dark grey= not assessed or not available Û on white background = tested and no difference clearly shown in manuscript and/or supplementary material , Û on light grey background= 
testing is inferred within manuscript and/or supplementary material and no difference shown but statistical tests not shown and/or level of assessment is unclear
4.3 Vaginal microbiota characterisation methods chosen 
Based on Table 4.3 six methods of VMB data reduction that had previously shown an 
association with PTB were selected. 
 Richness 
This was calculated by counting the number of discrete ASVs, identified in each sample. 
4.3.1.1.1 Simpson Diversity Index  
This is a value from 0-1 calculated by: 
 
Key 
D  Simpson diversity 
n Relative abundance of each taxa  
N  Total number of taxa in the sample 
 
Simpson’s diversity index is the probability that two taxa drawn at random from an 
infinitely large community will be different species. Simpson's diversity index is expressed 
as the reciprocal (1 minus the diversity), meaning that higher values represent higher 
diversity.  
 Community State Types 
Each sample was allocated to one of five mutually exclusive groups defined by the 
dominance of a particular species of Lactobacillus, or a group with non-dominance of a 
Lactobacillus species. Table 4.4 shows the community state type definitions used, as first 
described by Ravel et al.84 
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Table 4.4: Description of the Community State Types (CSTs) 
 
 Groups based on relative abundance of Lactobacillus species 
Each sample was allocated to one of three mutually exclusive groups based on the relative 
abundance of Lactobacillus species as described by Brown and MacIntyre et al.103,172,173 
These were: (1) Lactobacillus dominant (≥75% Lactobacillus species); (2) Intermediate (50-
74.9% Lactobacillus species); and (3) Lactobacillus deplete (≤50% Lactobacillus species). 
 Stability groups 
Only participants who had valid VMB sample results available for both study visits 
(approximately 16 and 20 weeks gestation) were eligible for this analysis. Each eligible 
participant was allocated to a mutually exclusive stability group (Table 4.5). These groups 
were based on the method used by Romero et al, 95 modified to account for only two visits.  
  
Community State Type 
(CST) 
Dominant species 
I Lactobacillus crispatus 
II Lactobacillus gasseri 
III Lactobacillus iners 
IV Group without dominance of a Lactobacillus species 
V Lactobacillus jensenii 
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Table 4.5: VMB stability groups. LD, Lactobacillus Dominant 
Group name Descriptor 
Same Lactobacillus 
Both visits ≥75% relative abundance of Lactobacillus with the 
same Lactobacillus dominance at each (either L.iners, 
L.crispatus or other Lactobacillus) 
Different 
Lactobacillus 
Both visits ≥75% relative abundance of Lactobacillus with 
different Lactobacillus dominance at each (either L.iners, 
L.crispatus or other Lactobacillus) 
Remain non-LD Both visits <75% relative abundance of Lactobacillus 
Non-LD to LD 
First visit <75% relative abundance of Lactobacillus to second 
visit ≥75% relative abundance of Lactobacillus 
LD to non-LD 
First visit ≥75% relative abundance of Lactobacillus to second 
visit <75% relative abundance of Lactobacillus 
 
 The presence/absence and relative abundance of taxa of interest 
Taxa that had previously shown a relationship to PTB, as described in section 4.1, were 
identified and two variables created: the presence/absence of each taxon and; if present, 
the relative abundance each taxon.  
4.3.2 New approaches 
The final three sets of VMB variables are based on previous work of the study team174–177 
and were applied to PTB research for the first time. 
 Vaginal microbiota types 
These VMB types are similar to Ravel’s CSTs84 but with an increased emphasis on 
pathobionts. These were based on VMB types described previously,175 and modified to 
apply to the pregnant population which is expected to have high relative abundances of 
Lactobacillus (Table 4.6). We defined pathobionts as bacteria that are considered more 
pathogenic than BV-anaerobes and that often co-occur with lactobacilli instead of BV-
anaerobes, such as streptococci. 
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abundance (RA)  
of Lactobacillus 
Further details 
L. crispatus Lcr  ≥75% 
Relative abundance of L. crispatus > 
relative abundance of other 
Lactobacillus species 
L. iners Li ≥75% 
Relative abundance of L. iners > 






Relative abundance of Lactobacillus 
>75% but not fitting Lcr or Li 
categories (mostly L. jensenii or L. 
gasseri dominated) 
Bifidobacterium BL <75% Relative abundance of Bifidobacterium > 50% 
Lactobacillus 
and anaerobes  
LA  ≥25% & <75% 
With relative abundance of 
Bifidobacterium < 50% 
Bacterial 
Vaginosis 
BV <25% With or without Gardenerella genus 
 
 Bacterial groups 
Each non-minority (present in at least 1 sample with a relative abundance of >1%) ASV in 
each sample was allocated to one of four ‘bacterial groups’176 based on the published 
literature (Appendix G): (1) lactobacilli; (2) BV-anaerobes (Actinobacteria, Bacteroidetes, 
Firmicutes, Fusobacteria, and Tenericutes except those included in the other 3 groups); (3) 
pathobionts (most Proteobacteria, and streptococci, staphylococci, enterococci, 
Spirochaetaceae, Listeria, C. trachomatis, and N. gonorrhoeae); and (4) “other bacteria” (a 
rest group, containing Actinobacteria that are known to be [facultative] aerobic skin 
bacteria, Bifidobacterium species, and difficult-to-classify minority species). Within each 
sample, read counts of ASVs belonging to the same bacterial group were summed. This 
resulted in four continuous relative abundance variables (one for each bacterial group) per 
sample, expressed as a percentage within each sample. Finally, we converted these 
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bacterial group relative abundances into estimated concentrations (again four continuous 
variables, one for each bacterial group) making use of the BactQuant results. 
 Bacterial load 
The total bacterial load was estimated by summing the concentration of all ASVs present in 
each sample. 
4.4 Summary 
We systematically reviewed the published literature to identify VMB variables that have 
been associated with PTB previously, and developed three new VMB variables for 
assessment based on the previous work of our group outside of pregnancy. We will now 
assess the distribution of these variables in low-risk pregnancies with term birth, and then 
whether these variables are able to detect characteristics associated with sPTB/PPROM in 
high-risk pregnancies.
 
5 Results- Demographic and clinical outcomes 
5.1 Recruitment 
A total of 227 low-risk women and 137 high-risk women were recruited between 2/6/2015 
and 23/11/2017. Two low-risk and three high-risk participants were excluded from the 
analysis because they did not have a sample that passed the quality control process as 
described in section 3.8.   
5.2 Pregnancy outcomes 
Birth outcomes for the low and high-risk populations are shown in Table 5.1 and Table 5.2, 
respectively. Based on the pregnancy outcomes 145 low-risk and 109 high-risk participants 
were retained for the primary analysis and a further 4 low-risk and 14 high-risk for 
supplementary analysis (Figure 5.1).  
Eleven high-risk participants (11/137, 8%) were excluded due to medically indicated 
preterm birth, two of which were prior to 34 weeks gestation (one case of maternal cancer 
requiring cytotoxic chemotherapy at 32+0 weeks gestation and one case of severe maternal 
anxiety due to previous poor pregnancy outcomes at 33+6 weeks gestation). There were no 
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Caregiver initiated preterm birth 0 0 
Early PPROM 
PPROM ≤33+6 weeks gestation with early 
chorioamnionitis 0 0 
PPROM ≤33+6 weeks gestation without 
early chorioamnionitis 2 0.9 
Late PPROM 
PPROM 34+0-≤36+6 weeks gestation with 
early chorioamnionitis 0 0 
PPROM 34+0-≤36+6 weeks gestation 
without early chorioamnionitis 0 0 
Early sPTB sPTB ≤33+6 0 0 
Late sPTB sPTB 34+0-≤36+6 2 0.9 
Unknown Unable to ascertain birth details 4 1.8 
Early term birth 
in low risk 
Birth 37+0-≤38+6 weeks in low risk 
population without PPROM 72 31.7 
No sample  All samples failed quality control 2 0.9 
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Table 5.2: Birth outcomes for high-risk participants 
Major 
classification 








Caregiver initiated preterm birth 11 8.0 
Early PPROM 
PPROM 16+0-33+6 weeks gestation with 
early chorioamnionitis 2 1.5 
PPROM 16+0-33+6 weeks gestation without 
early chorioamnionitis 10 7.3 
Late PPROM 
PPROM 34+0-≤36+6 weeks gestation with 
early chorioamnionitis 0 0 
PPROM 34+0-≤36+6 weeks gestation 
without early chorioamnionitis 2 1.5 
Early sPTB sPTB 16+0-33+6 10 7.3 
Late sPTB sPTB 34+0-≤36+6 12 8.8 
Unknown Unable to ascertain birth details 0 0 
No sample All samples failed quality control 3 2.2 
 
Figure 5.1: Selection of participants to retain for further analysis
Numbers Exclusions Numbers
NA Early term delivery 37+0-38+6 (low risk only) 72
11 Caregiver initiated preterm birth 0




Birth ≥ 37+0 weeks 
(without PPROM)
High-risk pregnancy
(Previous sPTB or PPROM <34 weeks)
High-risk early preterm
n=22




(Parous women with all previous births at term)
Low risk term
n=145









PPROM <34+0 weeks n=2
sPTB 34+0 -36+6 n=2
3 All samples failed quality control 2
5.3 Participant demographics 
The participant characteristics of the three groups retained for the primary analysis were 
broadly similar (Table 5.3), except for those that are known risk factors for sPTB/PPROM: a 
higher proportion of high-risk women with a recurrence, compared to those who delivered 
at term, had two or more previous early sPTB/PPROM events (31.8% vs. 9.2%) and multiple 
previous LLETZ or knife cone biopsies (13.6% vs. 1.1%). The median gestational age at 
sampling was slightly later in the low-risk group (16+5 weeks) than in the high-risk group 













Table 5.3: Participant characteristics by pregnancy risk group and outcome for primary analysis 
 
Age (years) mean (SD) 31.1 (4.5) 30.0 (4.5) 31.4 (5.4) 0.145 0.211
BMI ﻿(kg/m2)* median (IQR) 24.5 (22-29) 25 (22-28) 27.5 (22-35) 0.619 0.139
Current smoker* number (%) 15 (10.6) 15 (17.4) 5 (23.8) 0.096 0.537
White 139 (95.9) 81 (93.1) 22 (100.0)
Black 3 (2.1) 4 (4.6) 0 0.0
Asian 0 0.0 0 0.0 0 0.0
Other 2 (1.4) 0 0.0 0 0.0
Not recorded 1 (0.1) 2 (2.3) 0 0.0
0 0 0.00 9 (10.34) 1 (4.55)
1 102 (70.34) 43 (49.43) 10 (45.45)
2 36 (24.83) 27 (31.03) 4 (18.18)
≥ 3 7 (4.83) 8 (9.20) 7 (31.82)
1 79 (90.8) 15 (68.2)
﻿≥ 2 8 (9.2) 7 (31.8)
Nil significant 131 (90.3) 79 (90.8) 17 (77.3)
Single LLETZ 14 (9.7) 7 (8.0) 2 (9.1)
Multiple LLETZ or knife cone 1 (1.1) 3 (13.6)
Gestational age at first valid VMB 
sample (weeks)
median and IQR 16+5 (16+2-17+1) 16+2 (16+0-16+6) 16+3 (15+6-17+3) 0.000 0.794
16 weeks 41 (36-47.1) 35.5 (31-42) 36 (26.5-43.5) 0.000 0.578
20 weeks 41 (37-45) 35 (30-40) 30 (26-37) 0.000 0.097
16 weeks 7 (5-16) 7 (5-22) 9 (6-23.5) 0.766 0.410
20 weeks 7 (5-12) 7 (5-14) 7 (6-12) 0.274 0.914
None 139 (100.0) 61 (70.1) 17 (77.3)
Cervical cerclage 4 (4.6) 2 (9.1)
Progesterone 2 (2.3) 1 (4.5)
Arabin pessary 20 (23.0) 2 (9.1)
None 115 (79.3) 65 (74.7) 17 (77.3)
Metronidazole or clindamycin 0 0.0 4 (4.6) 1 (4.5)
Other antibiotic 21 (14.5) 9 (10.3) 3 (13.6)
Clotrimazole 1 (0.7) 0 0.0 0 0.0
Not recorded/ unsure 8 (5.5) 9 (10.3) 1 (4.5)
Antimicrobial in pregnancy prior to 
sampling (%)
0.038 0.895
Cervical length*  (mm)                  
(median and IQR)
qfFN* (ng/ml)                                   
(median and IQR)
Preterm birth prevention treatment 
used after study visit
na 0.097
Number of previous PPROM or sPTB 
16+0-33+6 weeks (%)
na 0.012
Previous cervical surgery na 0.033
Ethnicity (%) 0.540 0.732
Parity (%) 0.000 0.017
Low-risk pregnancy (LR) High-risk pregnancy (HR) P value LR 
vs HR
P value HR 
term vs 
HR 
Term birth n=145 Term birth n=87 Early sPTB or PPROM n=22
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Notes about Table 5.3 
*BMI has 1 missing value for low-risk and 1 for HR term birth. 
Smoking has 3 missing values for LR, and 1 each for HR term and 
early sPTB or PPROM . Cervical length at 16 weeks n=136 LR, n=80 
for HR-term, n=20 HR early preterm. CL at 20 weeks , LR n=135, HR 
term n=79, HR early preterm  n=14. qfFN at 16 weeks LR  n=142,  HR 
term n=77, HR early preterm n=20. qfFN at 20 weeks LR  n=136,  HR 
term n=75, HR early preterm n=19. Birthweight has 2 missing values 
for HR term and 2 missing values for HR early sPTB or PPROM. 
GROW birthweight centile138 LR n=138, HR  term birth n=83 and HR  
early sPTB/PPROM n=19. Parity was recorded as number of previous 
pregnancies with live births, or stillbirths ≥ 24+0 weeks gestation. 
Eligibility for the high-risk cohort included ≥1 sPTB or PPROM at 16+0 
to 33+6  weeks gestation. Therefore all high-risk participants with 
parity=0 had at least one previous late miscarriage. 16 weeks 
gestation is abbreviated for the first study visit that was carried out 
at 15+1-18+6 weeks and 20 weeks gestation indicates the second 
study visit that was carried out at 19+0-23+0 weeks  P values 
calculated using Student’s t-test for age,  Mann-Whitney U test for 
BMI, cervical length, qfFN and gestational age at sampling, and 




1 (most deprived) 74 (51.0) 50 (57.5) 15 (68.2)
2 19 (13.1) 6 (6.9) 2 (9.1)
3 24 (16.6) 9 (10.3) 2 (9.1)
4 20 (13.8) 11 (12.6) 2 (9.1)
5 (least deprived) 7 (4.8) 6 (6.9) 0 0.0 
Not recorded 1 (0.7) 5 (5.7) 1 (4.5)
None 145 (100.0) 0 0.0 0 0.0 
sPTB (≥1) 56 (64.4) 6 (27.3)
PPROM  (≥1) 28 (32.2) 13 (59.1)
≥1 pregnancy with 
PPROM and ≥1 
pregnancy with sPTB
3 (3.4) 3 (13.6)
None 145 (100.0) 69 (79.3) 20 (90.9)
1 17 (19.5) 1 (4.5)
≥2 1 (1.1) 1 (4.5)
Gestational age at 
PPROM (weeks+days)
median and range 31+1 (18+0-
33+6)
Gestational age at birth 
(weeks+days)






Birthweight (g)* mean (SD) 3594 (439) 3234 (489) 1778 (673)
GROW birthweight 
centile*








Type of previous PTB (all 
under 34 weeks) (%) na 0.003 















Term birth n=145 Term birth n=87 Early sPTB or 
PPROM n=22
5.4 Birthweight 
The GROW birthweight centile138 was calculated to facilitate comparison of birthweights 
across the groups despite differences in gestation at birth (Table 5.3 and Figure 5.2). High-
risk early sPTB/PPROM and high-risk term birth babies had a similar distribution of GROW 
birthweight centiles. There was a non-significant trend towards a lower GROW birthweight 
centile in the high-risk pregnancies than the low-risk pregnancies (p=0.102, Table 5.3). 
 
Figure 5.2: Birthweight centile by pregnancy outcome. Women were only included in this analysis if all 
components of the GROW calculation138 were available, as such low risk n=138, high-risk term birth n=83 and 
high risk early sPTB/PPROM n=19. 
 
5.5 Discussion about demographics 
5.5.1 Ethnicity 
Over 90% of participants in each group were white ethnicity. The 2011 UK census showed 
88.9% of Liverpool city residents to be of white ethnicity, so this is broadly in keeping with 
the local population.178 The vaginal microbiome has been reported as differing by 
ethncity,97 and analysis stratified by ethnicity has been advocated99 and performed.100 
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However, with so few Black, Asian and minority Ethnic (BAME) participants this analysis was 
not possible in our population. The study team considered restricting the analysis to 
participants of white ethnicity, however any positive findings would be expected to be 
applied to the population as a whole and was judged inappropriate. As such all participants 
were included in the analysis. 
5.5.2 Parity and number of previous PPROM or sPTB 
Parity is reported because it is recommended by the PREBIC consortium,99,159 however it is a 
little misleading because in the high-risk population all participants who were recorded as 
nulliparous had had a previous pregnancy loss after 16+0 weeks gestation. Therefore the 
number of previous sPTB/PPROM pregnancies is also given (Table 5.3). 
High risk participants with a recurrent sPTB/PPROM were more likely to have: a parity ≥3;  
≥2 previous sPTB/PPROM; and a history of both sPTB and PPROM (p=0.017, p=0.012 and 
p=0.003 respectively). Having had more previous preterm births is a recognised risk factor 
for preterm birth.179 Whether having had more previous sPTB/PPROM alters the VMB is 
unknown, but differences in the VMB during the first trimester by pregnancy history have 
been previously described,128 so this is possible.  
5.5.3 Gestation of sampling 
The low-risk group had a slightly later median gestation of first valid VMB sample than 
either of the high-risk groups (low-risk group 16+5 weeks, IQR 16+2-17+1; high-risk term birth 
16+2 weeks, IQR16+0-16+6; high-risk early sPTB/PPROM group 16+3 weeks, IQR 15+6-17+3 
weeks, p value for difference between high and low risk groups <0.000). This is likely to be 
because the high-risk cohort were offered recruitment at the preterm birth prevention 
clinic, which although targeted at 16 weeks gestation was often scheduled to fit with 
patient and clinic availability and in practice recruitment of some women was performed 
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during 15th gestational week. Conversely low-risk participants were offered recruitment by 
telephone and a specific study visit was arranged. This was arranged during the 16th or 17th 
gestational week. The vaginal microbiota is recognised to alter as pregnancy 
progresses.97,173 However, the median gestational age differences were only 2 and 3 days 
respectively between the low-risk and high-risk term/high-risk early sPTB/PPROM groups. 
Such a short difference in gestational age was felt to be unlikely to have a material effect on 
the VMB, and so no adjustment for gestational age at sampling was performed.  
5.5.4 Cervical length and quantitative fetal fibronectin 
These were primarily measured for other components of the ‘Biomarkers of Preterm Birth’ 
study,180 and reported within this work as recommended by the PREBIC consortium.99,159 
The cervical length of high-risk participants at both 16 and 20 weeks gestation was shorter 
than the low-risk group, as expected.181 The median cervical length at approximately 20 
weeks gestation (19+0-23+0 weeks) was 30mm in the high-risk early sPTB/PPROM group and 
35mm in the high-risk term birth group. Importantly this study excluded women who were 
using PTB prevention treatment at the time of their first visit/valid sample, in order to 
exclude alterations in the VMB that could be due to the PTB prevention treatment. PTB 
prevention treatment is normally offered to women with a short cervical length, as per UK 
standard practice.26 Therefore women with short cervical length are likely to be under-
represented in this study. 
5.5.5 Preterm birth prevention treatment used after the study visit 
The use of preterm birth prevention treatment (cervical cerclage, vaginal progesterone or 
Arabin pessary) after the study visit was broadly similar between the high-risk term (29.9%, 
21/87) and high-risk early sPTB/PPROM groups (22.7%, 5/22) (Table 5.3). We chose to 
retain women who used PTB prevention treatment after their vaginal sample collection in 
our analysis. This approach has recently been advised against182 as it is possible that women 
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destined to deliver preterm may have had their delivery delayed by the therapy, weakening 
the ability of our analysis to detect a relationship between the VMB and sPTB/PPROM.  
However, any future therapy developed based upon VMB analysis would likely be applied in 
combination with current treatments, and so by retaining these participants we were able 
to assess the contribution of the VMB to recurrent sPTB/PPROM within current clinical 
practice. 
5.5.6 Antimicrobial therapy in pregnancy prior to sampling 
High-risk participants were slightly more likely to have used an antimicrobial in the 
pregnancy prior to sampling (24.8%, 82/109) compared to the low-risk group (21.7%, 
40/145), p=0.038. However, there were only two participants (both high-risk) in whom the 
antibiotic was metronidazole or clindamycin; the antibiotics with the most evidence to 
support their use for the treatment of bacterial vaginosis.44 Supplementary analysis was 
performed to account for use of antimicrobials when a positive association was found 
between a VMB parameter and PTB.  
5.5.7 Index of multiple deprivation 
Liverpool Women’s Hospital is situated in the 4th most deprived local authority area in 
England (out of 343).140 A woman’s lived environment, including her diet, is likely to 
influence her vaginal microbiota.89 Given the differing recruitment processes for the low 
and high risk groups, including the need for extra hospital visits in the low risk group, we 
were concerned that participants with lower IMD scores may have been under-represented 
in the low-risk group. Reassuringly the IMD scores did not show a statistically significant 
difference between participants in each pregnancy outcome group (Table 5.3).   
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5.5.8 Birthweight 
The median GROW138 birthweight centile for the high-risk cohort who delivered at term was 
not statistically different to those who had an early sPTB/PPROM at 35.5 (IQR 18.5-63.1) 
and 35.9 (IQR 15.3-50.8) respectively (p=0.760) (Table 5.3). When comparing the low and 
high risk women the median birthweight centiles were 45.0 (IQR 23.2-71.9) and  35.5 
(IQR18.2-58.6) respectively. This difference was not statistically significant (p= 0.102) 
(Figure 5.2). The difference between the high and low risk groups is in keeping with 
previous literature showing common risk factors for preterm birth and growth 
restriction.121 Conversely in our high-risk group recurrence of early sPTB/PPROM did not 
seem to be associated with growth restriction, potentially suggesting that risk factors for 
recurrence are different for risk factors for growth restriction. 
5.5.9 Selection of covariates for multiple regression analysis 
The proposed multiple regression analysis was designed to understand the contribution of 
the VMB characteristics to recurrent early sPTB/PPROM, this is referred to as aetiological 
modelling.183 This contrasts to predictive modelling in which the aim is to design the best 
model to detect cases, irrespective of whether the variables are causative of the event.  
In order to optimise aetiological modelling the aim is to control for covariates which may 
have an effect upon both the variable (VMB) and the outcome (early sPTB/PPROM). 
Importantly the variable should not have an effect on the covariate. In aetiological 
modelling the covariates should be determined based on existing knowledge, rather than 
the data. It is irrelevant whether there is a direct relationship between the covariate and 
the outcome, although of course the covariate does need to have been reliably recorded. 
The study team considered including history of ≥2 previous sPTB/PPROM as a covariate 
within the logistic regression models, however it is uncertain how and why the number of 
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previous sPTB/PPROM would affect the VMB. Using obstetric history within aetiological 
modelling has previously been discussed as statistically problematic.184 Therefore obstetric 
history was not selected as a covariate. 
Cervical length may have an effect on the VMB, or conversely the VMB may affect the 
cervical length, so this was also considered an inappropriate co-variate. However, previous 
cervical surgery was deemed to be an appropriate covariate, because it may have an effect 
on the VMB, but the present VMB cannot have an effect on whether or not previous 
cervical surgery has happened,185 and previous cervical surgery has been comprehensively 
been shown to have an effect on risk of preterm birth.186  
Body mass index (BMI) was selected as a covariate because it may have an association with 
the VMB,187,188 and does have an effect on the risk of preterm birth.189,190 BMI was 
converted to a quadratic term due to the bimodal association with PTB. 
The final covariate selected was smoking at the time of enrolment. Smoking has been 
suggested to have an effect on the VMB outside of pregnancy,191 and is associated with 
preterm birth.192 
 Given the small number of participants with our primary outcome (sPTB/PPROM <34+0 
weeks gestation), and therefore the limited number of covariates we could feasibly control 
for, the study team decided that three covariates was the maximum appropriate. Each of 
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5.6 Contributory factors to preterm birth 
5.6.1 Allocation of contributory factors to PTB 
All participants who had PPROM or sPTB <37+0 weeks gestation had a review of the clinical 
notes to ascertain whether there were clinically evident factors that may have contributed 
to the event. 54.2% of participants who had early sPTB/PPROM at 16+0-33+6 weeks (Table 
5.4) and 50% of participants who had late sPTB/PPROM (Table 5.5) had at least one 
contributory factor identified. The most common contributory factors to sPTB/PPROM 
<34+0 weeks were chorioamnionitis and cervical insufficiency. 
In the low-risk population there were two cases of PPROM without chorioamnionitis <34+0 
weeks gestation. In both cases there was a placental contribution to birth. Of the remaining 
two low-risk women who delivered preterm there was one late spontaneous PTB with a 
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Table 5.4: Details of factors that were identified as contributing to the event for women with PPROM or sPTB 
16+0-33+6 weeks gestation. Note contributing factors are not mutually exclusive, so total number of contributing 
factors are more than total number of pregnancies in each pregnancy outcome group. 
Contributing 
factors at birth 
High-risk participants Low-risk participants 
Total n=24 
PPROM 16+0-33+6 weeks 
sPTB 16+0-

















None 0 6 (60%) 5 (50%) 0 11(45.8%) 
Chorioamnionitis 2 (100%) 2 (20%) 1 (10%) 0 5 (20.8%) 
Placental 
dysfunction 
0 0 2 (20%) 2 (100%) 4 (16.7%) 
Extra amniotic 
infection 
0 0 0 0 0 
Polyhydramnios 0 0 1 (10%) 0 1 (4.2%) 
Uterine anomaly 0 1 (10%) 0 0 1 (4.2%) 
Maternal 
comorbidities 
0 1 (10%) 1 (10%) 0 2 (8.3%) 
Cervical 
insufficiency 
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Table 5.5:Details of factors that were identified as contributing to the event for women with PPROM or sPTB 
34+0-36+6 weeks gestation. 
Contributing 
factors at birth 












None 1 (50%) 6 (50%) 1 (50%) 8 (50%) 
Chorioamnionitis 0 0 0 0 
Placental 
dysfunction 
0 1 (8.3%) 0 1 (6.3%) 
Extra amniotic 
infection 
0 0 0 0 
Polyhydramnios 0 0 0 0 
Uterine anomaly 0 0 1 (50%) 1 (6.3%) 
Maternal 
comorbidities 
0 0 0 0 
Cervical 
insufficiency 
1 (50%) 5 (41.7%) 0 6 (37.5%) 
Multiple 
contributing factors 
0 0 0 0 
Note: There were no cases of late PPROM with chorioamnionitis within 7 days. 
 
5.7 Discussion of contributory factors to preterm birth 
We used a modified version of the preterm birth classification system proposed by Villar et 
al in 2012141 to allocate contributory factors to the preterm birth cases. Villar et al 
developed the system for use in the INTERGROWTH-21st project to identify phenotypes of 
preterm birth across 8 countries between 2009 and 2014. The system was applied to 5828 
births under 37+0 weeks and was able to allocate a phenotype in 70% of births,193 slightly 
more than the 52.5% allocation in our study. The INTERGROWTH project included multiple 
pregnancies (which accounted for 10.4% of their preterm births) and medically indicated 
preterm births (which, by definition identify a contributory factor/phenotype). This is likely 
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to be why they were able to identify a contributory factor in more cases than we were. 
Infection, approximately equally split between chorioamnionitis and extrauterine infection, 
accounted for approximately 15% of INTERGROWTH preterm births, similar to the 12.5% 
(5/40) of all births under 37+0 weeks with chorioamnionitis as a contributing factor in the 
current study. Of note in the current study all of these were births under 34+0 weeks 
gestation, accounting for 20.8% of births <34+0 weeks. The INTERGROWTH project did not 
have access to cervical assessment data, so we are not able to compare this.  
A modified version of the Villar et al141 classification system has also been applied to 
preterm births in Ontario, Canada between 2012 and 2014.194 When isolated to 
spontaneous recurrent preterm births (n=1274) the authors identified phenotypes 
(comparable to our contributory factors) in 32% of preterm births (under 37+0 weeks 
gestation). This study did not identify any cases of chorioamnionitis as contributing to 
preterm birth but did attribute extra-amniotic infection to 18.4% (235/1274) of 
spontaneous recurrent preterm births. The current study had a wider definition of 
chorioamnionitis, and so these are likely to be different labels for a similar pathology. The 
Villar et al141 study also did not have access to cervical length assessments.  
An alternative phenotype allocation system was developed by Manuck et al to account for 
the likelihood that a particular factor contributed to the PTB (graded as 
strong/moderate/possible evidence).195 This was applied to 1025 births (of both high and 
low-risk women) under 34+0 weeks gestation in the United States of America and described 
possible cervical insufficiency in 11.6% of cases.195 Given that cervical insufficiency is a risk 
factor for recurrent preterm birth the higher rate in our population (5/22, 20.8%) is 
unsurprising. Manuck et al described possible and strong evidence of infection in 18% of 
births, and possible evidence of infection in a further 27% of births. The differential grading 
makes further comparison difficult, but in summary there appears to be some evidence of 
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infection contributing to preterm birth in between 10 and 40% of cases, and the rate 
appears higher in the earlier preterm births, as summarised by Lamont in 2015.196 
5.8 Conclusion of recruitment, pregnancy outcomes and 
demographics 
This study was able to meet the recruitment targets set within the initial funding bid.197 
There were 22 cases of recurrent early sPTB/PPROM available for analysis after recruitment 
of 137 high-risk women, along with 87 cases of high-risk term birth and 145 cases of low-
risk term birth. 14 cases of late sPTB/PPROM were available for supplementary analysis. 
The research team selected the covariates smoking, previous cervical surgery and BMI to be 
used in the multiple regression aetiological modelling based on previous literature. These 
were well recorded, with two or less missing values in the high-risk group for each 
covariate. 
Eleven high-risk participants were excluded from the analysis due to medically indicated 
late preterm birth. Without medical intervention these pregnancies may have progressed 
to term births, which potentially could have changed the composition of high-risk term 
birth group slightly. However previous early sPTB/PPROM is a risk factor for common 
obstetric complications such as growth restriction,198 indeed in this study babies of the 
high-risk participants had approximately a 10% lower birthweight centile than the low-risk 
participants. The poor obstetric history inevitably increases maternal anxiety, and often 
clinician anxiety too, increasing the chance of intervention, therefore this attrition is likely 
to be inevitable. The high rate of medically indicated late preterm births gives further 
justification for the decision to focus the primary analysis on early sPTB/PPROM; to both 
focus on the pregnancies with the worst morbidity and mortality and obtain a cleaner 
phenotype of sPTB/PPROM. Infection appears to play a stronger role in early sPTB/PPROM 
 
 
   
   102 
than late sPTB/PPROM, and so it is plausible that the VMB may have a stronger link to the 
earlier events too. 
The research team attempted to attribute contributory factors to the cases of preterm 
birth. This was not possible in approximately half of both early and late sPTB/PPROM cases. 
When it was possible the most common contributory factors identified were cervical 
insufficiency and chorioamnionitis. The higher rate of cervical insufficiency in this group 
with recurrent sPTB/PPROM is unsurprising compared to previous literature which has used 
mixed populations with primary and secondary sPTB/PPROM cases, often without 
knowledge of the cervical length in pregnancy. The other common contributory factor 
identified was chorioamnionitis. The vaginal microbiota is often thought to be the source of 
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6 Results- vaginal microbiota in low-risk women  
6.1 Overview 
This group was designed to describe the expected distribution of VMB characteristics in our 
local population in healthy, multiparous women who gave births at ≥ 39 weeks gestation. 
145 low-risk women were eligible for inclusion in the low-risk term birth group. 136 
participants had a VMB sample with a valid result at approximately 16 weeks gestation 
(15+1-18+6 weeks) and 129 participants had a VMB sample with a valid result at 
approximately 20 weeks gestation (19+0-23+0 weeks). For the majority of the analysis the 
first available sample was used, with the exception of two parts. Heatmaps were produced 
for samples at each visit to visualise the distribution of the VMB at each visit, and the 
stability analysis was performed on the subset of participants with valid results at each visit. 
6.2 Heatmaps 
The four most common taxa at both study visits were the Lactobacillus species of  L. iners, 
L. crispatus, L. gasseri  and L. jenseni. As described by Ravel et al95 the distribution of VMB 
characteristics broadly fell into 5 groups according to dominant species of lactobacilli, and 





Figure 6.1: Heatmap of 20 most abundant taxa in low-risk term birth group at 16 weeks gestation, n=136. 
 
Figure 6.2: Heatmap of 20 most abundant taxa in low-risk term birth group at 20 weeks gestation, n=129  
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6.3 Richness 
The median richness was 7, IQR 4-14, with a left skew to the data as shown in Figure 6.3. 
 
Figure 6.3: Richness in low-risk term birth group at 16 weeks gestation, n=145 
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6.4 Simpson diversity index 
The median Simpson diversity index was 0.38, IQR 0.07-0.53. The distribution showed a left 
skew, as displayed in Figure 6.4. 
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6.5 Community State Types 
The most common CST within the LR term birth group was I (L. crispatus dominance), 
corresponding to 29.7% (43/145) of participants. The distribution of all CSTs is shown in 
Table 6.1. 
Table 6.1: Distribution of CSTs in  low-risk term birth group n=145 
Community State Type n (%) 
I (L. crispatus) 43 (29.7) 
II (L. gasseri) 16 (11.0) 
III (L. iners) 31 (21.4) 
IV (mixed non Lactos) 35 (24.1) 
V (L. jensenii) 20 (13.8) 
Total 145 (100) 
 
6.6 Group according to Lactobacillus relative abundance 
The majority of participants (72.5%, 105/145) had a relative abundance of Lactobacillus 
over 75% (Lactobacillus dominance group). The distribution of all participants is shown in 
Table 6.2. 
Table 6.2: Distribution of group according to Lactobacillus relative abundance in low-risk term birth group, 
n=145 
Group according to Lactobacillus 
relative abundance n (%) 
Lactobacillus dominance 105 (72.4) 
Intermediate 14 (9.7) 
Lactobacillus deplete 26 (17.9) 
Total 145 (100.0) 
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6.7 Stability groups 
The majority of participants remained dominated by the same Lactobacillus species, or 
remained with a non- Lactobacillus dominant microbiota (Table 6.3). Only 5.4% (7/129) 
swapped from a state of Lactobacillus dominance to not, or vice versa. 
Table 6.3: VMB stability groups in the subset of low-risk term birth participants who had a VMB sample available 
for both study visits 
Change in VMB between 16 and 
20 weeks gestation (stability)                                                                              
n (%) 
Same Lactobacillus 83 (64.3) 
Different Lactobacillus 3 (2.3) 
Remain non-LD 29 (22.5) 
Non-LD to LD 7 (5.4) 
LD to non-LD 7 (5.4) 
Total 129 (100) 
n=129. LD, Lactobacillus Dominant 
6.8 Vaginal microbiota types 
The most common VMB type in the low-risk term birth group was Lcr (L. crispatus 
dominance), 26.9% of participants, closely followed by Lo (other Lactobacillus species) and 
Li (L. iners dominance). The VMB type ‘BL’ was notably rare, with only 2.8% (4/145) 
participants meeting this criterion. Bifidobacterium are proposed to be either protective of 
preterm birth,106 or at least not associated with an increased risk of PTB (Table 4.3). 
Therefore, a decision was made to combine the VMB types of BL (Bifidobacterium 
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Table 6.4: VMB type in low-risk term birth participants, n=145. 
VMB type  n (%) 
Lcr  39 (26.9) 
Li 32 (22.1) 
Lo 33 (22.8) 
BL 4 (2.8) 
LA 18 (12.4) 
BV 19 (13.1) 
Total 145 (100.0) 
VMB type was defined based on relative abundance of applicable taxa as follows:  (1) L. crispatus (Lcr; ≥75% 
lactobacilli of which L. crispatus was the most common); (2) L. iners-dominated (Li; >75% lactobacilli of which L. 
iners was the most common; (3) other lactobacilli-dominated (Lo; ≥75% lactobacilli of which L. jensenii or L. 
gasseri were the most common; (4) Bifidobacterium dominated (Bifidobacterium ≥50%); (5) lactobacilli, and 
anaerobes (LA; 25%- 75% lactobacilli); and (6) polybacterial G. vaginalis-containing (BV_GV; <25% lactobacilli 
and <50% Bifidobacterium). 
 
6.9 Taxa of interest 
We assessed the presence/absence, and if present the relative abundance of the 4 species 
of Lactobacillus and 19 taxa of interest identified in Table 4.3. All species of Lactobacillus 
and 18 of the taxa of interest were identified in at least one participant. Mageeibacillus 
indolicus was not identified in any participants and so excluded from further analysis. The 
percentage of participants with each taxon present, and median relative abundance (with 
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Table 6.5: Percentage of low-risk term birth participants with taxa of interest present, and when present median 
















crispatus 125 (86.21) 3.45 (0.82-94.19) 
Lactobacillus gasseri 47 (32.41) 20.44 (0.18-58.13) 
Lactobacillus iners 82 (56.55) 38.87 (5.09-86.28) 
Lactobacillus jensenii 53 (36.55) 21.16 (1.81-69.57) 
Relative 
abundance 
of taxon of 
interest (%)  
Aerococcus 24 (16.55) 0.82 (0.27-3.27) 
Atopobium vaginae 44 (30.34) 3.04 (0.27-14.17) 
Bifidobacterium breve  14 (9.66) 1.45 (0.27-31.70) 
Clostridiales BVAB2 11 (7.59) 2.36 (0.54-6.12) 
Dialister 34 (23.45) 0.27 (<0.1-0.72) 
Gardnerella vaginalis  57 (39.31) 15.44 (0.91-33.51) 
Lachnospiracea 
BVAB1 3 (2.07) 0.18 (<0.1-32.97) 
Megasphaera 21 (14.48) 9.90 (6.09-12.81) 
Mobiluncus 4 (2.76) 0.18 (<0.1-0.50) 
Mycoplasma 2 (1.38) 0.91 (0.82-1.00) 
Parvimonas 15 (10.34) 0.63 (0.18-2.36) 
Peptoniphilus 26 (17.93) 0.18 (0.18-0.45) 
Prevotella 57 (39.31) 0.91 (0.27-6.99) 
Porphyromonas 
species 7 (4.83) 0.18 (<0.1-0.99) 
Sneathia species 14 (9.66) 4.77 (1.18-10.90) 
Streptococcus species 19 (13.10) 0.27 (<0.1-10.8) 
BVAB TM7-H1 2 (1.38) 7.20 (2.0-12.3) 
Ureaplasma species 26 (17.93) 0.22 (0.18-0.45) 
 
6.10 Bacterial groups 
All taxa present in the ASV table (section 3.7.5) were allocated to one of four bacterial 
groups (Appendix G) as follows: (1) lactobacilli; (2) BV-anaerobes (Actinobacteria, 
Bacteroidetes, Firmicutes, Fusobacteria, and Tenericutes except those included in the other 
3 groups); (3) pathobionts (most Proteobacteria, and streptococci, staphylococci, 
enterococci, Spirochaetaceae, Listeria, C. trachomatis, and N. gonorrhoeae); and (4) “other 
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bacteria” (a rest group, containing Actinobacteria that are known to be [facultative] aerobic 
skin bacteria, Bifidobacterium species, and difficult-to-classify minority species). The 
presence/absence and if present relative abundance and concentration of taxa in each 
bacterial group is shown in Table 6.6 
Table 6.6: Presence/ absence and if present relative abundance and estimated concentration of taxa in each 
bacterial group in low-risk women with term births, n=145 
Bacterial group 
Presence/absence 
of bacterial groups 
Relative abundance of 
bacterial groups (%) 
Bacterial group 
concentration in log10 
cells/μl 
n  (%) Median IQR Median IQR 
Total Lactobacillus 143 (98.62) 98.64 (71.75-99.90) 7.31 (6.46-8.03) 
Total BV associated 109 (75.17) 3.00 (0.54-45.32) 6.40 (4.85-7.58) 
Total pathobionts 34 (23.45) 0.18 (<0.1-0.82) 4.33 (3.63-4.99) 
Total other bacteria 50 (34.48) 0.27 (0.18-0.64) 4.72 (4.14-5.63) 
 
6.11 Total bacterial load 
The total bacterial load was estimated by summing the estimated concentration of all taxa 
in each sample. The median bacterial load was 7.68 log10 cells/µL, IQR 6.80-8.35 log10 
cells/µL. The distribution is displayed in Figure 6.5. 
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Figure 6.5: : Distribution of total bacterial load in low-risk women with term births, n=145 
 
6.12 Discussion of vaginal microbiota in low-risk term group 
The VMB of the low-risk term birth group in the second trimester was predominantly 
comprised of Lactobacillus. Over 98% of participants had at least one species of lactobacilli 
present, and 72% of participants met our definition of Lactobacillus dominance by having 
over 75% relative abundance of  Lactobacillus. This is consistent with findings within the 
NIH microbiome project that found 78% of women of European ancestry had Lactobacillus 
dominance in pregnancies that progress to term births in the USA (n=40), at a similar 
gestation to our cohort.97 Analysis of the metadata available online for the largest group of 
pregnancies that have undergone VMB assessment in women that had term births shows a 
very similar picture, with 76% of white women having had a VMB dominated by 
Lactobacillus at 16-20 weeks gestation (68/90).101 This contrasts to 51% (161/313) of VMB 
assessments at 16-20 weeks having Lactobacillus dominance in women of black ethnicity in 
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the same study. This is consistent with the previously recorded differences in VMB 
composition by ethnicity.97 
The VMB of the majority of our low-risk participants had relatively low species richness, 
with a median of only 7 species observed (IQR 4-14), although there was a left skew to this 
data with a maximum richness of 48 species. This is consistent with the original study 
assessing the VMB in uncomplicated pregnancies with term births, in which analysis of 
metadata available online shows a median richness of 9 species, IQR 7-14 (n=22).95 This is 
markedly less than the median richness of non-pregnant women of reproductive age, which 
was 19, IQR 10-30 (n=32) in the same study, and consistent with later studies that have 
confirmed a lower richness in pregnancy compared to non-pregnant women.199 
Comparisons of species richness between VMB studies are particularly vulnerable to be 
differences inherent in the DNA extraction, sequencing techniques and downstream 
processing of each study.107 This is because an extraction technique may not lyse certain 
types of cells, a primer set may preferentially amplify certain types of bacteria more than 
others, and each study will choose to rarefy at a different depth. However, those that have 
measured richness in a similar manner to the present study have found that participants 
who had a term birth have similar median richness to our study of approximately 4.5,102 
8,103 and 12166 species per sample, suggesting our findings are broadly in keeping with the 
published literature. 
We chose to express the Simpson diversity index as the reciprocal (1-D) whereas other 
recent studies have expressed this variable as an inverse (1/D). By converting the reciprocal 
to the inverse (inverse Simpson=1/(1-D)) it is possible to make comparisons with Brown et 
al103 and Fettweis et al.100  Our median Simpson diversity index (1-D) was 0.38, IQR 0.07-
0.53. This is equivalent to inverse Simpson index (1/D) of median 1.61, IQR 1.07-2.13. This is 
very similar to the median inverse Simpson diversity at 18+0-23+6 weeks of approximately 
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1.5 in pregnancies to progressed to term birth as sampled by Brown et al103 and 
approximately 1.8 in in pregnancies to progressed to term birth as sampled by Fettweis et 
al.100   
The most common VMB types and CSTs in the low-risk term birth participants were those 
dominated by L. crispartus, closely followed by the CSTs and VMB types with domination of 
L. iners and other species of lactobacillus. These findings are consistent with other VMB 
assessments in the second trimester of pregnancies that have progressed to term in 
Caucasian populations.97,101,106 In keeping with the differences in Lactobacillus dominance, 
previous work has also noted differences in the normal distribution of CSTs by 
ethnicity,96,97,101 and indeed the distribution of Lactobacillus dominance and CSTs in the 
current study was closer to that of previous studies in Caucasian populations106 than in 
women of African American ethnicity.95 
The VMB was notably stable for the majority of low-risk term birth participants who had 
both study visits available for analysis. Between approximately 16 and 20 weeks gestation 
64.3% (83/129) of participants remained dominated by the same lactobacilli, and a further 
22.5% (29/129) remained in a state of non-lactobacilli dominance. Only 2.3% (3/129) of 
participants became dominated by a different Lactobacillus and 7 (5.4%) of participants 
switched from lactobacilli dominance to non-lactobacilli dominance, or vice versa (Table 
6.3). This stability is also highlighted visually by the very similar heatmaps of the two visits 
(Figure 6.1 and Figure 6.2). The stability of the VMB in the second trimester is consistent 
with previous studies.95,97 
The stability of the VMB between the 16 and 20 week sampling has three benefits. Firstly, it 
suggests good reproducibility of our technique used to assess the VMB. The current study 
only used a single sample and VMB analysis method to assess the VMB at each time point, 
and early work into the VMB had raised concerns about poor reproducibility within VMB 
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assessment.200 Indeed, optimal assessment of the VMB would utilise multiple samples and 
sequencing techniques.110 However, this is rarely achieved in practice due to pressures of 
laboratory time and costs. The high VMB stability in this study indirectly suggests that there 
is good reproducibility within the current work, increasing the confidence in the accuracy of 
the results.  
Secondly the relative stability between the 16 and 20 week assessments suggests that it is 
reasonable to combine the VMB assessments at each time point. This increases the number 
of early sPTB/PPROM participants available for analysis from 17 to 22, increasing our 
statistical power. Thirdly the relative stability of the VMB between approximately 16 and 20 
weeks gestation suggests that, if there is a VMB characteristic associated with early 
sPTB/PPROM, there is potentially a window of time during which therapy could be given to 
modify the VMB, aimed at improving the pregnancy outcome. 
There was a notable minority of participants who had low-risk term births and a VMB that 
could be considered to have unfavourable characteristics.  21.4% of low-risk term birth 
participants had a VMB in CST III (L. iners domination), that has been associated with 
sPTB102 and 24.1% had a VMB in CST IV (Lactobacillus deplete), that has been associated 
with both sPTB and PPROM.101,106,162   Likewise, 32% (46/145) of low-risk term birth 
participants had a Simpson diversity index over 0.5, higher diversity has been associated 
with sPTB and PPROM in three studies.110,162,168  7.5% (11/145) of low-risk term birth 
participants also had a richness of 20 or greater, another VMB characteristic that has been 
(inconsistently) associated with sPTB/PPROM. 103,168 However, different analytical measures 
inhibit direct comparison. Likewise differential computation of the bacterial load101,168 
inhibited direct comparison of this metric with previous work. 
It is possible to directly compare the distribution of the group according to Lactobacillus 
relative abundance in the low-risk term birth group with that described in the term birth 
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group, as described by Brown et al.103 In the present study 17.9% (26/145) of low-risk term 
birth participants were Lactobacillus deplete (<50% relative abundance of lactobacillus), 
this is slightly higher than the 10% (3/30)173 at 20-22 weeks gestation and 2.7% (1/36)103 
and of term birth participants at 23-26 weeks gestation as described by Brown et al. This 
may partly be accounted for by the earlier sampling gestation, as the VMB tends to 
Lactobacillus dominance as pregnancy progresses.95,96 The difference could also be 
accounted for by different sequencing methods, the MacIntyre group103,173 at this time 
were using primers targeted at the V1-2 hypervariable regions, which could have 
preferentially sequenced the lactobacillui and led to under- sequencing of non-lactobacilli 
species such as Gardnerella vaginalis and Bifidobacterium bifidum.201 In contrast the 
current study used primers targeted at the V3-4 hypervariable regions, which recent 
research indicates gives a more accurate representation of non-lactobacilli species.201 
Therefore, whether the current population truly has more low-risk participants who go on 
to have term births with lactobacilli depletion than the London population, as sampled by 
the MacIntyre group, is unclear.  
It is also noteworthy that a small proportion of participants in the low-risk term birth group 
had rarer taxa that have previously been associated with PTB. For example, the recently 
sequenced BVAB TM7-H1 was reported as associated with preterm birth in the NIH funded 
vaginal microbiome study, and indeed appears not to have been present prior to 24 weeks 
gestation in pregnancies that delivered at term in that study (n=59).110 BVAB TM7-H1 was 
present in two (2/145, 1.3%) low-risk term birth participants in the present study (at 
relative abundances of 2% and 12.3% respectively). When assessing rare taxa in 16S rRNA 
sequencing studies it is important to consider the chance of spurious taxa due to 
undetected contamination or taxonomic mis-assignment.107 Nevertheless the presence of  
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BVAB TM7-H1 in 1.3% of our low-risk term birth participants is plausible given our larger 
sample size than the NIH funded vaginal microbiome study.110 
Six taxa that have been shown to be associated with sPTB/PPROM in three or more 
previous studies were present in a notable proportion of the low-risk term birth group: 
Dialister, Mobiluncus, Parvimonas, Peptoniphilus, Prevotella and Streptococcus. These taxa 
were present in 23.5%, 2.76%, 10.34%, 17.9%, 39.3% and 13.1% respectively of low-risk 
term birth pregnancies. Of note, when present the median relative abundances of these 
taxa were under 1% (Table 6.6), so in the majority of participants with these taxa present 
they comprised a small part of the whole VMB.  
It is important to be mindful that association does not imply causation. Within clinical 
practice it is fairly common for women at low-risk of preterm birth to be prescribed 
antibiotic treatment for asymptomatic bacterial vaginosis, despite lack of evidence of 
benefit in this situation.46,202 16S rRNA sequencing is not currently clinically applicable 
because of the long sequencing timeline. However, if this data had been available during 
pregnancy there could have potentially been un-necessary clinician and patient anxiety 
caused by the presence of unfavourable VMB characteristics. This group was particularly 
low-risk of preterm birth because they had all given birth before, and all births had been at 
term and without major obstetric complications.121 In the future, if more detailed VMB 
characteristics are clinically available, then this group of participants, who ultimately all had 
live births at ≥ 39+0 weeks gestation, may provide reassurance to clinicians and women 
faced with such information in pregnancy. 
Based on current evidence196 there is unlikely to be a single taxon, or even VMB 
characterisation method, that directly causes sPTB/PPROM. There are likely to be multiple 
protective factors that lead to term birth in the majority of pregnancies, as demonstrated in 
this low-risk term birth group. 
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6.13 Conclusion 
The low-risk term birth group have demonstrated the distribution of VMB characteristics in 
our population. This data will be used to compare to the high-risk group in the following 
chapter.  
The low-risk term birth VMB characteristics are in keeping with other pregnancy cohorts 
with term birth sampled in the second trimester, particularly in those of predominantly 
Caucasian ethnic origin. The VMB showed a high degree of stability between the two study 
visits (approximately 16 and 20 weeks gestation), this therefore justified the combination of 
study samples for both visits to increase statistical power. There was a notable minority of 
low-risk term birth participants who demonstrated VMB characteristics that previous 
studies have high-lighted as associated with preterm birth. These women had a very low 
baseline risk of preterm birth and are likely to possess multiple protective factors that 
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7 Results- vaginal microbiota in high-risk women  
7.1 Overview 
This chapter describes the outcome of our primary analysis: a nested case-control study of 
the contribution of the VMB to recurrent early sPTB/PPROM. The VMB is characterised of 
the 109 high-risk participants who had either term birth (≥37+0 weeks), sPTB <34+0 weeks or 
PPROM <34+0 weeks. Assessment is made of whether the VMB characteristics identified in 
chapter 4 are able to identify a contribution of the VMB to early sPTB/PPROM, using 
aetiological modelling. The VMB characteristics of the high-risk participants are presented 
alongside those of the low-risk term births in order to give a frame of reference for the 
expected distribution of our parameters within the local population. 
For the majority of analysis the first valid sample from each participant is used, with the 
exception of the stability analysis whereby only the subset of participants with samples 
available at both visits (approximately 16 and 20 weeks gestation) are included, and both 
samples used. 
7.2 Heatmap 
The relative abundance of taxa in each bacterial group, and the 13 taxa with the highest 
relative abundance assessed visually, did not show a clear difference by pregnancy 
outcome group (Figure 7.1). The most common taxa were the species of Lactobacillus: L. 
iners and  L. crispatus followed by all other types of Lactobacillus pooled.
 
Figure 7.1: Heatmap. This diagram depicts all samples (n = 254) on the x-axis. The top four rows of the y-axis show 
each amplicon sequence variants (ASVs) attributed to one of four mutually exclusive groups (appendix G). The lower 
bars on the y-axis show the 13 most common ASVs. The top bar depicts pregnancy outcome group. Abbreviations: 
BV, bacterial vaginosis; BVAB1, BV-associated bacterium type 1; BVAB TM7, BV-associated bacterium (phylum TM7). 
7.3 Assessment as to whether to analyse phenotypes together or 
separately 
In order to assess whether the early sPTB and early PPROM groups should be analysed 
together or separately, the VMB characteristics of richness, diversity, VMB type and 
bacterial load were initially visualised, looking for differences between early sPTB and early 
PPROM. These four VMB characteristics were selected because they assess different 
components of the VMB. 
7.3.1 VMB characteristics separated by type of preterm birth  
Graphical representation showed no difference in species richness (Figure 7.2), Simpson 
diversity (Figure 7.3), VMB type (Figure 7.4), or bacterial load (Figure 7.5) between high-risk 
participants with early sPTB or early PPROM. 
 
 
Figure 7.2: Richness of high-risk participants by pregnancy outcome in high-risk group. Dots show individual 
values, box plot shows median, interquartile range and whiskers show 2.5% and 97.5% percentiles. Difference 
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Figure 7.3: Simpson Diversity according to pregnancy outcome in high-risk group. Dots show individual values, 
box plot shows median, interquartile range and whiskers show 2.5% and 97.5% percentiles. Difference between 
early sPTB and early PPROM groups p-value= 0.129, Mann-Whitney U test 
 
Figure 7.4:  Distribution of VMB types by in participants with early PPROM (n=12) and early sPTB (n=10)  VMB 
type was defined based on relative abundance of applicable taxa as follows: (1) L. iners-dominated (Li; >75% 
lactobacilli of which L. iners was the most common); (2) L. crispatus (Lcr; ≥75% lactobacilli of which L. crispatus 
was the most common); (3) other lactobacilli-dominated or Bifidobacterium dominated (Lo+BL; either≥75% 
lactobacilli of which L. jensenii or L. gasseri were the most common, or Bifidobacterium ≥50%); (4) lactobacilli, 
and anaerobes (LA; 25%- 75% lactobacilli); and (5) polybacterial G. vaginalis-containing (BV; <25% lactobacilli 
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Figure 7.5: Bacterial load according to pregnancy outcome in high-risk group. Dots show individual values, box 
plot shows median, interquartile range and whiskers show 2.5% and 97.5% percentiles. Difference between early 
sPTB and early PPROM groups p-value= 0.742, Mann-Whitney U test 
 
Based on the similar distribution of VMB characteristics for high-risk participants with early 
sPTB and early PPROM, and in order to reduce the risk of false positive results due to 
multiple testing and false negative results due to lack of statistical power, the research 
team decided to combine these groups.  
 
7.4 Richness and Diversity 
In the high-risk women we did not identify any association between recurrent sPTB/PPROM 
and VMB richness or Simpson (1-D) diversity (Table 7.1) 
7.5 Community State Type 
In the  high-risk  women we  did not identify any association between recurrent 
sPTB/PPROM and allocation to CST95 group (Table 7.2) 
7.6 Group according to relative abundance of Lactobacillus 
In the high-risk women we did not identify an association between recurrent sPTB/PPROM 
and allocation to group according to relative abundance of Lactobacillus103 (Table 7.2). 
7.7 Vaginal microbiota stability 
The VMB of the majority of participants with samples available from both visits between 15 
and 23 weeks gestation was stable (Table 7.3). About two thirds of the high-risk (65.9%) 
and low-risk women (64.3%) were dominated by the same Lactobacillus species at both 
visits, and 14.8% of high-risk and 22.5% of low-risk women continued to have some degree 
of anaerobic dysbiosis. The remaining women switched Lactobacillus species (n=5) or 
fluctuated between lactobacilli-domination and anaerobic dysbiosis (n=12) or vice-versa 
(n=17). 
In the high-risk women we did not identify an association between recurrent sPTB/PPROM 
and allocation to categorical stability groups.95 
7.8 Vaginal microbiota types 
We did not identify an association between VMB type and reoccurrence of sPTB/PPROM 
(Table 7.4).
Table 7.1: VMB richness and diversity and the association with sPTB/PPROM in high risk women 
  Low-risk pregnancy (LR) High-risk pregnancy (HR) Unadjusted logistic 
regression model of HR ≥ 37 
vs <34 weeks (n=109) 
Adjusted** logistic 
regression model of HR ≥ 
37 vs <34 weeks (n=106)   Birth ≥39 weeks                             n=145 
All high-risk 
pregnancies                   
n=109 
Birth ≥37 weeks                                      
n=87 
sPTB or PPROM <34 




HR ≥ 37 
vs. <34 
weeks 
  Median  (IQR) Median  (IQR) Median  (IQR) Median  (IQR) OR 95% CI P OR 95% CI P 
Richness (n) 7 (4-14) 7 (4-15) 7 (4-15) 8 (5-14) 0.351 1.00 (0.94-1.06) 0.976 0.99 (0.93-1.06) 0.785 
Simpson 








0.45) 0.599 0.34 
(0.06-
1.99) 0.231 0.29 (0.04-2.18) 0.232 
Table 7.1 notes *P values based on Mann-Whitney U test for continuous variables **Logistic regression adjusted for body mass index (BMI) as a quadratic term, history of cervical surgery 
(none/single LLETZ/multiple LLETZ and/or knife cone biopsy) and smoking (yes/no at time of visit). The adjusted analyses excluded two high risk women with missing smoking data, and one 
high risk woman with missing BMI data, the remainder of the exclusions were because of collinearity within the regression. 
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Table 7.2: CST and group according to Lactobacillus relative abundance and the association with sPTB/PPROM in high-risk women 
  Low-risk pregnancy (LR) High-risk pregnancy (HR) Unadjusted logistic 
regression model of HR ≥ 
37 vs <34 weeks (n=109) 
Adjusted** logistic 
regression model of HR ≥ 
37 vs <34 weeks (n=106)   Birth ≥39 weeks                             n=145 
All high-risk 
pregnancies                   
n=109 
Birth ≥37 weeks                                      
n=87 
sPTB/PPROM 





HR ≥ 37 
vs. <34 
weeks 
  Number  (%) Number  (%) Number  (%) Number  (%) OR 95% CI P OR 95% CI P 
Community State Type                               
I (L. crispatus) 43 (29.7) 23  (21.1) 17 (19.5) 6 (27.3) 
0.848 
Comparator Comparator 
II (L. gasseri) 16 (11.0) 11  (10.1) 9 (10.3) 2 (9.1) 0.63 (0.10-3.78) 0.613 0.38 (0.04-3.95) 0.421 
III (L. iners) 31 (21.4) 33  (30.3) 26 (29.9) 7 (31.8) 0.76 (0.22-2.66) 0.671 0.55 (0.13-2.24) 0.402 
IV (mixed non Lactos) 35 (24.1) 29  (26.6) 25 (28.7) 4 (18.2) 0.45 (0.11-1.85) 0.271 0.43 (0.09-2.01) 0.287 
V (L. jensenii) 20 (13.8) 13  (11.9) 10 (11.5) 3 (13.6) 0.85 (0.17-4.17) 0.841 0.94 (0.17-5.12) 0.944 
Group according to 
Lactobacillus relative 
abundance             
  
Lactobacillus dominance 
(>75%) 105 (72.4) 80  (73.4) 61 (70.1) 19 (86.4) 
0.277 
Comparator Comparator 
Intermediate (50-74.9%) 14 (9.7) 6  (5.5) 5 (5.7) 1 (4.5) 0.64 (0.07-5.84) 0.69 0.91 (0.09-9.36) 0.940 
Lactobacillus deplete (<50%) 26 (17.9) 23  (21.1) 21 (24.1) 2 (9.1) 0.31 (0.07-1.42) 0.13 0.29 (0.05-1.53) 0.140 
Table 7.2 notes:.*P value calculated by Fisher’s exact test **Logistic regression adjusted for body mass index (BMI) as a quadratic term, history of cervical surgery (none/single LLETZ/multiple 
LLETZ and/or knife cone biopsy) and smoking (yes/no at time of visit). The adjusted analyses excluded two high risk women with missing smoking data, and one high risk woman with missing 
BMI data, the remainder of the exclusions were because of collinearity within the regression.  
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Table 7.3: Stability assessment and the association between VMB stability and recurrent sPTB/PPROM in high-risk women 
Stability: change in 
VMB between 16 
and 20 weeks 
gestation 
Low-risk 
pregnancy (LR) High-risk pregnancy (HR) Unadjusted logistic regression 
model of HR ≥ 37 vs <34 
weeks (n=88) 
Adjusted** logistic 
regression model of HR ≥ 37 
vs <34 weeks (n=84) Birth ≥39 weeks                             
n=129 
All high-risk 
pregnancies                   
n=88 
Birth ≥37 weeks                                      
n=71 
sPTB/PPROM 





HR ≥ 37 vs. 
<34 weeks Number  (%) Number  (%) Number  (%) Number  (%) OR 95% CI P OR 95% CI P 
Same lactobacilli 83 (64.3) 58  (65.9) 46 (64.8) 12 (70.6) 
0.579 
Comparator Comparator 
Different lactobacilli 3 (2.3) 2  (2.3) 1 (1.4) 1 (5.9) 3.83 (0.22-65.85) 0.354 4.40 (0.19-104) 0.359 
Remain non-LD 29 (22.5) 13  (14.8) 12 (16.9) 1 (5.9) 0.32 (0.04-2.71) 0.295 0.42 (0.04-4.11) 0.457 
Non-LD to LD 7 (5.4) 10  (11.4) 8 (11.3) 2 (11.8) 0.96 (0.18-5.11) 0.960 0.96 (0.16-5.90) 0.965 
LD to non-LD 7 (5.4) 5  (5.7) 4 (5.6) 1 (5.9) 0.96 (0.10-9.38) 0.971 0.41 (0.02-7.21) 0.543 
Table 7.3 notes: LD, Lactobacillus dominant.*P value calculated by Fisher’s exact test **Logistic regression adjusted for body mass index (BMI) as a quadratic term, history of cervical surgery 
(none/single LLETZ/multiple LLETZ and/or knife cone biopsy) and smoking (yes/no at time of visit). The adjusted analyses excluded two high risk women with missing smoking data, and one 
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Table 7.4 Distribution of VMB types by pregnancy outcome and the association between VMB type and recurrent sPTB/PPROM in high risk women:  
  Low-risk pregnancy (LR) High-risk pregnancy (HR) Unadjusted logistic regression 
model of HR ≥ 37 vs <34 weeks 
(n=109) 
Adjusted** logistic regression 
model of HR ≥ 37 vs <34 weeks                     
(n=106)   Birth ≥39 weeks                             n=145 
All high-risk 
pregnancies                   
n=109 
Birth ≥37 weeks                                      
n=87 
sPTB/PPROM <34 





≥ 37 vs. <34 
weeks   Number  (%) Number  (%) Number  (%) Number  (%) OR 95% CI P OR 95% CI P 
Lcr  39 (26.9) 23  (21.1) 17 (19.5) 6 (27.3) 
0.696 
Comparator Comparator 
Li 32 (22.1) 36  (33.0) 28 (32.2) 8 (36.4) 0.810 (0.24-2.74) 0.734 0.592 (0.15-2.34) 0.455 
Lo+BL 37 (25.5) 22  (20.2) 17 (19.5) 5 (22.7) 0.885 (0.23-3.48) 0.862 0.814 (0.17-3.79) 0.793 
LA 18 (12.4) 14  (12.8) 13 (14.9) 1 (4.5) 0.202 (0.02-1.89) 0.161 0.156 (0.01-1.98) 0.154 
BV 19 (13.1) 14  (12.8) 12 (13.8) 2 (9.1) 0.472 (0.08-2.75) 0.404 0.480 (0.07-3.24) 0.451 
Table 7.4 notes: P value calculated by Fisher’s exact test **Logistic regression adjusted for body mass index (BMI) as a quadratic term, history of cervical surgery (none/single LLETZ/multiple 
LLETZ and/or knife cone biopsy) and smoking (yes/no at time of visit). The adjusted analyses excluded two high risk women with missing smoking data, and one high risk woman with missing 
BMI data, the remainder of the exclusions were because of collinearity within the regression. VMB type was defined based on relative abundance of applicable taxa as follows: (1) L. iners-
dominated (Li; >75% lactobacilli of which L. iners was the most common); (2) L. crispatus (Lcr; ≥75% lactobacilli of which L. crispatus was the most common); (3) other lactobacilli-dominated or 
Bifidobacterium dominated (Lo+BL; either≥75% lactobacilli of which L. jensenii or L. gasseri were the most common, or Bifidobacterium ≥50%); (4) lactobacilli, and anaerobes (LA; 25%- 75% 
lactobacilli); and (5) polybacterial G. vaginalis-containing (BV_GV; <25% lactobacilli and <50% Bifidobacterium). 
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Table 7.5: Relative abundance of bacterial groups and taxa of interest by pregnancy outcome and association with sPTB/PPROM in the high-risk group  
 
Table 7.5 notes: Grey box, value not applicable due to no sample fitting this criterion. P values based on Fisher’s exact test for presence/absence and Mann-Whitney U test for relative 
abundance. Test of significance based on relative abundance includes all participants for relative abundance of bacterial groups and species of lactobacilli but is limited to only those 


























Total Lactobacillus 143 (98.62) 98.55 (69.75-99.90) 85 (97.70) 99.18 (53.04-99.90) 22 (100.00) 98.46 (91.64-99.82) 1.00 0.91
Total BV associated 109 (75.17) 0.82 (0.09-20.44) 62 (71.26) 0.64 (0-46-32) 19 (86.36) 1.14 (0.18-8.23) 0.18 0.74
Total pathobionts 34 (23.45) 0 (0-0) 20 (22.99) 0 (0-0) 4 (18.18) 0 (0-0) 0.78 0.73
Total other bacteria 50 (34.48) 0 (0-0.18) 35 (40.23) 0 (0-0.09) 10 (45.45) 0 (0-0.09) 0.81 0.89
Lactobacillus crispatus 125 (86.21) 2.00 (0.18-79.29) 71 (81.61) 1.09 (0.17-16.71) 18 (81.82) 1.73 (0.09-68.84) 1.00 0.84
Lactobacillus gasseri 47 (32.41) 0 (0-0.18) 31 (35.63) 0 (0-0.64) 5 (22.73) 0 (0-0) 0.32 0.28
Lactobacillus iners 82 (56.55) 0 (0-48.59) 63 (72.41) 21.98 (0-78.11) 13 (59.09) 16.21 (0-79.93) 0.30 0.76
Lactobacillus jensenii 53 (36.55) 0 (0-3.09) 24 (27.59) 0 (0-0.02) 9 (40.91) 0 (0-4.81) 0.30 0.30
Aerococcus 24 (16.55) 0.82 (0.27-3.27) 18 (20.69) 1.27 (0.54-1.81) 3 (13.64) 0.36 (0.18-0.36) 0.34 0.08
Atopobium vaginae 44 (30.34) 3.04 (0.27-14.17) 28 (32.18) 7.58 (0.77-13.81) 4 (18.18) 2.04 (1.14-7.81) 0.30 0.53
﻿Bifidobacterium ﻿breve 14 (9.66) 1.45 (0.27-31.70) 7 (8.05) 3.63 (0.36-10.90) 0 0.00 0.34
﻿Clostridiales BVAB2 11 (7.59) 2.36 (0.54-6.12) 10 (11.49) 1.68 (0.27-3.63) 2 (9.09) 2.45 (0.27-0.46) 1.00 0.83
﻿Dialister 34 (23.45) 0.27 (<0.1-0.72) 29 (33.33) 0.27 (0.18-0.82) 2 (9.09) 0.86 (0.18-1.54) 0.03 0.78
﻿Gardnerella vaginalis 57 (39.31) 15.44 (0.91-33.51) 33 (37.93) 18.62 (0.64-35.06) 10 (45.45) 11.26 (1.72-19.16) 0.63 0.22
﻿Lachnospiracea BVAB1 3 (2.07) 0.18 (<0.1-32.97) 4 (4.60) 16.03 (0.14-48.82) 1 (4.55) 16.26 1.00 1.00
﻿Megasphaera 21 (14.48) 9.90 (6.09-12.81) 18 (20.69) 10.40 (3.54-12.26) 3 (13.64) 19.26 (11.90-21.44) 0.56 0.04
Mobiluncus 4 (2.76) 0.18 (<0.1-0.50) 2 (2.30) 0.59 (0.27-0.91) 2 (9.09) 6.90 (0.27-13.5) 0.18 0.68
Mycoplasma 2 (1.38) 0.91 (0.82-1.00) 4 (4.60) 0.45 (<0.1-0.90) 1 (4.55) 0.18 1.00 1.00
﻿Parvimonas 15 (10.34) 0.63 (0.18-2.36) 12 (13.79) 0.45 (<0.1-1.18) 2 (9.09) 0.59 (0.27-0.91) 0.73 0.85
Peptoniphilus 26 (17.93) 0.18 (0.18-0.45) 21 (24.14) 0.18 (<0.1-0.54) 6 (27.27) <0.1 (<0.1-0.18) 0.79 0.22
﻿Prevotella 57 (39.31) 0.91 (0.27-6.99) 42 (48.28) 2.86 (0.18-11.35) 7 (31.82) 0.54 (0.18-0.91) 0.23 0.40
﻿Porphyromonas  species 7 (4.83) 0.18 (<0.1-0.99) 12 (13.79) 0.18 (<0.1-1.45) 1 (4.55) 0.45 0.46 0.41
﻿Sneathia species 14 (9.66) 4.77 (1.18-10.90) 15 (17.24) 1.81 (0.36-6.17) 2 (9.09) 3.45 (0.18-6.72) 0.52 0.82
Streptococcus species 19 (13.10) 0.27 (<0.1-10.8) 10 (11.49) 0.13 (<0.1-0.27) 2 (9.09) <0.1 (<0.1-<0.1) 1.00 0.23
BVAB TM7-H1 2 (1.38) 7.20 (2.0-12.3) 0 0.00 1 (4.55) 0.36 0.20
﻿Ureaplasma  species 26 (17.93) 0.22 (0.18-0.45) 11 (12.64) <0.1 (<0.1-0.36) 7 (31.82) <0.1 (<0.1-0.45) 0.05 0.84
High-risk pregnancy
Relative abundance 
of taxon of interest 
(%) 
Low-risk pregnancy
Relative abundance of 
species of Lactobacillus 
(%) 
Birth ≥ 39 weeks n=145 Birth ≥ 37 weeks n=87 sPTB or PPROM <34 weeks n=22
Relative abundance 
of bacterial groups 
(%)
P value HR ≥ 37 vs <34 
weeks
7.9 Taxa of interest 
We assessed the presence/absence and, if present, the relative abundance of the 4 species 
of Lactobacillus and 19 taxa of interest identified in Table 4.3. All species of Lactobacillus 
and 18 of the taxa of interest were identified in at least one participant. Mageeibacillus 
indolicus was not identified in any participants and was, therefore, excluded from further 
analysis. The percentage of participants with each taxa present, median relative abundance 
(with IQR) and association between presence/absence and early sPTB/PPROM in the high-
risk group are displayed in Table 7.5.  
Contrary to previous studies, the Dialister species was present in more high-risk 
participants who had term birth (29/87, 33.3%) than early sPTB/PPROM (2/22, 9.1%), 
p=0.03. Megasphaera species was only present in 3 high-risk participants with recurrent 
sPTB/PPROM, but when present, the relative abundance was higher (median 19.3%, IQR 
11.9-21.4) than in the high-risk participants with term births (median 10.5%, IQR 3.5-12.3), 
p=0.04 (Figure 7.6).  
The median relative abundance of Ureaplasma and BVAB TM7-H1 were very low, but 
Ureaplasma species and BVAB TM7-H1 were present in a higher proportion of women with 
recurrent early sPTB/PPROM (31.8% and 4.6%) than those without (12.6% and 0%;Table 
7.5, Figure 7.7). In contrast, Bifidobacterium breve was present in a lower proportion of 
women with a recurrence, but its relative abundance when present was also low. The 
proportions of low-risk women with these taxa present were similar to those in high-risk 
women without a recurrence (Table 7.5, Figure 7.7). These differences did not reach 
traditional statistical significance of p<0.05 (Figure 7.7). 
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Figure 7.6: Relationship between relative abundance of Megasphaera and pregnancy outcome. Analysis 
restricted to the subset of participants with Megasphaera present. Dots show individual values, box plot shows 
median, interquartile range and whiskers show 2.5% and 97.5% percentiles. P value calculated by Mann-
Whitney U test. 
 
 
Figure 7.7: Positive trends identified between presence/absence of taxa of interest and recurrent early (<34 
weeks) sPTB or PPROM (abbreviated to HR preterm for diagram), and low risk cohort for comparison. Dark 
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7.9.1 Benjamini-Hochberg false discovery rate (FDR) procedure 
The Benjamini- Hochberg false discovery rate (FDR) procedure157 was performed for the 
positive associations identified in Table 7.5 with an FDR rate of 25%. The associations 
between Ureaplasma and Megasphaera and high-risk pregnancy outcome were no longer 
statistically significant after accounting for multiple comparisons. 
7.10 Concentration of taxa in bacterial groups and total bacterial load 
High-risk women with an early PTB recurrence had a higher overall vaginal bacterial load 
(8.64 vs. 7.89 log10 cells/μl, adjusted odds ratio (aOR) 1.90, 95% CI 1.01-3.56, p=0.047) and a 
higher total estimated Lactobacillus concentration (8.59 vs. 7.48 log10 cells/μl, aOR 2.35, 
95%CI 1.20-4.61, p=0.013) than high-risk women without an early PTB recurrence (Table 
7.6, Figure 7.8).  These findings remained significant after adjustment for smoking, previous 
cervical surgery and BMI. The remainder of the bacterial groups and major species of 
Lactobacillus were not statistically different according to pregnancy outcome in the high-
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Figure 7.8: Concentration of total Lactobacillus by pregnancy outcome. Dots show individual values, scale shows 
mean and 95% CI of mean. P values quoted as difference between HR and LR cohort and between HR term and 
HR preterm within HR cohort (Mann-Whitney test). 
 
    
p=0.0017 
p=0.0018 
Table 7.6: Total bacterial concentration, concentration of taxa within each bacterial group and concentration of major species of Lactobacillus by pregnancy outcome and relationship to early 
sPTB/PPROM in the high risk group. 
 
Table 7.6 notes: * P values based on Mann-Whitney U test **Logistic regression adjusted for body mass index (BMI) as a quadratic term, history of cervical surgery (none/single LLETZ/multiple 
LLETZ and/or knife cone biopsy) and smoking (yes/no at time of visit). The adjusted analyses excluded two high risk women with missing smoking data, and one high risk woman with missing 




HR≥ 37 vs. 
<34 weeks 
n=109
P OR 95% CI P OR 95% CI P
Overall assessment
Bacterial load 7.68 (6.80-8.35) 7.89 (7.22-8.80) 8.64 (7.47-9.08) 0.030 1.78 (1.04-3.04) 0.035 1.90 (1.01-3.56) 0.047
Bacterial 
group
Total Lactobacillus 7.31 (6.42-8.01) 7.48 (6.87-8.45) 8.59 (7.47-8.87) 0.002 2.30 (1.28-4.13) 0.005 2.35 (1.20-4.61) 0.013
Total BV associated 5.41 (1.91-7.03) 5.20 (0-7.65) 6.65 (5.09-8.36) 0.111 1.14 (0.97-1.33) 0.102 1.15 (0.96-1.38) 0.126
Total pathobionts 0.00 (0-0) 0.00 (0-0) 0.00 (0-0) 0.639 0.94 (0.74-1.19) 0.596 0.93 (0.712-1.22) 0.596
Total other bacteria 0.00 (0-4.24) 0.00 (0-4.84) 0.00 (0-5.12) 0.612 1.04 (0.88-1.23) 0.671 1.04 (0.86-1.25) 0.698
Type of Lactobacillus
L. crispatus 5.88 (4.41-6.83) 6.17 (4.08-6.91) 6.32 (5.79-7.76) 0.188 1.10 (0.91-1.32) 0.319 1.02 (0.83-1.25) 0.843
L. iners 4.65 (0-7.14) 6.55 (0-7.98) 7.42 (0-8.81) 0.496 0.97 (0.85-1.11) 0.684 0.97 (0.84-1.12) 0.644
Other Lactobacilli 5.49 (3.77-6.91) 5.81 (4.21-7.09) 5.95 (5.34-7.61) 0.154 1.17 (0.93-1.48) 0.172 1.14 (0.88-1.47) 0.311
Unadjusted logistic regression model of 
HR ≥ 37 vs <34 weeks (n=109)
Adjusted * logistic regression model of HR 
≥ 37 vs <34 weeks (n=106)
Birth ≥ 39 weeks n=145 Birth ≥ 37 weeks n=87
sPTB or PPROM <34 weeks  
(early preterm) n=22
Median (IQR) Median (IQR) Median (IQR)
Low risk pregnancy (LR) High risk pregnancy (HR)
     
   136 
Table 7.7: : High risk participants were allocated to quartiles based on the concentration of total bacterial load, total Lactobacillus, L. iners and L. crispartus. 
 
Table 7.7 notes: * P values based Fisher’s exact test**Logistic regression adjusted for body mass index (BMI) as a quadratic term, history of cervical surgery (none/single LLETZ/multiple LLETZ 
and/or knife cone biopsy) and smoking (yes/no at time of visit). The adjusted analyses excluded two high risk women with missing smoking data, and one high risk woman with missing BMI 
data, the remainder of the exclusions were because of collinearity within the regression. The lower two logistic regressions by quartile of species of Lactobacillus were restricted only to samples 
with the species present (top two included all participants). Bold indicates P<0.05. 
 
n (%) n (%) n (%) n (%)
OR 95% CI P OR 95% CI P
1 37 (25.5) 12 (11.0) 11 (12.6) 1 (4.5)
2 36 (24.8) 34 (31.2) 28 (32.2) 6 (27.3)
3 35 (24.1) 18 (16.5) 17 (19.5) 1 (4.5)
4 37 (25.5) 45 (41.3) 31 (35.6) 14 (63.6)
1 36 (24.8) 13 (11.9) 12 (13.8) 1 (4.5)
2 36 (24.8) 25 (22.9) 24 (27.6) 1 (4.5)
3 36 (24.8) 29 (26.6) 23 (26.4) 6 (27.3)
4 37 (25.5) 42 (38.5) 28 (32.2) 14 (63.6)
1 32 (22.1) 10 (9.2) 10 (11.5) 0 0.0
2 30 (20.7) 19 (17.4) 16 (18.4) 3 (13.6)
3 31 (21.4) 37 (33.9) 29 (33.3) 8 (36.4)
4 32 (22.1) 23 (21.1) 16 (18.4) 7 (31.8)
nil present 20 (13.8) 20 (18.3) 16 (18.4) 4 (18.2)
1 21 (14.5) 12 (11.0) 11 (12.6) 1 (4.5)
2 20 (13.8) 17 (15.6) 17 (19.5) 0 0.0
3 21 (14.5) 12 (11.0) 10 (11.5) 2 (9.1)
4 20 (13.8) 35 (32.1) 25 (28.7) 10 (45.5)









Adjusted ** logistic regression 
model of HR ≥ 37 vs <34 weeks 




Birth ≥37 weeks                        
n=87
sPTB or PPROM <34 
weeks  n=22
Unadjusted logistic regression 




High-risk pregnancy (HR) p value* 
difference 
between HR ≥ 




Quartile of                 
L. crispatus
0.240 2.32 (1.09-4.97) 0.030
Quartile of.                
L. iners



























7.11 Allocation of high-risk participants to quartiles of low-risk 
participants 
In order to contextualise the VMB characteristics in the high-risk group, the low-risk group 
was used to create quartiles of VMB characteristics when the variable was present in over 
30% of participants. The VMB characteristics selected for analysis were: 1) total bacterial 
load; 2) concentration of total Lactobacillus; 3) concentration of L. iners and; 4) 
concentration of L. crispartus.  
Assessment was then made of the contribution that each increase in quartile of the VMB 
characteristics had to risk of early sPTB/PPROM in the high-risk group (Table 7.7, Figure 
7.9.). This showed that high-risk participants had an aOR of 2.61 (95%CI 1.27-5.33, p=0.006) 
of early sPTB/PPROM for each increase in quartile of total Lactobacillus (visualised in Figure 
7.10), and an aOR of 2.32 (95%CI 1.09-4.97, p=0.030) for each increase in quartile of L. 
crispatus. 
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Figure 7.10: Percentage of high-risk participants for each pregnancy outcome in each quartile of total 
lactobacillus 
 
7.12 Exploratory analysis  
Based on the finding of the association between a higher bacterial load, and higher 
concentration of Lactobacillus and sPTB/PPROM in the high-risk group an exploratory 
analysis was developed by the research team to assess the VMB characteristics that 
contributed to the relationship between a high bacterial load and recurrent sPTB/PPROM. 
All participants were stratified by VMB type (Table 4.6), and the logistic regression analyses 
were repeated for each stratum. For this analysis the research team decided to combine 
the VMB types ‘LA’ (25%- 75% Lactobacillus and <50% Bifidobacterium) and ‘BV’ (<25% 
Lactobacillus and <50% Bifidobacterium) in order to conserve statistical power for these 
rarer groups (each group had only 14/109, 12.8%, of high risk participants) (Table 7.4). 
Participants in both of these groups have vaginal dysbiosis (non-dominance of 
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Lactobacillus), and so this combination was felt to be biologically plausible.  Table 7.8 shows 
estimated concentrations of total vaginal bacteria, the four bacterial groups, L. cripatus, L. 
iners, and other Lactobacillus in high-risk women with and without a recurrence after 
stratification by VMB type. In women with the VMB type ‘Li’ (domination by L. iners) 
participants with a recurrent sPTB/PPROM had a significantly higher median bacterial loads, 
and estimated concentrations of total Lactobacillus and L. iners compared to high-risk 
participants with a term birth. However, the associations were no longer significant after 
adjustment for confounders. Within each of the other VMB type strata there were similar, 
but non-significant, trends for participants with recurrent early sPTB/PPROM to have higher 
bacterial loads, and concentrations of both total Lactobacillus and total BV-associated 
bacteria, than high-risk participants with term birth. The median estimated concentrations 
in high-risk women who had a term birth were similar to those in low-risk women. 
High-risk women with anaerobic dysbiosis (LA and BV group) had higher median vaginal 
bacterial loads than women with domination by L. iners, L. crispatus, or other 
Lactobacillus/bifidobacteria (8.54, 7.79, 7.63, 7.53 log10 cells/μl, respectively (Table 7.8 and 
Table 7.9). High-risk participants with domination of L. iners  had the highest median 
bacterial load of  women with the Lactobacillus dominated VMB types, but these 
differences did not reach P<0.05 in comparison to the other Lactobacillus dominated VMB 
types (Table 7.9). 
.
Table 7.8: Stratified Assessment of the relationship between concentration of total bacterial load, taxa in bacterial groups and types of Lactobacillus by VMB types 
 
OR 95% CI P OR 95% CI P
7.75 (6.44-8.46) 7.63 (7.14-8.63) 7.55 (7.14-8.32) 8.20 (7.42-9.06) 1.67 (0.57-4.89) 0.349 1.35 (0.41-4.40) 0.623
Total Lactobacillus 7.73 (6.42-8.46) 7.63 (7.14-8.59) 7.55 (7.14-8.25) 8.20 (7.41-8.86) 1.64 (0.55-4.85) 0.375 1.32 (0.40-4.30) 0.649
Total BV associated 4.74 (0-6.29) 4.62 (0-6.07) 4.29 (0-5.36) 5.24 (0-6.71) 1.09 (0.79-1.50) 0.601 0.87 (0.55-1.36) 0.535
Total pathobionts 0.00 (0-0) 0.00 (0-0) 0.00 (0-0) 0.00 (0-0) 0.93 (0.49-1.75) 0.825 1.07 (0.48-2.39) 0.866
Total other bacteria 0.00 (0-3.19) 0.00 (0-0) 0.00 (0-0) 0.00 (0-0) 1.01 (0.59-1.71) 0.980 0.97 (0.56-1.68) 0.904
L. crispatus 7.72 (6.41-8.45) 7.63 (7.12-8.37) 7.55 (7.12-8.22) 8.19 (7.41-8.80) 1.66 (0.55-5.02) 0.365 1.31 (0.40-4.27) 0.658
L. iners 0.00 (0-4.23) 0.00 (0-4.81) 0.00 (0-5.32) 0.00 (0-0) 0.71 (0.41-1.21) 0.204 0.84 (0.49-1.42) 0.514
Other Lactobacilli 5.09 (3.39-5.94) 5.34 (3.02-7.16) 4.64 (3.02-6.14) 6.20 (5.34-7.39) 1.17 (0.77-1.76) 0.457 1.03 (0.93-1.80) 0.930
7.64 (6.94-8.25) 7.79 (6.93-8.65) 7.79 (6.93-8.65) 9.03 (8.02-9.12) 3.44 (1.06-11.15) 0.040 2.38 (0.71-7.95) 0.160
Total Lactobacillus 7.61 (6.90-8.25) 7.96 (7.23-8.83) 7.79 (6.93-8.60) 8.91 (8.02-9.10) 3.40 (1.04-11.11) 0.042 2.37 (0.70-8.04) 0.165
Total BV associated 4.55 (0-6.37) 5.16 (0-6.60) 4.75 (0-5.79) 6.77 (5.33-7.73) 1.45 (0.98-2.15) 0.061 1.57 (0.95-2.59) 0.079
Total pathobionts 0.00 (0-0) 0.00 (0-0) 0.00 (0-0) 0.00 (0-2.31) 1.21 (0.84-1.74) 0.307 1.15 (0.69-1.91) 0.590
Total other bacteria 0.00 (0-3.61) 0.00 (0-4.26) 0.00 (0-3.38) 4.07 (0-5.69) 1.39 (1.00-1.94) 0.050 1.43 (0.95-2.16) 0.085
L. crispatus 5.89 (3.75-6.60) 6.19 (4.45-6.84) 6.02 (3.83-6.78) 6.38 (6.12-7.79) 1.26 (0.82-1.94) 0.295 1.09 (0.69-1.72) 0.695
L. iners 7.52 (6.90-8.12) 7.93 (7.13-8.79) 7.73 (6.93-8.59) 8.82 (8.02-9.07) 3.35 (1.03-10.86) 0.044 2.33 (0.70-7.76) 0.169
Other Lactobacilli 4.97 0-6.75) 5.59 (4.08-6.59) 5.40 (4.41-7.30) 5.81 (4.08-6.59) 1.20 (0.78-1.85) 0.398 1.06 (0.69-1.63) 0.782
7.12 (6.32-7.69) 7.53 (7.24-8.64) 7.48 (7.21-8.73) 7.64 (7.46-8.61) 1.36 (0.48-3.86) 0.563 3.47 (0.61-19.7) 0.161
Total Lactobacillus 7.12 (6.08-7.69) 7.45 (7.10-8.61) 7.36 (6.94-7.89) 7.61 (7.42-8.61) 1.68 (0.54-5.29) 0.371 5.96 (0.65-54.5) 0.114
Total BV associated 4.64 (0-5.59) 4.29 (0-6.19) 0.00 (0-4.94) 6.36 (6.31-6.58) 1.84 (0.97-3.50) 0.063
Total pathobionts 0.00 (0-2.98) 0.00 (0-4.11) 0.00 (0-4.11) 0.00 (0-0) 0.87 (0.53-1.41) 0.560 0.66 (0.23-1.87) 0.430
Total other bacteria 0.00 (0-5.01) 1.13 (0-5.93) 0.00 (0-5.95) 5.09 (0-5.12) 1.05 (0.76-1.44) 0.769 1.21 (0.77-1.91) 0.410
L. crispatus 5.17 (4.00-5.88) 5.55 (4.44-6.54) 5.52 (5.26-6.54) 5.59 (0-6.16) 0.85 (0.59-1.21) 0.362 0.83 (0.53-1.29) 0.410
L. iners 0.00 (0-6.41) 0.00 (0-7.09) 4.42 (0-7.09) 0.00 (0-0) 0.84 (0.61-1.16) 0.297 0.87 (0.58-1.30) 0.497
Other Lactobacilli 6.99 (5.97-7.51) 7.46 (6.84-8.51) 7.24 (6.93-7.84) 7.61 (7.42-8.30) 1.87 (0.58-6.05) 0.293 8.97 (0.66-121) 0.099
7.93 (7.44-8.52) 8.54 (8.11-9.22) 8.31 (8.07-9.16) 9.15 (9.11-9.28) 9.46 (0.28-318) 0.210 12.42 (0.31-501) 0.182
Total Lactobacillus 6.98 (6.30-7.45) 7.38 (6.63-8.37) 7.25 (6.56-8.19) 8.26 (8.15-8.86) 4.57 (0.54-38.5) 0.162 5.49 (0.17-63.1) 0.172
Total BV associated 7.93 (7.19-8.51) 8.41 (8.07-9.19) 8.18 (8.07-9.15) 9.05 (8.83-9.24) 6.58 (0.33-133) 0.219 9.93 (0.42-237) 0.156
Total pathobionts 0.00 (0-0) 0.00 (0-3.92) 0.00 (0-4.49) 0.00 (0-0)
Total other bacteria 0.00 (0-4.40) 4.57 (0-6.07) 4.59 (0-5.96) 0.00 (0-6.30) 0.83 (0.54-1.28) 0.402 0.70 (0.30-1.62) 0.407
L. crispatus 4.98 (0-5.93) 5.21 (0-6.41) 4.88 (0-6.60) 5.79 (0-5.90) 1.04 (0.69-1.55) 0.859 0.84 (0.48-1.46) 0.537
L. iners 5.65 (0-7.11) 6.68 (4.80-8.21) 6.56 (4.74-7.98) 8.26 (8.15-8.86) 4.74 (0.49-45.6) 0.179 9.82 (0.35-274) 0.179





Low risk pregnancy (LR)
Unadjusted logistic regression model of 
HR ≥ 37 vs <34 weeks (n=109)Birth ≥ 39 weeks n=145 Birth ≥ 37 weeks n=87
sPTB or PPROM <34 weeks  
(early preterm) n=22
Median (IQR) Median (IQR)



































Adjusted* logistic regression model of HR 
≥ 37 vs <34 weeks (n=106)
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Table 7.8 notes: 95% CI, 95% confidence interval; HR, high-risk pregnancy; IQR, interquartile range; LR, low-risk pregnancy; OR, odds ratio; PPROM, preterm prelabour rupture of membranes; 
sPTB, spontaneous preterm birth; VMB, vaginal microbiota. Concentration data quoted in log10 cells/μl.*Logistic regression adjusted for body mass index as quadratic term, history of cervical 
surgery (none/single LLETZ/multiple LLETZ and/or knife cone biopsy) and smoking (yes/no at time of visit). Adjusted analyses excluded two HR women with missing smoking data, one with 
missing BMI data, and variable numbers because of collinearity within the regression. Participants were included in these analysis even if a taxa wasn’t present in that sample (with 
concentration =0). ¶VMB type definitions: Li=L. iners-dominated (≥75% lactobacilli with L. iners the most common); Lcr=L. crispatus-dominated (≥75% lactobacilli with L. crispatus the most 
common); Lo+BL=other lactobacilli- or Bifidobacterium dominated (Lo+BL; either≥75% lactobacilli with L. jensenii or L. gasseri the most common, or ≥50% Bifidobacterium); lactobacilli and 
anaerobes (LA; 25%- 75% lactobacilli); and BV=mixture of BV-anaerobes (<25% lactobacilli). 
 
Table 7.9: P-values for mean bacterial load comparisons between VMB types in high-risk women. 
  N Lcr Li Lo+BL LA+BV 
L. crispatus-dominated (Lcr) 23  0.475 0.946 0.008 
L. iners-dominated (Li) 36   0.361 0.033 
Other Lactobacillus - or Bifidobacterium-
dominated (Lo+BL) 22    0.007 
Lactobacillus with anaerobes or BV (LA+BV) 28     
Table 7.9 notes: The p-values (by Mann-Whitney U test) are for mean bacterial load comparisons between VMB 
types in high-risk women (n=109). The mean bacterial loads for each VMB type are reported in Table 7.8 
 
7.13 Correlation with clinical phenotype 
The distribution of VMB types and participants in the highest quartile of bacterial load by 
clinical phenotype is shown in Table 7.10.  Of note, both participants with early PPROM and 
early chorioamnionitis had bacterial loads in the highest quartile, as did the participant with 
early sPTB and chorioamnionitis. Conversely, the two participants who had early PPROM 
and developed chorioamnionitis more than 7 days after PPROM (as described in Table 3.2) 
did not have bacterial loads in the highest quartile. Visually, there did not appear to be a 
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Table 7.10: Distribution of VMB types and top quartile of bacterial load by clinical phenotype of early 
sPTB/PPROM 
 High-risk participants 
Contributing factors at birth 
PPROM 16+0-33+6 weeks 
sPTB 16+0-
33+6 weeks    
n=10  
With early 


























Placental dysfunction 0 0 
LiBact cells 
Lo+BLBact cells 
Extra amniotic infection 0 0 0 
Polyhydramnios 0 0 LiBact cells 
Uterine anomaly 0 LiBact cells 0 
Maternal comorbidities 0 LCrBact cells LiBact cells 












Table 7.10 notes:Li=L. iners-dominated (≥75% lactobacilli with L. iners the most common); LCr =L. crispatus-
dominated (≥75% lactobacilli with L. crispatus the most common); Lo+BL=other lactobacilli- or Bifidobacterium 
dominated (either≥75% lactobacilli with L. jensenii or L. gasseri the most common, or ≥50% Bifidobacterium); 
lactobacilli and anaerobes (LA+BV; either LA, 25%- 75% lactobacilli, without ≥50% Bifidobacterium or BV, 
mixture of BV-anaerobes (<25% lactobacilli).) Each participant is represented by the symbol for their VMB type, 
and if that participant also had a concentration of bacterial cells in the top quartile then the VMB type has the 
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7.15 Characteristics associated with recurrent early preterm birth  
The VMB characteristics identified throughout Chapter 7 as potentially associated with 
recurrent sPTB/PPROM in the high-risk group are: 
1) Highest quartile of total bacterial load 
2) Highest quartile of total Lactobacillus concentration 
3) Highest quartile of L. iners concentration 
4) Highest quartile of L. crispatus concentration 
5) Presence of Ureaplasma species 
6) Highest quartile of Megasphaera species 
7) Presence of BVAB TM7-H1 
18/22 (81.2%) of HR early sPTB/PPROM and 63/87 (72.4%) of HR term participants had at 
least one VMB characteristic associated with early sPTB/PPROM recurrence (Figure 7.11). 
All high-risk early sPTB/PPROM patients in the highest quartile of Lactobacillus 
concentration were also in the highest quartile of bacterial load (n=14) (Table 7.7). The 
majority (25/28, 89.2%) of high-risk term participants in the highest quartile of Lactobacillus 
concentration were also in the highest quartile of total bacterial load.  Over 97% of 
participants in all pregnancy outcome groups had Lactobacillus present, and it was by far 
the most common species identified in the population, with a median relative abundance 
over 98% in all pregnancy outcome groups (Table 7.5). Therefore, as expected, the most 
common species, Lactobacillus, contributes to the most to the total bacterial load.  
In both the high-risk term and the high-risk early sPTB/PPROM there was a high degree of 
overlap between highest quartile of L. iners and total bacterial load (Figure 7.11). 
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This is consistent with the findings in Table 7.8 which showed that women with domination 
of L. iners (VMB type Li) had higher bacterial loads. Eight high-risk participants with 
sPTB/PPROM had the VMB type Li (Table 7.8). These participants had particularly high total 
bacterial loads (median 9.03, IQR 8.02-9.12 log10 cells/μl); this is over 10-fold higher than 
the low-risk term birth participants with the same domination of L. iners (median bacterial 
load 7.52, IQR 6.90-8.12 log10 cells/μl). 
Compared to the over-lap with L. iners there was less overlap between highest quartile of L. 
crispatus and highest quartile of total bacterial load (Figure 7.11). Only 57% (4/7) of high-
risk early sPTB/PPROM participants with the highest quartile of L. crispatus also had highest 
quartile of total bacterial load, and 37.5% (6/16) of high-risk term birth participants shared 
these traits.  
When L. crispatus was dominant there were very low concentrations of L. iners (median 
concentration of L. iners 0 for all pregnancy outcome groups in Table 7.8). Conversely when 
L. iners was dominant L. crispatus was also present (median concentration of L. crispatus in 
L. iners dominated pregnancies 5.89 and 6.19 log10 cells/μl in the low and high-risk groups 
respectively). This appears to account for the relationship between quintile of L. crispatus 
and recurrent sPTB/PPROM when the whole high-risk population is assessed (Table 7.7), 
which is no longer seen within the L. crispatus dominant VMB type (aOR of recurrent 
sPTB/PPROM in the high risk group 1.31, 95% CI 0.40-4.27, p=0.658, Table 7.8). 
 
 
   




Figure 7.11: Euclan diagrams showing the co-location of VMB characteristics that were positively associated 
with early sPTB/PPROM within the high-risk cohort. 18/22 (81.2%) of HR early sPTB/PPROM and 63/87 (72.4%) 
of HR term participants had at least one VMB characteristic associated with early sPTB/PPROM recurrence. The 
highest quartile of Lactobacillus was omitted from this diagram because of almost complete overlap with 
highest quartile of bacterial load (see section 7.9.1)  RA, relative abundance. 
High risk term n=63 
High risk early sPTB/PPROM n=18 
Highest quartile of L. iners concentration 
Highest quartile of total bacterial load 
RA  Megasphaera species over 12% 
Presence of Ureaplasma species 
Highest quartile of L. crispatus 
concentration 
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The proportion of high-risk participants with Ureaplasma present and other VMB features 
associated with sPTB/PPROM was similar for both the high-risk term (6/11, 54.5%) and 
high-risk preterm groups (3/7, 42.9%) (Figure 7.11). This suggests that presence of 
Ureaplasma does not closely correlate with other VMB characteristics associated with 
sPTB/PPROM, and it may be acting independently to increase the risk of sPTB/PPROM. 
Two (9.1%) of high-risk early sPTB/PPROM participants had a high relative abundance of 
Megasphaera species (defined as over 12% based on the distribution in the low-risk term 
group, Figure 7.6). Both these participants were also in the highest quartile of bacterial load 
and L. iners concentration and one also had BVAB-TM7 present (Figure 7.11). Both of these 
participants had anaerobic dysbiosis (one VMB type BV and one LA).  
Five (5.75%) high-risk term birth participants had a high relative abundance of 
Megasphaera species, all of whom also had anaerobic dysbiosis (four VMB type BV and one 
LA). However, only one of these participants also had the combination of highest quartile of 
bacterial load and L. iners (Figure 7.11). Consistent with Table 7.8 and Table 7.9 it appears 
that anaerobic dysbiois is associated with an overall higher bacterial load, but it is when the 
bacterial load is particularly high that the risk of recurrence of sPTB/PPROM appears to be 
the raised.    
7.16 Characteristics protective of term birth 
Two VMB characteristics were potentially associated with term birth: 
1) Presence of Bifidobacterium 
2) Presence of Dialister species 
The presence of Dialister species was associated with term birth in this analysis (Table 7.5). 
This is contrary to previous work showing this taxa associated with PTB/PPROM (Table 
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4.3).100,103,165,168 The assessment of taxa associated with sPTB/PROM was designed as a 
confirmatory analysis based on previous literature (section 3.10.4). On the basis of this 
association being in the opposite direction to previous work, and no longer significant after 
correction for multiple comparisons the research team deemed this to be likely to be a 
type-1 statistical error and no further analysis of this characteristic was carried out. 
The only other VMB characteristic associated with a reduction in risk of early sPTB/PPROM 
was the presence of Bifidobacterium breve. This taxon was totally absent from the group 
with early sPTB/PPROM. Within the low-risk term birth group and the high-risk term birth 
group women with Bifidobacterium breve present tended to have a lower concentration of 
total Lactobacillus; only 1.38% (2/145) of the low-risk group had Bifidobacterium breve 
present and were in the highest quartile of total Lactobacillus, compared to 5.52% (8/145) 
of in the lowest quartile of total Lactobacillus (Table 7.11). However less than 10% of these 




   
   149 









 Birth ≥ 39 weeks 
n=145 
Birth ≥ 37 weeks 
n=87 
    
Concentration of 
total Lactobacillus 
 (log10 cells/μl) 
n (%) n (%) 
Quartile of total 
Lactobacillus 
1 <6.42 8 (5.52) 1 (1.15) 
2 ≥6.42- >7.31 3 (2.07) 3 (3.45) 
3 ≥7.31- >8.01 1 (0.69) 3 (3.45) 
4 ≥8.01 2 (1.38) 0 0.00  
Absence of Bifidobacterium 
breve not applicable 131 (90.34) 80 (91.95) 
Fisher's exact test P value   0.043 0.185 
 Total   145 (100.00) 87 (100.00) 
Table 7.11 notes: P value shows that within the low-risk group there was a significant association between 
presence of Bifidobacterium and quartile of total Lactobacillus (p=0.043). 
 
7.17 Effect of antimicrobials 
In order to assess whether the use of an antimicrobial in pregnancy, prior to VMB sampling, 
affected the bacterial load an assessment was made of bacterial load according to 
antimicrobial usage in pregnancy prior to VMB sampling. 20.1% of low-risk and 24.8% of 
high-risk participants had used antimicrobials in the current pregnancy (Table 7.12). The 
most common indication for antibiotic prescription was urinary tract infection, accounting 
for 11/21 (52.4%) of the low-risk group prescriptions and 5/12 (41.7%) of the high-risk 
group prescriptions. The majority of participants received cefalexin for treatment of urinary 
tract infections, with two participants in each group receiving nitrofurantoin, and two low-
risk participants receiving trimethoprim (before pregnancy was known about). The other 
common antibiotic used was amoxicillin; prescribed for chest, ear and dental infections 
(8/21, 38% of low-risk prescriptions and 3/12, 33% of high-risk prescriotions). Only high-risk 
participants had received treatment targeted at bacterial vaginosis (5/12, 41.7% 
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participants, one of whom also received cephalexin for a UTI)  in the form of either oral 
metronidazole (n=1) or vaginal clindamycin cream (n=4). A single low-risk participant 
received vaginal clotrimazole for symptomatic vaginal candidiasis. No association was 
noted, in either the high or low-risk pregnancy groups, between bacterial load and use of 
antimicrobials (whether targeted at bacterial vaginosis, or not) (Table 7.12). 
Table 7.12: Bacterial load (in log10 cells/μl) based on antimicrobial use in the pregnancy prior to VMB 
assessment. 
Table 7.12 notes: A single low-risk participant who used clotrimazole prior to VMB sampling is excluded from this 
analysis. One  high-risk participant  received multiple antimicrobials including metronidazole and was included in 
the clindamycin or metronidazole group only.  P value calculated by Mann-Whitney U test. 
 
7.18 Relationship with cervical length 
Visual assessment was performed to assess whether there was a relationship between 
cervical length and bacterial load.  
Visually no association was noted between bacterial load and cervical length at either the 
time of VMB assessment (15+1-23+0 weeks gestation, Figure 7.12), or at approximately 20 
weeks gestation  days gestation (19+0-21+6 weeks, Figure 7.13). 
 
Median IQR Median IQR Low-risk High-risk




21 14.6 7.60 6.75-8.45 12 11.0 8.19 7.29-8.77 0.940 0.991
Clindamycin or 
metronidazole
0 0.0 5 4.6 8.47 8.06-8.64 0.412
Not known/unsure 8 5.6 7.42 7.18-7.65 10 9.2 7.42 6.97-8.92 0.460 0.452
Total 144 109
P value of difference in 
bacterial load compared 
to no antimicrobial
Low-risk High-risk
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Figure 7.12: Relationship between bacterial load and cervical length at time of VMB assessment (15+1-23+0 weeks 
gestation) gestation in the high-risk group. High-risk term n=87, high-risk preterm n=22. PTB, preterm birth. 
 
 
Figure 7.13: Relationship between bacterial load and cervical length at approximately 20 weeks (19+0-23+0 weeks 
gestation) gestation in the high-risk group. High-risk term n=79, high-risk preterm n=19 (participants without 
cervical length assessment at 20 weeks omitted). PTB, preterm birth. 
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7.19 Discussion 
We identified a positive association between the total vaginal bacterial load, predominantly 
comprised of Lactobacillus, and early sPTB/PPROM recurrence. Women with a recurrence, 
compared to those without, had a fivefold higher median vaginal bacterial load (after 
inverse log10 transformation). There was a gradient effect with a 2.61-fold increased 
adjusted odds of recurrence for each increase of total Lactobacillus concentration quartile.  
When we went on to divide our population by ‘VMB type’; a classification system based on 
the dominant species of lactobacilli, or non-dominance of lactobacilli. Particularly high 
overall bacterial loads were present in participants with recurrent sPTB/PPROM and 
dominance of L. iners, or non-dominance of lactobacilli. The high bacterial loads were 
comprised of high concentrations of lactobacilli, along with high concentrations of BV 
associated bacteria and ‘other’ bacteria (as defined in Appendix G). The groups were small 
and after controlling for confounders the associations did not reach pre-specified statistical 
significance. The VMB types dominated by L. crispatus, other Lactobacillus and 
Bifidobacterium, had slightly higher total bacterial loads and concentrations of Lactobacillus 
in the early sPTB/PPROM group compared to the high-risk term birth group, but the 
differences were not as striking and were much further from statistical significance. High-
risk and low-risk participants who had term births had similar bacterial loads within VMB 
types. 
We postulate that some women with L. iners domiance, or non-dominance of lactobacilli, 
reach higher overall bacterial loads than women dominated by L. crispatus or other species 
of lactobacilli, or conversely the later women are protected from higher bacterial loads. The 
combination of dominance of L. iners or non-dominance of lactobacilli, along with a high 
bacterial load, shows stronger association with recurrent sPTB/PPROM. This would be 
consistent with previous work suggesting an association between the relative abundance of 
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L. iners and sPTB.101,102 This would also explain the lack of consistency in the reproduction of 
this finding (Table 4.3); if L. iners dominance is only associated with PTB when there is a 
concurrent high bacterial load, then women with L. iners domination and a normal bacterial 
load would not show this association. We also postulate that the women who have high 
bacterial loads and do go on to have sPTB/PPROM could be at higher risk of early onset 
chorioamnionits (Table 7.10). 
Brown et al assessed the relationship between bacterial load and PPROM prior to 37 weeks 
gestation.172 This work showed no difference in bacterial load at 8-12 weeks gestation 
between pregnancies destined for PPROM <37+0 weeks and pregnancies destined for term 
birth. This study is not directly comparable to the current work because the gestation of 
sampling was earlier and the gestation of PPROM later; giving a longer latency period 
between sampling and event. Brown et al also found no difference in bacterial load after 
PPROM when comparing women with PPROM who did, and did not, go on to develop 
chorioamnionitis with funisitis. The current study’s equivalent definition of the 
chorioamnionitis with funisitis cases could be the cases with early onset chorioamnionitis 
(Table 3.2). We only had three early sPTB/PPROM cases meeting this definition, but 
interestingly all of these were in the highest quartile of bacterial load in the second 
trimester (Table 7.10). This difference in findings is not surprising; in the Brown et al study 
the bacteria contributing to PPROM may have already ascended into the uterine cavity in 
order to contribute to the PPROM,203 and after the rupture of membranes there will be a 
substantial shift in vaginal fluids, so the crucial time when the high bacterial load 
contributes to the pathology may be prior to the PPROM.  
To our knowledge, assessment of the association between the vaginal bacterial load and 
PTB has been applied in two other studies. Freitas et al168 found a higher concentration of 
16S rRNA genes per swab (taken at 16 weeks gestation) in women who went on to have an 
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sPTB <37 weeks compared to a term birth ≥37 weeks (8.1 vs. 7.8 log10 copies/swab, 
respectively). Elovitz et al101 found similar concentrations of 16S rRNA genes in women who 
went on to have sPTB <37 weeks and term births ≥37 weeks when they assessed samples 
taken at less than 24 weeks gestation (approximately 8 log10 copies/swab in each group), 
and found a lower concentration (approximately 7.5 vs 7.9 log10 copies/swab) of 16S rRNA 
genes in women who went on to have a PTB in samples taken at 28 gestation. This may 
indicate that high vaginal bacterial load is only associated with PTB when present prior to 
24 weeks gestation, but additional studies are needed to replicate these findings.  
Bacteria have between one and fourteen 16S rRNA genes per bacterial cell, and the average 
gene copy number per cell varies by taxon (Appendix G). The concentration of 16S rRNA 
genes in a vaginal swab is therefore not directly analogous to the concentration of bacterial 
cells (bacterial load) in that swab, but only provides a crude estimate. We corrected our 
bacterial load estimations by average 16S gene copy number per cell for each taxon present 
in the sample in an effort to improve the estimations.  
In non-pregnant women, a higher vaginal bacterial load is usually associated with bacterial 
vaginosis.176 Pregnant women are protected from bacterial vaginosis due to the high 
oestrogen levels during pregnancy.204,205 Oestrogen increases vaginal glycogen stores in the 
vagina, which provide Lactobacillus with a competitive advantage compared to bacterial 
vaginosis-associated bacteria. Lactobacillus very efficiently convert glycogen into lactic acid, 
creating an acidic vaginal environment in which they thrive and most competing bacteria do 
not.  
In our study, the prevalence of anaerobic dysbiosis, and the relative abundances and 
estimated concentrations of bacterial vaginosis-associated bacteria and pathobionts, were 
indeed low. In the high-risk group, the median estimated concentration of BV-associated 
bacteria (6.76 log10 cells/μl) was 68 times lower, and the median concentration of 
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pathobionts (4.81 log10 cells/μl) more than 6,000 times lower, than the median estimated 
concentration of Lactobacillus (8.59 log10 cells/μl). These very low concentrations of BV-
associated bacteria and pathobionts in the pregnant women in our cohorts may explain 
why we did not identify any associations between these bacterial groups and pregnancy 
outcome.  
We found that L. iners domination was associated with higher bacterial loads than the 
other lactobacilli,  and the combination of L. iners domination and high bacterial load was 
associated with early sPTB/PPROM recurrence. L. iners was first described in 1999.206 It has 
a genome of just 1.3 Mpb,207 strikingly smaller than the other common vaginal species of 
lactobacillus, for example L. crispatus, with a genome of about 2.3 Mbp.208 Species with 
such small genomes are normally dependent on exogenous sources for vital nutrients, and 
therefore either have a symbiotic or parasitic relationship with their host.209  However, 
which of these L. iners holds is still debated.210 Additionally, there are multiple strains of 
most bacterial species. The technology to differentiate bacteria to strain level is relatively 
new,211 but a recent study of 195 pregnant women in the USA found 21 different strains of 
L. iners present throughout their population, with 19% of participants having more than 
one strain of L. iners present at any one time.212 
Macklaim et al observed that that L.iners strains with high expression of CRISPR (clustered 
regularly inter- spaced short palindromic repeat) genes were present in bacterial vaginosis, 
but not in healthy conditions.213 CRISPR genes are the primary bacterial defence against 
phages (viruses that infect bacteria). This could suggest that the L.iners associated with high 
bacterial loads and recurrent sPTB/PPROM in our study may be different strains, or 
behaving in a different way, to the L.iners associated with lower bacterial loads in the high-
risk term birth and low-risk pregnancy groups.  
We had postulated that high-risk women, given the nature of their previous poor obstetric 
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history may seek more healthcare and be more likely to have used antimicrobials in 
pregnancy. This in turn could have had an effect on the bacterial load. We did find that 
slightly more high-risk participants had used antimicrobials in pregnancy prior to their study 
visit compared to low-risk participants (24.8% vs. 20.1%, Table 7.12). However, no 
difference was shown in the bacterial load between women who had used clindamycin or 
metronidazole (antibiotics recommended for treatment of bacterial vaginosis202), other 
antibiotics, or no antibiotics in pregnancy. There are some limitations with this analysis. We 
relied on participant recall only, the time when the antibiotics were administered was 
inconsistently recorded and could not be accounted for in the analysis, and 8/144 (5.5%) of 
low-risk and 10/109 (9.2%) of high-risk participant has missing data. Nevertheless, the 
proportions of participants using antimicrobials in pregnancy were similar for the high and 
low-risk groups, and there was no difference in bacterial load by antimicrobial usage. 
Therefore, the impact of antimicrobials on the bacterial loads in this study (and in turn the 
association identified between bacterial load and early sPTB/PPROM) is unlikely to be 
accounted for by differential antimicrobial usage in the highest risk pregnancies. 
In agreement with previous work95,97 we found that the VMB was relatively stable between 
study visits (approximately 16 and 20 weeks gestation). Like Fettweis et al100 we did not 
identify any association between VMB instability and PTB. This VMB stability in pregnancy 
means that, if a VMB characteristic were to be associated with PTB, there is a window in 
which an intervention to target this association could be applied. 
Three uncommon taxa (present in fewer than 20% of the women in the low risk group) 
showed non-significant trends towards an association with early sPTB/PPROM recurrence 
in our study and were also associated with PTB in studies by others: the presence of 
Ureaplasma162,168 and BVAB TM7-H1100, and the relative abundance of Megasphaera.101,168 
In women with early sPTB/PPROM recurrence, the presence of these taxa in the vagina did 
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not completely overlap with having high bacterial loads and lactobacilli concentrations. 
While uncommon, the presence or relative abundance of these types of BV-associated 
bacteria may therefore also play a role in PTB, for example by contributing to inflammatory 
pathways.21 We also found an association in the opposite direction to previous 
research,103,110,168,214 an increased prevalence of Dialister in high-risk participants with a 
term birth compared to recurrent sPTB/PPROM. This is likely to be a type-1 statistical error 
(false positive finding). 
Our data confirms that Bifidobacterium breve may have a protective effect against early 
sPTB/PPROM recurrence.103 This helped guide our decision to place women with 
Bifidobacterium ≥50% relative abundance within a ‘VMB type’ with lactobacillus. 
With regards to the remainder of the taxa of interest, as identified in Table 4.3, this study 
did not show an association between these taxa and early sPTB/PPROM. Most of these are 
rare taxa, also described as minority species, and comprise less that 1% of the bacterial 
species in a sample. Minority species are liable to under replication in the PCR steps 
necessary for 16S rRNA sequencing.107 This because the genetic material from species that 
make up proportionally more of the microbiome is a able to out-compete the genetic 
material of the rarer taxa for the limited sequencing reagents added to each sample. As 
such 16S rRNA sequencing has been shown to have good positive predictive value, but 
poorer negative predictive value for minority species when compared to culture based 
assays.215 Additionally minority taxa can be less well characterised within sequencing 
libraries, and so at higher risk of taxonomic misassignment.107 Finally different study 
protocols, including DNA extraction methods and primer sets may be better, or worse at 
amplifying particular microbial species. Therefore, whilst notable that the remainder of the 
taxa of interest did not show an association with early sPTB/PPROM in this study, this 
methodology (even if we had an appropriate sample size and power calculation) is not the 
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optimal mode of ruling out an association. Panels of PCR based assays targeted at the taxa 
of interest could be developed to better address this whether there is an association 
between these taxa and early sPTB/PPROM.  
Short cervical length in pregnancy, particularly in women with a previous preterm birth, 
was the predominant clinical parameter used to initiate preterm birth prevention 
treatment during the course of the study. 26,216,217 The relationship between cervical length 
and preterm birth has the strongest evidence after 18 weeks gestation,218 we therefore 
visualised the relationship between bacterial load and cervical length at both the study visit 
used for the majority of the analysis (median 16 weeks gestation, Table 5.3), and 
approximately 20 weeks gestation. No association was identified between cervical length 
and bacterial load in the high-risk participants at either time point.  
The cervical length of high-risk participants in this study is a little unusual because women 
with treatment for a short cervix at study initiation (approximately 16 weeks gestation) 
were not eligible for recruitment. Therefore we have may have preferentially recruited 
women with a longer cervix, in whom the contribution to preterm birth of cervical 
insufficiency may be less marked. This may be demonstrated by the finding of less women 
in the early PTB group having received preterm birth prevention treatment after 
recruitment than the high-risk term birth group (conversely the high-risk early sPTB/PPROM 
group may have had a short cervical length that our current practice did not detect).  
Possible explanations for the lack of association between short cervical length and bacterial 
load are either: a) this group of participants were not the predominant group with a 
cervical contribution to sPTB/PPROM, and so we did not have the power to detect an 
association which is present or b) bacterial load may act independently of cervical length 
and contribute to the approximately 9% recurrence rate of early sPTB/PPROM in women 
who maintain a normal cervical length.30  
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 Strengths and limitations 
We have identified a recurrent early sPTB/PPROM phenotype that is as pure as possible, 
and we applied methods of VMB data reduction that had been shown to have an 
association with PTB previously. In addition, we have developed and applied new methods 
of data reduction, that incorporate concentration estimation, for the first time in this area 
of research. These methods overcome some of the previous criticisms of using standard 
biostatistical methods for compositional data.219  Furthermore, recent work with human 
faecal samples found a stronger microbe- metabolite relationship when bacterial taxa 
concentrations were estimated by combining relative abundances with 16S rRNA qPCR 
compared to relative abundances alone.220   
We had limited statistical power due the small number of women with early sPTB/PPROM 
recurrence. This means that not all the associations consistent with our conclusion reached 
statistical significance. We had initially planned to analyse early sPTB and early PPROM,  
which may have different aetiological pathways,116 as two separate endpoints but these 
were combined to preserve statistical power. In addition, we chose to retain women who 
used PTB prevention treatment (cervical cerclage, Arabin pessary, or vaginal progesterone) 
after their 16 and/or 20-week vaginal sample collection in our analysis. This approach has 
recently been advised against182 as it is possible that women destined to deliver preterm 
may have had their delivery delayed by the therapy, weakening the ability of our analysis to 
detect a relationship between the VMB and sPTB/PPROM.  However, any future therapy 
developed based upon VMB analysis is likely to be applied in combination with current 
treatments, and so by retaining these participants we were able to assess the contribution 
of the VMB to recurrent sPTB/PPROM within current clinical practice. 
The primary way in which the VMB is thought to affect the risk of PTB is female genital tract 
inflammation.221 Another common inflammatory vaginal condition is vulvovaginal 
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candidiasis, for which pregnant women are at increased risk.222 Unfortunately the current 
study did not assess vaginal yeasts concentrations.  
We were not able to collect data about antimicrobial use after involvement in the study 
because of the wide range of sources that the participants could have obtained these from. 
This includes hospitals, primary care practitioners, walk-in centres and, in the case of 
antifungals, over the counter purchases. A final limitation is the lack of VMB data in the 
third trimester and/or closer to the birth. 
7.20 Conclusion 
Among women who had a previous early sPTB/PPROM, recurrence was associated with 
increased total vaginal bacterial load, which was mostly made up of lactobacilli. Women 
with a previous early sPTB/PPROM were especially likely to have a recurrent event if they 
had a VMB dominated by L.iners or anaerobic dysbiosis and a high bacterial load. These 
findings should be confirmed in larger, longitudinal studies that incorporate quantification 
of vaginal bacteria and yeasts.. If they are confirmed, interventions that maintain a non-
iners lactobacilli/ bifidobacteria-dominated VMB may protect women from inflammation-
associated PTB. 
8 Association of vaginal microbiota with late preterm 
birth 
The primary focus of this thesis was to assess the association between the VMB in the 
second trimester and recurrent early sPTB/PPROM. Our findings suggest that eight VMB 
characteristics may be associated with recurrence (chapter 7), the most striking being a 
high vaginal bacterial load, predominantly comprised of lactobacillus.  
Women with a previous early sPTB/PPROM who avoid a recurrent event have previously 
been shown to be at an increased risk of late sPTB/PPROM compared to parous women 
without previous sPTB/PPROM.223 This study concurred with the previous work; 10.2% 
(14/137) of high-risk women had a late sPTB/PPROM, compared to only 0.9% (2/227) of 
low-risk women (Figure 5.1).  This chapter takes the opportunity provided by the these 
participants to assesses whether the VMB characteristics described in chapter 7 are also 
associated with late sPTB/PPROM in our high-risk population. 
The authors are mindful that a large number of comparisons have already been performed 
throughout this process, and to repeat the analysis within the late sPTB/PPROM group 
would further increase our chance of false-positive results. Therefore, a targeted analysis 
was performed focusing only on the contribution the VMB characteristics identified in 
chapter 7 to late sPTB/PPROM.  We chose to maximise statistical power by combining the 
outcomes of late sPTB and late PPROM, based on the work in the early sPTB/PPROM groups 
(section 7.3). 
8.1 Demographics of participants with late preterm birth 
The high-risk late sPTB/PPROM group had similar demographics to the high-risk early 
sPTB/PPROM group (Table 8.1). When compared to the high-risk term birth group those 
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with a late sPTB/PPROM were more likely to have had ≥2 previous sPTB/PPROM 
pregnancies (42.9% vs 9.2%). 
8.2 Association between vaginal microbiota characteristics and late 
preterm birth 
8.2.1 Distribution of vaginal microbiota characteristics associated with early 
preterm birth in the late preterm birth group 
The distribution of these VMB characteristics by pregnancy outcome, comparing the late 
sPTB/PPROM group to both the other high-risk groups are shown in Table 8.2. There was no 
statistically significant difference between the distribution of the VMB characteristics 
assessed in the high-risk term and high-risk late sPTB/PPROM groups. The only non-
significant trend noted was the presence of BVAB TM7-H1 in a single high-risk late 
sPTB/PPROM participant, and no high-risk term birth participants.  
When comparing the early and late sPTB/PPROM groups the only statistically significant 
differences noted were more participants in the top quartiles of bacterial load and 
concentration of Lactobacillus in the early sPTB/PPROM groups (63.6% vs. 21.4%, p=0.019 
and 63.6% vs. 14.3%, p=0.006) (Table 8.2). 
 
 
Table 8.1: Participant characteristics by pregnancy outcome  group.  
 
vs. HR term
vs. HR early 
sPTB/PPROM
Age (years) mean (SD) 31.1 (4.5) 30.0 (4.5) 30.4 (5.0) 31.4 (5.4) 0.750 0.589
BMI ﻿(kg/m2) * median (IQR) 24.5 (22-29) 25 (22-28) 25.5 (21-30) 27.5 (22-35) 0.679 0.505
Current smoker * number (%) 15 (10.6) 15 (17.4) 6 (42.9) 5 (23.8) 0.069 0.283
White 139 (95.9) 81 (93.1) 12 (85.7) 22 (100.0)
Black 3 (2.1) 4 (4.6) 1 (7.1) 0 0.0
Asian 0 0.0 0 0.0 0 0.0 0 0.0
Other 2 (1.4) 0 0.0 0 0.0 0 0.0
Not recorded 1 (0.1) 2 (2.3) 1 (7.1) 0 0.0
1 (most deprived) 74 (51.0) 50 (57.5) 8 (57.1) 15 (68.2)
2 19 (13.1) 6 (6.9) 3 (21.4) 2 (9.1)
3 24 (16.6) 9 (10.3) 1 (7.1) 2 (9.1)
4 20 (13.8) 11 (12.6) 1 (7.1) 2 (9.1)
5 (least deprived) 7 (4.8) 6 (6.9) 0 0.0 0 0.0
Not recorded 1 (0.7) 5 (5.7) 1 (7.1) 1 (4.5)
1 79 (90.8) 8 (57.1) 15 (68.2)
﻿≥ 2 8 (9.2) 6 (42.9) 7 (31.8)
Nil significant 131 (90.3) 79 (90.8) 11 (78.6) 17 (77.3)
Single LLETZ 14 (9.7) 7 (8.0) 1 (7.1) 2 (9.1)
Multiple LLETZ or knife cone 1 (1.1) 2 (14.3) 3 (13.6)
Gestational age at sample (weeks) median and range** 16+5 (16+0-21+2) 16+2 (15+1-21+6) 16+3 (15+4-20+6) 16+3 (15+2-19+4) 0.871 0.935
None 139 (100.0) 61 (70.1) 8 (57.1) 17 (77.3)
Cervical cerclage 4 (4.6) 1 (7.1) 1 (4.5)
Progesterone 2 (2.3) 2 (14.3) 1 (4.5)
Arabin pessary 20 (23.0) 3 (21.4) 2 (9.1)
Progesterone and cerclage 0 0.0 0 0.0 1 (4.5)
Gestational age at PPROM (weeks+ days) median and range 35+6 34+0-36+6 31+1 18+0-33+6
Gestational age at birth (weeks+days) median and range 40+1 (39+0-41+6) 38+6 37+0-41+5 35+6 34+4-37+1 31+5 18+0-35+5
Birthweight (g)* mean (SD) 3594 439.0 3234 489.0 2602 379.0 1778 673.0
GROW birthweight centile median and IQR 44.7 (23.2-71.0) 35.5 (18.6-62.1) 24.6 (9.6-52.3) 36.9 (16.2-54.6) 0.337 0.484
16 weeks 41 (36-47.1) 35.5 (31-42) 35 (29-40) 36 (26.5-43.5) 0.591 0.956
20 weeks 41 (37-45) 35 (30-40) 31 (23-35) 30 (26-37) 0.018 0.465
16 weeks 7 (5-16) 7 (5-22) 12 (6-45) 9 (6-23.5) 0.298 0.696









Low-risk pregnancy (LR) High-risk pregnancy (HR)
Late sPTB/PPROM n=14
P value late sPTB/PPROM
0.306 0.144
Number of previous PPROM or sPTB <34 
weeks (%)
Previous cervical surgery *
Preterm birth prevention treatment used 
after study visit
Cervical length median and IQR
qfFN median and IQR
Term birth n=145 Term birth n=87 Early sPTB or PPROM n=22
Ethnicity (%)
Index of multiple deprivation score 
quintile (%)
     
   164 
Table 8.1 notes: BMI has 1 missing value for low-risk and 1 for HR term birth. Smoking has 3 missing values for LR, and 1 each for HR term and early sPTB or PPROM . Cervical length at 16 
weeks n=136 LR, n=80 for HR-term, n=13 HR late preterm, n=20 HR early preterm. CL at 20 weeks , LR n=135, HR term n=79, HR late preterm n=14, HR early preterm n=14. qfFN at 16 weeks LR  
n=142,  HR term n=77, HR late preterm n=12, HR early preterm n=20. qfFN at 20 weeks LR  n=136,  HR term n=75, HR late preterm n=14, HR early preterm n=19. Birthweight has 2 missing 
values for HR term and 2 missing values for HR early sPTB or PPROM. GROW birthweight centile LR n=138, HR  term birth n=83, HR late preterm n=14, and HR  early sPTB/PPROM n=19. 16 
weeks gestation is abbreviated for the first study visit that was carried out at 15+1-18+6 weeks and 20 weeks gestation indicates the second study visit that was carried out at 19+0-23+0 weeks  P 
values calculated using Student’s t-test for age,  Mann-Whitney U test for BMI, cervical length, qfFN and gestational age at sampling, and Fisher’s exact test for remainder of variables. 
 
Table 8.2: Distribution of VMB characteristics associated with early sPTB/PPROM by pregnancy outcome. 
 
Table 8.2 notes: P value by Fisher’s exact test comparing the distribution of each VMB characteristic in the late sPTB/PPROM group and both the high-risk term birth group and the high-risk 
early sPTB/PPROM groups.  Bold denotes p<0.05
n (%) n (%) n (%) n (%)
Top quartile of bacterial load 37 (25.5) 31 (35.6) 3 (21.4) 14 (63.6) 0.373 0.019
Top quartile of total Lactobacillus concentration 37 (25.5) 28 (32.2) 2 (14.3) 14 (63.6) 0.221 0.006
Highest quartile of L. iners concentration (if present) 20 (13.8) 25 (28.7) 4 (28.6) 10 (45.5) 1.000 0.485
Highestet quartile of L. crispatus concentration (if present) 32 (22.1) 16 (18.4) 4 (28.6) 7 (31.8) 0.469 1.000
Presence of Ureaplasma 26 (17.9) 11 (12.6) 1 (7.1) 7 (31.8) 1.000 0.115
Highest quartile of Megasphera relative abundance 8 (5.5) 5 (5.7) 0 0.0 2 (9.1) 1.000 0.511
Prescence of BVAB TM7-H1 2 (1.4) 0 0.0 1 (7.1) 1 (4.5) 0.139 1.000
Prescence of Bifidobacertium 14 (9.7) 7 (8.0) 2 (14.3) 0 0.0 0.608 0.144
Low-risk pregnancy (LR) High-risk pregnancy (HR) P value late sPTB/PPROM
Term birth n=145 Term birth n=87 Late sPTB/PPROM n=14 Early sPTB or PPROM n=22
vs. HR term
vs. HR early 
sPTB/PPROM
8.2.2 Association between vaginal microbiota characteristics and clinical 
phenotypes of late preterm birth 
There does not appear to be a pattern of distribution of the VMB types and highest quartile 
of bacterial load by clinical phenotype of late sPTB/PPROM (Table 8.3). Of potential interest 
all the participants with the highest quartile of bacterial load had cervical insufficiency. One 
of the participants with cervical insufficiency, VMB type LA+BL and the highest quartile of 
bacterial load was also the participant with BVAB-TM7 H1 present.  
We modified our definition of clinical phenotypes from the work of Villar et al (2012).141 
Cervical insufficiency was defined as treatment for short cervical length offered prior to 
28+0 weeks gestation. Our participants were not eligible for the study if they were using PTB 
prevention treatment at the time of potential enrolment, so in this study all participants 
who received treatment did so after VMB assessment. Three out of five (60%) of the 
participants who went on to have late sPTB/PPROM after PTB prevention treatment were 
in the top quartile of bacterial load, compared to none of the participants who had late 
sPTB/PPROM and did not have PTB prevention treatment (n=9) (Table 8.4). This difference 
is significant, p=0.028, Fisher’s exact test. The three participants who had high bacterial 
loads and subsequent cervical shortening prompting initiation of preterm birth prevention 
treatment all had different preterm birth prevention treatments; one each of vaginal 
progesterone, cervical pessary and cervical cerclage. 
The difference in initiation of preterm birth prevention treatment, which implies detected 
cervical shortening, in the late sPTB/PPROM group by quartile of bacterial load prompted 
similar assessments in the early sPTB/PPROM and high-risk term birth groups (Table 8.5 and 
Table 8.6). In these pregnancy outcome groups there was no significant association noted 
between bacterial load and subsequent use of PTB prevention treatment, although a trend 
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in the same direction as the late sPTB/PPROM group was seen in the high-risk term birth 
group. 
 Table 8.3: Distribution of VMB types and top quartile of bacterial load by clinical phenotype of late sPTB/PPROM 
Table 8.3 notes :Li=L. iners-dominated (≥75% lactobacilli with L. iners the most common); LCr =L. crispatus-
dominated (≥75% lactobacilli with L. crispatus the most common); Lo+BL=other lactobacilli- or Bifidobacterium 
dominated (either≥75% lactobacilli with L. jensenii or L. gasseri the most common, or ≥50% Bifidobacterium); 
lactobacilli and anaerobes (LA+BV; either LA, 25%- 75% lactobacilli, without ≥50% Bifidobacterium or BV, 
mixture of BV-anaerobes (<25% lactobacilli).) Each participant is represented by the symbol for their VMB type, 
and if that participant also had a concentration of bacterial cells in the top quartile then the VMB type has the 
superscript ‘Bact cells’. 
 
 
 High-risk participants 
Contributing factors at birth 













Chorioamnionitis 0 0 
Placental dysfunction 0 LA+BV 
Extra amniotic infection 0 0 
Polyhydramnios 0 0 
Uterine anomaly 0 0 
Maternal comorbidities 0 0 






Multiple contributing factors 0 0 
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Table 8.4: : Distribution of high-risk participants who had late sPTB/PPROM by whether they had PTB prevention 
treatment after their study visit and quartile of bacterial load 
 Top quartile 
bacterial load 





3 (60%) 2 (40%) 5 
No PTB prevention 
treatment 
0 9 (100%) 9 
Total 3 11 14 
Table 8.4 statistics: p=0.028, Fisher’s exact test. 
 
Table 8.5: : Distribution of high-risk participants who had term birth by whether they had PTB prevention 
treatment after their study visit and quartile of bacterial load 
 Top quartile 
bacterial load 





12 (48%) 13 (52%) 25 
No PTB prevention 
treatment 
19 (30.6%) 43 (69.4%) 62 
Total 31 56 87 
Table 8.5 statistics: p=0.144, Fisher’s exact. 
 
Table 8.6: Distribution of high-risk participants who had early sPTB/PPROM by whether they had PTB prevention 
treatment after their study visit and quartile of bacterial load 
 Top quartile 
bacterial load 





2 (40%) 3 (60%) 5 
No PTB prevention 
treatment 
12 (70%) 5 (30%) 17 
Total 14 8 22 




   
   168 
8.3 Discussion 
No association was identified between the VMB characteristics associated with recurrent 
early sPTB/PPROM and late sPTB/PPROM in the high-risk group. On an individual level, 
there were three notable participants who had VMB characteristics that could be identified 
as similar to those that were associated with early sPTB/PPROM. These three participants 
had bacterial loads in the highest quartile, one also had BVAB TM7 present, and two were 
in the VMB group LA+BV (which was associated with particularly high bacterial loads in the 
early sPTB/PPROM group). All of these participants received PTB prevention treatment for 
short cervical length. It is possible that the PTB treatment averted the early sPTB/PPROM 
under 34+0 weeks gestation in these participants.  
In order to assess whether high bacterial load in the second trimester was associated with 
subsequent PTB treatment initiation (implying subsequent cervical shortening) the 
association between highest quartile of total bacterial load and subsequent PTB treatment 
was assessed for all high-risk pregnancy outcomes. 60% of the high-risk late sPTB/PPROM 
participants who had subsequent PTB prevention treatment were in the top quartile of 
bacterial load, compared to none of the late sPTB/PPROM participants who didn’t have PTB 
treatment. A similar trend was seen within the high-risk term birth group; 48% (12/25) of 
the participants who had subsequent PTB prevention treatment were in the highest 
quartile of bacterial load, compared to 30.6% (19/62) of participants who didn’t have PTB 
prevention treatment. This difference did not reach statistical significance.  
Within the high-risk early sPTB/PPROM group an opposite trend was noted, with more 
participants who didn’t have PTB prevention treatment having a higher bacterial load 
(12/17, 70% vs. 2/5, 40%, Table 8.6). The 17 participants who had an early sPTB/PPROM 
without PTB prevention treatment are those that our current practice of cervical length 
surveillance didn’t detect as having a short cervix, but they did nevertheless have an early 
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PTB/PPROM. This is consistent with previous work from our group showing that 9% of 
women with a previous sPTB/PPROM <34+0 weeks gestation have a recurrent event despite 
normal cervical length screening.30 If the current work is replicable then assessment of 
bacterial load may be able to complement cervical length assessment in preterm birth risk 
stratification. Further work would then be required to assess whether this is also able to 
help with targeting preterm birth prevention treatment. 
To our knowledge only a single study has previously assessed the association between the 
VMB by separating early and late PTB in the same population. Tabatabaei et al106 also found 
VMB characteristics that were associated with early, but not late PTB, also in a 
predominantly Caucasian population. Despite different laboratory and bioinformatic 
techniques there are some similarities in the taxa of interest between this study and our 
own. Bifidobacterium species showed a similar distribution to our work; it was only present 
in a single participant, at low relative abundance with early sPTB/PPROM (n=1/17, 5.8%), 
but was present in 4/77 (5.2%) of participants with late sPTB/PPROM and about 27/356 
(7.6%) of participants with term births. This is comparable to the 0%/14.3%/8.0% in our 
high-risk early sPTB/PPROM/late sPTB/PPROM /term groups respectively. 
8.3.1 Conclusion 
The VMB characteristics that this work identified as associated with early sPTB/PPROM did 
not replicate in the late sPTB/PPROM group. It was noted that the late sPTB/PPROM 
participants who were in the highest quartile of bacterial load all subsequently had cervical 
shortening and received PTB prevention treatment. It is possible that this PTB prevention 
treatment averted an early sPTB/PPROM in these participants.   
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9 Discussion and conclusion 
This thesis assesses the relationship between the VMB in the second trimester and 
recurrent sPTB/PPROM. This chapter provides a summary and discussion of the key 
findings. 
9.1 Vaginal microbiota characteristics of interest 
Molecular assessment of the vaginal microbiota by next generation sequencing has only 
been possible in the past decade. Previous attempts to meta-analyse prior studies have 
been hampered by technical differences in every aspect of study design.110,182 Therefore, 
instead of re-attempting meta-analysis we focused on the findings interpreted as 
associated with PTB, or term birth, by each previous research team. Through this method 
we were able to identify six global VMB characteristics and 18 taxa that had shown an 
association with preterm birth in at least two previous studies and we selected an 
additional five taxa of interest based on scientific plausibility (Table 4.3). 
In addition we developed three VMB variables specifically for this study. The first variable 
was a modified version of the mutually exclusive VMB types that had been previously been 
correlated with Nugent score and risk of STI acquisition outside of pregnancy by our 
research group.176  The modifications accounted for the expected increased relative 
abundance of Lactobacillus in pregnancy and corresponding reduction in BV-anaerobes and 
pathobionts. Secondly the distribution in each sample of broad groups of taxa was assessed 
by allocating each taxon to one of four ‘bacterial groups’, based on the published 
literature; lactobacilli; BV-anaerobes; pathobionts; and a rest group of ‘other bacteria’. This 
allowed assessment of the percentage of each bacterial group in each sample. The final 
new variable was the concentration of taxa in each bacterial group, estimated by combining 
the BactQuant assay with the relative abundance of taxa in each bacterial group. This was 
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expressed as a continuous variable on a log scale10, and also by quartile of the distribution 
in the low risk group. 
Individual research groups have developed and used their own VMB characterisation 
methods across research studies,103,172,173 and the community state type grouping133 has 
been commonly used, with some adaptions. However, the optimal method of VMB 
assessment in pregnancy is yet to be determined, and no previous studies have focused on 
replicability of previous work from outside of their own research group. This study gave the 
opportunity to assess replicability of VMB characteristics associated with PTB by an 
independent group.  
9.2 Vaginal microbiota in healthy pregnancies 
We found that the 2nd trimester VMB was dominated by Lactobacillus in 72.5% of low-risk 
participants with term birth. The most common VMB type and CST was that dominated by 
L. crispartus, closely followed by the CSTs and VMB types with domination of L. iners and 
other species of Lactobacillus. These findings are consistent with other VMB assessments in 
the second trimester of pregnancies that have progressed to term in Caucasian 
populations.97,101,106,110  
The VMB was stable for the majority of low-risk term birth participants who had two study 
visits available for analysis. The global sample characteristics such of sample richness, 
diversity and bacterial load of our low-risk term birth group were broadly in keeping with 
results from participants who have had term births in previous studies. 
There were a notable minority of participants who had low-risk term births and a VMB that 
could be considered to have unfavourable characteristics.  There are likely to be multiple 
protective factors that lead to term birth in the majority of pregnancies, even in the 
presence of unfavourable VMB characteristics. 
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9.3  Contribution of the vaginal microbiota to recurrent early preterm 
birth 
This exploratory study suggests that high vaginal bacterial load in the second trimester is 
associated with early sPTB/PPROM recurrence in high-risk pregnant women. High-risk 
participants who had an early sPTB/PPROM had approximately a five times higher bacterial 
load in the second trimester than high-risk participants who had a term birth.  
Our statistical power was limited because only 22 women had an early sPTB/PPROM 
recurrence. Not all associations in line with our conclusion reached statistical significance, 
especially after stratification by bacterial composition. 
However, there are a number of reasons why we believe the hypothesis warrants further 
research. Firstly, the recurrence risk of early sPTB/PPROM increased for each increase in 
bacterial and Lactobacillus concentration quartile, when compared to the distribution of 
these parameters within the low-risk term birth participants.  Secondly, within each VMB 
type, the high-risk term birth and low-risk term birth participants had similar median 
bacterial loads, suggesting that it is the bacterial load, independent of the VMB type, that is 
contributing to the increased risk of early sPTB/PPROM. Finally, bacterial load reached 
higher levels in participants dominated by L. iners or with non-dominance of Lactobacillus 
than for participants with other lactobacilli or bifidobacteria. Therefore our findings do not 
contradict earlier findings that showed increased PTB risk with non-dominance of 
lactobacilli and high L. iners relative abundance.101,102,162,165 In fact, the inconsistent findings 
related to L. iners in the literature might be due to the lack of quantification in most 
studies. 
We attempted correlation between VMB findings and clinical phenotype of sPTB/PPROM. 
This was hampered by small numbers in each subgroup, however we did note that both 
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participants who had early PPROM with early onset chorioamnionitis had high bacterial 
loads. It is possible that the high bacterial loads increase the chance of ascension of 
bacteria into the upper genital tract and adverse outcome. 
Three taxa were non-significantly associated with early sPTB/PPROM recurrence in our 
study and were also associated with PTB in other studies: Ureaplasma,162,168 
Megasphera101,168 and BVAB TM7-H1100. In women with early sPTB/PPROM recurrence, the 
presence of Ureaplasma species in the vagina did not completely overlap with having high 
bacterial loads and lactobacilli concentrations. Ureaplasma species may therefore play a 
role in PTB that is independent from overall vaginal bacterial composition and load. Our 
data concurs with earlier work suggesting that Bifidobacterium breve may have a protective 
effect against early sPTB/PPROM recurrence.103    
The remainder of the VMB characteristics assessed did not show an association with early 
sPTB/PPROM. Lack of an association, particularly in this small study, does not imply no 
association, although the magnitude of association appears too small to be detected with 
recruitment of 137 high-risk women.  
9.4 Contribution of the vaginal microbiota to late preterm birth 
The VMB characteristics that were associated with early sPTB/PPROM were not replicable 
in the high-risk late sPTB/PPROM group. 
There were only three (3/14, 21%) participants in the highest quartile of bacterial load in 
the late sPTB/PPROM group. No participants were using preterm birth prevention therapy 
at the time of VMB sampling, but preterm birth prevention therapy was offered if there 
was cervical shortening, in line with standard UK care.26  The three participants in the 
highest quartile of bacterial load in the late sPTB/PPROM group received preterm birth 
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prevention treatment after study involvement. It is possible that this treatment averted 
early sPTB/PPROM in these participants.  
This prompted assessment of preterm birth prevention therapies in the other high-risk 
pregnancy outcome groups. The high-risk term group had a similar trend, with more 
participants who received PTB prevention treatment having a higher bacterial load 
(suggesting the treatment might have averted PTB in some of these cases too). When 
assessing the early sPTB/PPROM group the opposite was true, there was a non-significant 
trend for more participants without PTB prevention treatment to have a high bacterial load. 
The participants who were high-risk, but our current cervical surveillance methods do not 
identify as having cervical shortening, in order to target PTB prevention treatment, are 
arguably the women who we currently least well served by PTB prevention clinics. If the 
current work is replicable then it would be desirable to utilise bacterial load as another 
method of risk stratification for preterm birth, and ideally develop an intervention to target 
this. 
9.5 Strengths and limitations 
Strengths of this study are that we carefully selected and assessed pregnancy outcomes to 
achieve as clean a phenotype as possible of recurrent early sPTB/PPROM. VMB 
characteristics were carefully selected to cover different aspects of VMB composition and 
when possible were semi-quantified.  
The most notable limitations are our limited statistical power and lack of data about vaginal 
yeasts. We are also unable to comment on the functional capacity of the bacteria 
identified, nor identify the bacteria to species level. The wider availability of 
metatranscriptomics and metagenomics may make this possible in future work. We had 
initially planned to analyse early sPTB and PPROM as separate outcomes but limited 
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statistical power did not permit this. There were 11 participants excluded from the high-risk 
group due to medically indicated PTB. This high rate of medically indicated PTB may be 
inevitable within such a high-risk cohort, but nevertheless changes the composition of the 
term group by removing a section of the participants who are likely to have progressed to 
term without intervention. 
9.6 Implications for future research  
Larger, longitudinal studies should assess whether the findings of this work are replicable. 
In particular assessment should be made of the gestational period during which increased 
bacterial load is associated with early sPTB/PPROM, so that any intervention can be 
optimally timed. Concomitantly quantification should be made of the yeasts present, and 
functional assessment undertaken to detect the transcriptional activity of bacteria present. 
As our ability to detect different strains of lactobacilli improves this should also be 
incorporated into future work to better understand how and why some VMB types appear 
to reach higher bacterial loads. If they are confirmed, interventions that maintain a non-
iners lactobacilli/ bifidobacteria-dominated VMB may protect women from inflammation-
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Appendix B 
Control group information leaflet  
Version: 2.0          
Date:  22.01.2016     







The Development of Novel Biomarkers for Preterm Labour  
  
Dr Angharad Care – Harris Preterm Birth Clinical Research Fellow, Liverpool Women’s Hospital  
Professor Zarko Alfirevic – Professor in Fetal & Maternal Medicine, Liverpool Women's Hospital  
  
We are inviting pregnant women who are very likely to have a normal and healthy 
pregnancy to take part in a research study to help mums and babies who suffer with 
prematurity (babies born too early). Before you decide whether or not to take part it is 
important for you to understand why the research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it with others if 
you wish. One of our team will go through the information sheet with you and answer any 
questions you may have.   
  
Why are we doing the study?  
A baby being born too early is a really important area for us to research as we still 
understand very little about why some mothers go into labour too early and who it is going 
to affect. Premature infants are at greater risk for death, cerebral palsy, delays in 
development, hearing problems, and problems seeing. These risks are greater the earlier a 
baby is born.  
The aim of this study is to develop earlier and safer ways of detecting preterm labour. 
Research has shown that it may be possible to use blood tests or vaginal swabs taken from 
the mother early in pregnancy to gather information which may help us to predict the 
likelihood of preterm labour. In this study we are taking blood and vaginal swabs from 
healthy women to compare them to women who have a baby born too early. If there are 
signals that can be used to predict early labour we hope to only find them in the mum’s 
that have a preterm labour and will not be in the group that carry their baby to term. For 
this we need to take blood and swabs from women like you who have had a normal 
pregnancy before.   
There is also evidence that women with less acidity (a higher pH) or certain types of 
bacteria in the vagina may be more at risk of preterm delivery. We will perform vaginal 
swabs for pH and bacteria check when you come to clinic at 16 weeks and 20 weeks of 
your pregnancy. This is not a swab for sexually transmitted diseases, if this is something 
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you want this should be done at a local family planning or sexual health clinic. We 
understand that at 16 weeks it would be an additional trip to hospital for you, therefore in 
addition to the tests we can provide you with a reassurance scan to show you your baby’s 
heartbeat and a picture of your baby. If you would like to know the sex of your baby, we 
could also tell you this information (but we warn all women a scan can never be 100% 
accurate). You will still need to attend your booked 20 week scan as this will look at all your 
baby’s organs to check they are developing normally and if you want we can arrange your 
visit to happen at the same time, (if you have your scan at Liverpool Women’s Hospital), so 
you don’t have additional trips to the hospital. However, if you attend a separate 
appointment we will still scan your baby and provide you with pictures to keep for free.   
There is a link between bacteria, infection and preterm birth but it is not clear how the 
bacteria cause preterm birth or how bacteria get into the womb. Certain “pro-biotics” are 
being developed for good gut health and help with digestive problems. In this project we 
are also analysing bacteria in urine (wee) and stool (poo) as well as vaginal bacteria. If 
there are “bad” bacteria that are linked with preterm birth we may be able to design a 
“probiotic” to replace the bacteria in the tummy with “good” bacteria to try and prevent 
preterm birth. We are also collecting stool samples which can be done at 16 and 20 weeks 
of pregnancy at home with our specially designed kits and posted back to our lab. These 
samples are optional, if you did not wish to provide them, you may still be included in the 
research study.   
It might be that a combination of these “biomarkers” or signals in the body that might 
allow us to predict preterm birth, so our statisticians will be putting all this data together to 
see if combinations of this information that we find can predict if women are protected 
from preterm birth or are at risk.   
Why have I been chosen?  
We are inviting all women over 18 years who have previously had a normal healthy 
pregnancy that delivered at term.   
Do I have to take part?  
It is up to you to decide whether or not to take part. If you decide to take part you are free 
to withdraw at any time without giving a reason. If you do not feel able to take part it will 
not in any way affect the care you or your family receives.  
What will happen to me if I take part?  
If you do decide to take part you will be given this information sheet to keep and asked to 
sign a consent form. We will make a special appointment for you to be seen at 16 weeks 
for a blood test, vaginal swab and a 3 minute internal scan of your cervix to measure the 
length (short cervix is a risk factor for preterm birth). If your cervix is very short we will 
provide you with preventative treatment and you will not be able to take part in the 
research study. We will then perform a scan of your baby for reassurance and provide you 
with pictures (and sex the baby if you would like to find out). We will also ask that you 
donate a urine samples and stool samples at 16 weeks and 20 weeks of pregnancy, these 
can be done at home. The appointment may take up to 55 minutes for us to chat about 
your pregnancy, collect information about you and perform the swabs and blood tests with 
you feeling comfortable. You will be given a second appointment at 20 weeks and the 
same will happen at this appointment.. We will be looking at genes that make it more likely 
that you might have a preterm birth but we will not be testing for genetic disease or 
paternity on any of these samples.  
Will my taking part in this study be kept confidential?  
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Yes. We will follow ethical and legal practice and all information will be handled in 
confidence. Any information you give us will only be used by the research team in the 
course of the research to develop these new tests. Any samples and data stored will be 
stored securely. They will be coded, and no personal data (name and address) will be 
available to the researchers. However, if any analysis provides clinically relevant 
information we will inform your medical doctor.  
What are the possible benefits of taking part?  
The results of this research will not benefit the course of your pregnancy. We hope that the 
results of the study overall will enable us to improve antenatal care provided to women by 
developing safer prenatal tests that will help us detect pregnancies at risk of preterm birth. 
We understand that you are doing research to benefit others and will perform an 
additional scan to give you the opportunity to see your baby and your baby’s heartbeat by 
one of the Obstetric doctors at the 16 week visit.  
What are the possible disadvantages and risks of taking part?  
We will take additional samples of blood, urine, stool (optional), vaginal swabs. This will be 
carried out by someone who is skilled in taking blood. Some women find it embarrassing to 
have a vaginal swab but this will be performed by a female doctor or researcher. 
Ultrasound has an excellent safety record and will not harm your baby but is optional.   
What will happen if I don’t want to continue in the study?  
You are free to withdraw at anytime. If you withdraw from the study we will not access any 
further samples and will destroy any of your samples that were collected for the study.   
What will happen to any samples I give?  
The samples will be coded and no personal data (name and address) will be stored with the 
sample. The development of these tests will be done in laboratories in the UK, Finland and 
Germany. We also ask whether you would be willing to gift samples to be used for other 
ethically approved research studies into pregnancy problems.   
What will happen to the results of the research study?  
The results from our project will be published as research papers in medical journals. No 
data will be published that will allow individuals to be identified.   
Where can I get further information or discuss any problems?  
Please contact a member of the fetal centre on 0151 702 4608 to discuss any questions or 
worries about the study, or if you have any complaints. If your concerns are not resolved, 
please contact Patient Advisory Liaison Services (PALS) on 0151 702 4353, if you have any 
concerns regarding the care you have received, or as an initial point of contact if you have 
a complaint. You can also visit PALS by asking at the hospital reception.  
Who is organising and funding the research?   
This research is organised by the Wellbeing-Harris Preterm Birth Research Centre part of 
the University of Liverpool Centre for Women and Children’s Health Research at the 
Liverpool Women’s Hospital.  
Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given 
favourable opinion by NRES Committee.  
 
Thank you for taking the time to read this information leaflet.   
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Appendix C 
PTL Clinic - Patient information   
Version:2.2         
Date: 22.01.2016     
Project ID number:11/NW/0720  
  
  
The Development of Novel Biomarkers for Preterm Labour  
  
Dr Angharad Care – Clinical Research Fellow, Liverpool Women’s Hospital  
Professor Zarko Alfirevic – Professor in Fetal & Maternal Medicine, Liverpool Women's Hospital  
We are inviting many of the women who attend our unit to take part in a research study. 
Before you decide whether or not to take part it is important for you to understand why 
the research is being done and what it will involve. Please take time to read the following 
information carefully and discuss it with others if you wish. One of our team will go 
through the information sheet with you and answer any questions you may have.   
Why are we doing the study?  
The aim of this study is to develop earlier and safer ways of detecting problems in 
pregnancy. Research has shown that it may be possible to use a blood tests, vaginal swabs, 
urine or stool taken from the mother early in pregnancy to gather information which may 
help us work out why preterm birth happens and to predict the chances of preterm labour. 
We will do this by assessing a number of ‘biomarkers’ within these samples including 
different proteins, different types of bacteria and DNA. We will be taking samples at 
approximately 16 and 20 weeks. We want to identify why some women fail to respond to 
certain treatments for preterm labour, so we can work out which treatments are best for 
which women.   
There is also evidence that women with less acidity (a higher pH) or certain types of 
bacteria in the vagina may be more at risk of preterm delivery. We wish to evaluate the 
ability of vaginal pH and types of bacteria to predict preterm birth or a short cervix. We will 
perform a vaginal swabs for pH and bacterial species check when you come to clinic at 16 
weeks and 20 weeks of your pregnancy. This is not a swab for sexually transmitted 
diseases, if this is something you want this should be done at a local family planning or 
sexual health clinic.   
There is a link between bacteria, infection and preterm birth but it is not clear how the 
bacteria cause preterm birth or how bacteria gets into the womb. Certain “pro-biotics” are 
being developed for good gut health and help with digestive problems. In this project we 
are also analysing bacteria in urine (wee) and stool (poo) on top of vaginal bacteria. If there 
are “bad” bacteria that are linked with preterm birth we may be able to design a 
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are also collecting stool samples which can be done at 16 and 20 weeks of pregnancy at 
home with our specially designed kits and posted to our lab.   
It might be that a combination of these “biomarkers” might allow us to predict preterm 
birth, so our statisticians will be putting all this data together to see if combinations of this 
information that we find out about you can predict if women are protected from preterm 
birth or if women are at risk.   
In the future this data may also help us target specific treatments to women to prevent 
preterm birth if we think we can work out why preterm birth may be happening.   
Before we can offer new tests routinely it is important to ensure they work well and are 
accurate. To do this we need the help of women who are at high risk of preterm labour, 
either because of a previous preterm birth or cervical surgery.   
 Why have I been chosen?  
We are inviting all women over 18 years of age attending the preterm labour clinic to take 
part in the study.   
 Do I have to take part?  
It is up to you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and asked to sign a consent form. If you decide to 
take part you are free to withdraw at any time without giving a reason. If you do not feel 
able to take part it will not in any way affect the care you or your family receives.  
 What will happen to me if I take part?  
If you agree to take part we will ask you to donate additional blood samples; 24ml (5 
teaspoons) of blood will be taken at 16 weeks and 20 weeks at your PTL clinic 
appointments.  We will arrange for you to have vaginal swab at the time of your internal 
scan to screen for bacterial vaginosis and provide you with treatment if required. As an 
optional part of the study, we will ask you provide a urine sample and stool sample which 
can be done either at clinic or at home with our specially designed kits and posted to the 
lab. We will not be testing for STI’s, genetic disease or paternity on any of these samples.   
 Will my taking part in this study be kept confidential?  
Yes. We will follow ethical and legal practice and all information will be handled in 
confidence. Any information you give us will only be used by the research team in the 
course of the research to develop these new tests. Any samples and data stored will be 
stored securely. They will be coded, and no personal data (name and address) will be 
available to the researchers. However, if DNA analysis provides clinically relevant 
information we will inform your medical doctor  
 What are the possible benefits of taking part?  
The results of this research will not be available in the course of your pregnancy and will 
not directly benefit you. We hope that the results of the study overall will enable us to 
improve antenatal care provided to women by developing safer prenatal tests that will 
help us detect pregnancies at risk of preterm birth. We will ensure that your doctor is 
informed of any progress that means these new tests could be available for you in future 
pregnancies.   
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 What are the possible disadvantages and risks of taking part?  
Providing samples for research will add on additional time to your clinic appointments.  An 
appointment may last for up to 45 mins. Blood taking can be uncomfortable and this will 
be carried out by someone who is skilled in venepuncture (taking blood). Some people may 
experience bruising at the site which will resolve over a few days. Ultrasound has an 
excellent safety record and will not harm your baby.   
 What will happen if I don’t want to continue in the study?  
You are free to withdraw at anytime. If you withdraw from the study we will not access any 
further samples and will destroy any of your samples that were collected for the study.   
 What will happen to any samples I give?  
Samples will be collected specifically for this study. The samples will be coded and no 
personal data (name and address) will be stored with the sample. The development of 
these tests will be done in laboratories in the UK, Finland and the Germany. We also ask 
whether you would be willing to gift samples to be used for other ethically approved 
research studies into pregnancy problems. Your samples will only be used in research 
studies designed to develop these new methods for the early detection of pregnancy 
complications.  
 What will happen to the results of the research study?  
The results from our project will be published as research papers in medical journals. No 
data will be published that will allow individuals to be identified.   
 Where can I get further information or discuss any problems?  
Please contact a member of the fetal centre on 0151 702 4608 to discuss any questions or 
worries about the study, or if you have any complaints. If your concerns are not resolved, 
please contact Patient Advisory Liaison Services (PALS) on 0151 702 4353, if you have any 
concerns regarding the care you have received, or as an initial point of contact if you have 
a complaint. You can also visit PALS by asking at the hospital reception.  
 Who is organising and funding the research?   
This research is organised by the Department of Women’s and Children’s Health, University 
of Liverpool.  
 Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given 




Thank you for taking the time to read this information leaflet.  
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Appendix D 
 
   
Study Number:  




Title of Project: Developing novel biomarkers for the prediction of preterm 
labour  
  
Name of Researcher:    
Dr Angharad Care, Clinical Research Fellow, University of Liverpool/Liverpool Women’s 
Hospital  
Dr Andrew Sharp, Clinical Lecturer, University of Liverpool/Liverpool Women’s Hospital  
Prof Zarko Alfirevic, Professor of Obstetrics, University of Liverpool/Liverpool Women’s 
Hospital  
  
Please initial box  
1. I confirm that I have read and understand the information sheet dated …      
    
(version ……) for the above study and have had the opportunity to ask questions.  
  
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time,   without giving any reason, without my medical care or legal rights being affected.  
  
3. I give permission for my medical notes and data collected during this research to be 
looked at by responsible individuals from the University of Liverpool & Liverpool 
Women’s Hospital   or from regulatory authorities where it is relevant to my taking part in 
research.    
 
4. I agree for DNA/RNA testing on my blood samples.          
    
5. I give permission for the researcher to contact my medical practitioner in the event of   
  clinically significant findings from this research.  
6. I give permission for my samples to be sent outside of the UK        
   
7. Once we carry out the study on the samples you kindly donate, if there is any 
surplus sample it will be stored in the Liverpool Women’s Research Tissue Bank, of 
which the University of Liverpool is the custodian.   
                      
    
 
 
   






Name of Patient  
  
  
 Date     Signature  
_________________________   ________________   ____________________  
Name of Person taking consent  
(if different from researcher)  
  
 Date     Signature  
_________________________   ________________   ____________________  
Researcher   Date     Signature  
  
1 for patient;  1 for researcher;  1 to be kept with hospital notes  
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Appendix E 
Preterm Labour Biomarker Study  
CONTROL Recruitment Data Collection Sheet 






Smoking: Yes / No           Per day: 1-5 / 6-10 / 10-15 / >15 
Ethnicity:  
Obstetric History 
Gestation:............wks………….days            Confirmed EDD (DD/MM/YYYY): __ 
__/__ __/__ __ __ __ 
G........P.........    EDD by scan / menstrual dating / IVF (delete as 
appropriate) 
No. of previous pregnancies complicated by:  
Previous spontaneous preterm birth <34 weeks (n)        Gestation: 
Previous PPROM <34weeks followed by sPTB(n)        Gestation: 
Previous PPROM <34 weeks with IOL (n)        Gestation: 
Clinical/placental histopathological chorioamnionitis (n)                                       
Birthweight centile <10th (n)                                        
Gestational Hypertension (n)  
Gestational diabetes requiring metformin/insulin therapy (n)  
Placental Abruption (n)  
Caregiver initiated preterm birth < 37 weeks (n)  
Multiple Pregnancy (n)  
Intrauterine Fetal Death (n)  
Polyhydramnios (n)  
Short Cervix (requiring treatment) (n)  




   
   201 
History recurrent miscarriage (3 or more consecutive):  Yes              No 
 
Medical History 
History of cervical surgery? (circle)   Yes   /  No    
If yes, please specify:     Single LLETZ                  Multiple LLETZ               Knife Cone 
Biopsy   
     Other / Year:.......................................................... 
NB. If cervical surgery only indication for referral – NOT eligible for recruitment 
Please list any medical conditions: 
 
Medication currently taking / taken in last 72 hours (give time, date and route): 
 
Antibiotic course in pregnancy?   Yes / No            
If yes, dates taken (if multiple, record date of most recent): ……../……../…….. - 
……../……../…….. 
Type of antibiotic:……………………………………..                  PO / PV / topical/ IV (delete as 
appropriate) 
Cervical length:…………………………….mm  
Current Pregnancy Screening 
Hepatitis B screening result:   Positive               Negative  Not Done 
Hepatitis C screening result:   Positive Negative Not Done 
HIV screening results:   Positive Negative Not Done 
Invasive Testing 
Invasive testing or procedures performed (CVS, amniodrainage):  Performed    
 Not Done 
Diet History: 
Vegetarian  Yes  No 
Vegan   Yes  No 
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Any use of probiotics in pregnancy? Yes No 
If so what taken and when (freetext): 
Other specific dietary requirement / intolerance (freetext): 
 
Sexual history:  
Have you had sex in the last 48 hours? 
No 
With condom 
No condom  
Any concerns about vaginal discharge or soreness in past week? Yes/ No 
What is the concern? Smell/ excessive volume /itch/sore/Other (free text) 
Samples taken (visit A): 
Urine sample   Yes Not done 
Fetal fibronectin:  Yes Not done  Result (ng/ml):  
HVS   Yes       Not done  Result: 
       BV:  yes    no      Treatment:      
yes no 
Vaginal pH:………………………. 
Vaginal dry swab:  x1 x2 Not done 
Vaginal RNA swab:  yes Not done 
Stool sample:   yes no  
Plasma   yes no 
Serum   yes no 
RNA   yes no 
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Preterm Labour Biomarker Study  




Cervical length:…………………………….mm  
Samples taken (visit B): 
Urine sample   Yes Not done 
Fetal fibronectin:  Yes Not done  Result (ng/ml):  
HVS   Yes       Not done  Result: 
       BV:  yes    no      Treatment:      
yes no 
Vaginal pH:…………………………. 
Vaginal dry swab:  x1 x2 Not done 
Vaginal RNA swab:  yes Not done 
Stool sample:   yes no  
Plasma   yes no 
Serum   yes no 
RNA   yes no 
Whole blood  yes no 
 
Is this patient currently on treatment for short cervical length?  Yes /  No 
If yes, please specify:  
 
Are there any other pathologies or concerns with this pregnancy? Yes / No 
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What medications have been taken within last 72hrs? (please detail dose, time, 
route) 
 
Any antibiotic courses since last study visit?                   Yes / No 
Details:        Dates taken: ……../……../…….. - ……../……../……..        
Name:_______________________ 
Any use of probiotics since last study visit? Yes No 
If so what taken and when (freetext): 
Have you had sex in the last 48 hours? 
No / With condom /No condom  
Any concerns about vaginal discharge or soreness in past week? Yes/ No 
What is the concern? Smell/ excessive volume /itch/sore/Other (free text) 
Follow up Data 
Gestational hypertension Yes    No      
Pre-eclampsia Yes    No      
PPROM Yes    No      
Low dose aspirin commenced <16+0 Yes    No      
Prophylactic dose LMWH  Yes    No      
Gestational diabetes requiring 
metformin/insulin Yes    No      
Antepartum haemorhage > 20+0 Yes    No      
Corticosteroids for fetal lung maturity 
Yes    No 
Gestational Age when  
steroids given:     
 
      
Treatment with a cervical cerclage 
Yes / No If yes, gestational age at Rx: WW+D 
Material used for 
suture: 
Braided polyfilament (tape) / 
monofilament 
Treatment with vaginal progesterone Yes / No If yes, gestational age at Rx: WW+D    
Treatment with arabin pessary Yes / No If yes, gestational age at Rx: WW+D    
 
      
 Other (please specify): 
Delivery Data 
Gestational Age at delivery 
Birthweight      Sex  
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Appendix F 
Preterm Labour Biomarker Study  
HIGH RISK CASE Recruitment Data Collection Sheet 






Smoking: Yes / No           Per day: 1-5 / 6-10 / 10-15 / >15 
Ethnicity:  
Obstetric History 
Gestation:............wks………….days Confirmed EDD (DD/MM/YYYY): __ __/__ 
__/__ __ __ __ 
G........P.........    EDD by scan / menstrual dating / IVF (delete as 
appropriate) 
No. of previous pregnancies complicated by:  
Previous spontaneous preterm birth <34 weeks (n)                Gestation: 
Previous PPROM <34weeks followed by sPTB(n)                Gestation: 
Previous PPROM <34 weeks with IOL (n)                 Gestation: 
Clinical/placental histopathological chorioamnionitis (n)                                       
Birthweight centile <10th (n)                                        
Gestational Hypertension (n)  
Gestational diabetes requiring metformin/insulin therapy (n)  
Placental Abruption (n)  
Caregiver initiated preterm birth < 37 weeks (n)  
Multiple Pregnancy (n)  
Intrauterine Fetal Death (n)  
Polyhydramnios (n)  
Short Cervix (requiring treatment) (n)  




   
   206 
History recurrent miscarriage (3 or more consecutive):  Yes  No 
 
Medical History 
History of cervical surgery? (circle)   Yes   /  No    
If yes, please specify:     Single LLETZ                  Multiple LLETZ               Knife Cone 
Biopsy   
     Other / Year:.......................................................... 
NB. If cervical surgery only indication for referral – NOT eligible for recruitment 
Please list any medical conditions: 
 
Medication currently taking / taken in last 72 hours (give time, date and route): 
 
Antibiotic course in pregnancy?   Yes / No            
If yes, dates taken (if multiple, record date of most recent): ……../……../…….. - 
……../……../…….. 
Type of antibiotic:……………………………………..                  PO / PV / topical/ IV (delete as 
appropriate) 
Cervical length:…………………………….mm  
 
Current Pregnancy Screening 
Hepatitis B screening result:   Positive Negative  Not Done 
Hepatitis C screening result:   Positive Negative Not Done 
HIV screening results:   Positive Negative Not Done 
Invasive Testing 
Invasive testing or procedures performed (CVS, amniodrainage):  Performed    
 Not Done 
Diet History: 
Vegetarian  Yes  No 
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Vegan   Yes  No 
Other specific dietary requirement / intolerance (freetext): 
Any use of probiotics in pregnancy? Yes/ No 
If so what taken and when (free text) 
 
Sexual history:  
Have you had sex in the last 48 hours? 
No/ With condom/ No condom  
Any concerns about vaginal discharge or soreness in past week? Yes/ No  
What is the concern? Smell/ excessive volume /itch/sore/Other (free text) 
 
Samples taken (visit A): 
Urine sample   Yes Not done 
Fetal fibronectin:  Yes Not done  Result (ng/ml):  
HVS   Yes       Not done  Result: 
       BV:  yes    no      Treatment:      
yes no 
Vaginal pH:………………………. 
Vaginal dry swab:  x1 x2 Not done 
Vaginal RNA swab:  yes Not done 
Stool sample:   yes no  
Plasma   yes no 
Serum   yes no 
RNA   yes no 
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Preterm Labour Biomarker Study  




Cervical length:…………………………….mm  
Samples taken (visit B): 
Urine sample   Yes Not done 
Fetal fibronectin:  Yes Not done  Result (ng/ml):  
HVS   Yes       Not done  Result: 
       BV:  yes    no      Treatment:      
yes no 
Vaginal pH:…………………………. 
Vaginal dry swab:  x1 x2 Not done 
Vaginal RNA swab:  yes Not done 
Stool sample:   yes no  
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Plasma   yes no 
Serum   yes no 
RNA   yes no 
Whole  blood yes no 
Is this patient currently on treatment for short cervical length? Yes /  No 
If yes, please specify:  
 
Are there any other pathologies or concerns with this pregnancy? Yes / No 
 
What medications have been taken within last 72hrs? (please detail dose, time, 
route) 
 
Any antibiotic courses since last study visit?                     Yes / No 
Details:        Dates taken: ……../……../…….. - ……../……../……..        
Name:_______________________ 
Any use of probiotics since last study visit? Yes No  
If so what taken and when (freetext):  
Have you had sex in the last 48 hours?  
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No / With condom /No condom   
Any concerns about vaginal discharge or soreness in past week? Yes/ No  
What is the concern? Smell/ excessive volume /itch/sore/Other (free text) 
Follow up Data 
Gestational hypertension Yes    No      
Pre-eclampsia Yes    No      
PPROM Yes    No      
Low dose aspirin commenced <16+0 Yes    No      
Prophylactic dose LMWH  Yes    No      
Gestational diabetes requiring 
metformin/insulin Yes    No      
Antepartum haemorhage > 20+0 Yes    No      
Corticosteroids for fetal lung maturity 
Yes    No 
Gestational Age when  
steroids given:     
 
      
Treatment with a cervical cerclage 
Yes / No If yes, gestational age at Rx: WW+D 
Material used for 
suture: 
Braided polyfilament (tape) / 
monofilament 
Treatment with vaginal progesterone Yes / No If yes, gestational age at Rx: WW+D    
Treatment with arabin pessary Yes / No If yes, gestational age at Rx: WW+D    
 
      
 Other (please specify): 
Delivery Data 






   




List of taxa (alphabetical 
order) Classification













Can reside, possibly indigenously, on the 
human skin and in the human respiratory 
tract. Can cause nosocomial infections such as 
bacteremia, secondary meningitis, 






Gram-stain-positive cocci associated with 






































Facultative anaerobic bacterium, part of the 














Facultative anaerobe that has often been 





Facultative anaerobe that has often been 
















yes Often described in molecular studies of BV.
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List of taxa (alphabetical 
order)







Comments based on Bergey's manual and 
published literature
Alloscardovia omnicolens Other Actinobacteria/Actinobacteria 
(Bifidobacteriales)
no Closely related to Bifidobacteria, which are 
considered to have probiotic properties.
Anaerococcus genus BV Firmicutes/Clostridia 
(Clostridiales)
no Often described in molecular studies of BV.
Anaerococcus hydrogenalis BV Firmicutes/Clostridia 
(Clostridiales)
no
Anaerococcus lactolyticus BV Firmicutes/Clostridia 
(Clostridiales)
no
Anaerococcus nagyae BV Firmicutes/Clostridia 
(Clostridiales)
no
Anaerococcus octavius BV Firmicutes/Clostridia 
(Clostridiales)
no
Anaerococcus prevotii BV Firmicutes/Clostridia 
(Clostridiales)
no
Anaerococcus provenciensis BV Firmicutes/Clostridia 
(Clostridiales)
no
Anaerococcus senegalensis BV Firmicutes/Clostridia 
(Clostridiales)
no Anaerobe described in stool samples 
Anaerococcus vaginalis BV Firmicutes/Clostridia 
(Clostridiales)
yes
Anaeroglobus geminatus BV Firmicutes/Negativicutes 
(Selenomonadales)
no Anaerobe described in periodontitis.
Anaeroglobus genus BV Firmicutes/Negativicutes 
(Selenomonadales)
no
Anaerobe described in periodontitis. Occurs 
in gastrointestinal tract and presumably in 
oral cavity 
Anaerostipes hadrus BV Firmicutes/Clostridia 
(Clostridiales)
yes Strict anaerobe described in the gut/faeces.
Arcanobacterium genus BV Actinobacteria/Actinobacteria 
(Actinomycetales)






Atopobium deltae BV Actinobacteria/Coriobacteriia 
(Coriobacteriales)
no
Atopobium genus BV Actinobacteria/Coriobacteriia 
(Coriobacteriales)
no Includes A. vaginae, which is known to be 
important in BV.
Atopobium minutum BV Actinobacteria/Coriobacteriia 
(Coriobacteriales)
no
Atopobium parvulum BV Actinobacteria/Coriobacteriia 
(Coriobacteriales)
yes
Atopobium rimae BV Actinobacteria/Coriobacteriia 
(Coriobacteriales)
yes
Atopobium vaginae BV Actinobacteria/Coriobacteriia 
(Coriobacteriales)
no
Bacillus subtilis Other Firmicutes/Bacilli (Bacillales) yes
Bacteroidales order BV Bacteroidetes/Bacteroidia 
(Bacteroidales)
yes Bacteroidales have commonly been described 
in BV.
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List of taxa (alphabetical 
order)







Comments based on Bergey's manual and 
published literature
Bacteroides genus BV Bacteroidetes/Bacteroidia 
(Bacteroidales)
no
Bacteroides stercoris BV Bacteroidetes/Bacteroidia 
(Bacteroidales)
yes
Bacteroides uniformis BV Bacteroidetes/Bacteroidia 
(Bacteroidales)
yes
Bacteroides vulgatus BV Bacteroidetes/Bacteroidia 
(Bacteroidales)
no
Bergeyella genus Other Bacteroidetes/Bacteroidia 
(Flavobacteriales)
yes Aeorbic. Rarely animal bites can become 
infected with these organisms
Bifidobacterium bifidum Other Actinobacteria/Actinobacteria 
(Bifidobacteriales)
no
Bifidobacterium breve Other Actinobacteria/Actinobacteria 
(Bifidobacteriales)
no
Bifidobacterium dentium Other Actinobacteria/Actinobacteria 
(Bifidobacteriales)
no
Bifidobacterium genus Other Actinobacteria/Actinobacteria 
(Bifidobacteriales)
no
Bifidobacterium longum Other Actinobacteria/Actinobacteria 
(Bifidobacteriales)
no
Bilophila wadsworthia BV Proteobacteria/Deltaproteobact
eria (Desulfovibrionales)
yes Anaerobic, isolated from gastrointestinal, 
genital, and oral cavities of humans
Blautia faecis BV Firmicutes/Clostridia 
(Clostridiales)
yes
Blautia genus BV Firmicutes/Clostridia 
(Clostridiales)
yes
Blautia massiliensis BV Firmicutes/Clostridia 
(Clostridiales)
yes








Bulleidia extructa BV Firmicutes/Erysipelotrichia 
(Erysipelotrichales)
yes
Bulleidia genus BV Firmicutes/Erysipelotrichia 
(Erysipelotrichales)






no Not all betaproteobacteria are pathobionts
BVAB TM7-H1 BV Unclassified (TM7 division) yes First identified in BV patients.
BVAB1 BV Firmicutes/Clostridia 
(Clostridiales)
no
BVAB2 BV Firmicutes/Clostridia 
(Clostridiales)
no Known to be important in BV.
Campylobacter genus Pathobionts Epsilonbacteraeota/Campylobac
teria (Campylobacterales)
no
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Most genera of this order have been described 
in molecular studies of BV.




Strict anaerobe, closely related to Atopobium 
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order)





































Aerobe, occasionally faculative anaerobe. 







Aerobe, skin commensal. Normally 



















































Strict anaerobe, only recently described in 













Facultative anaerobe closely related to 













no Known to be important in BV.
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Strict anaerobes. In same order as 
Leptotrichia and Sneathia, which have 















Strict anaerobe related to Anaerococcus and 










Gemella asaccharolytica BV Firmicutes/Bacilli (Bacillales) no
Gemella genus BV Firmicutes/Bacilli (Bacillales) no Often described in molecular studies of BV.





Facultative anaerobe closely related to 






Facultative anaerobe closely related to 
Abiotrophia, which has been described in the 













Strict anaerobe of Peptostreptococcaceae 
family, which have often been described in 
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Facultative anaerobe closely related to 





















yes Aerobes, often present on the skin.
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Oxygen-producting environmental bacteria 
















































Known pathogen, but included in the 






Known pathogen, but included in the 
pathobiont group due to small numbers of 
pathogens identified.
Nosocomiicoccus genus Other Firmicutes/Bacilli (Bacillales) yes
Aerobe of the Staphylococcaceae family, not 
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Includes genera Anaerococcus, Finegoldia, 
Fusobacter, Parvimonas, Peptoniphilus, and 
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order)







Comments based on Bergey's manual and 
published literature
Prevotella_6 corporis BV Bacteroidetes/Bacteroidia 
(Bacteroidales)
no
Prevotella_6 salivae BV Bacteroidetes/Bacteroidia 
(Bacteroidales)
yes
Prevotella_7 bergensis BV Bacteroidetes/Bacteroidia 
(Bacteroidales)
no
Prevotella_7 genus BV Bacteroidetes/Bacteroidia 
(Bacteroidales)
no
Prevotella_7 histicola BV Bacteroidetes/Bacteroidia 
(Bacteroidales)
yes
Prevotella_7 melaninogenica BV Bacteroidetes/Bacteroidia 
(Bacteroidales)
no
Prevotella_8 denticola BV Bacteroidetes/Bacteroidia 
(Bacteroidales)
yes
Prevotella_8 genus BV Bacteroidetes/Bacteroidia 
(Bacteroidales)
no







no Anaerobe, described in urinary tract 
infection.
Proteobacteria phylum Other Proteobacteria/NA (NA) no Not all proteobacteria in the vagina are 
pathobionts.
Pseudoclavibacter genus Other Actinobacteria/Actinobacteria 
(Micrococcales)
yes Aerobe mostly isolated from environment








Pseudoglutamicibacter genus Other Actinobacteria/Actinobacteria 
(Micrococcales)
yes Aerobe isolated from human blood and urine







yes Has been described in BV
Pyramidobacter genus BV Synergistetes/Synergistia 
(Synergistales)
yes Strict anaerobe, described in gut/faeces and 
periodontitis.
Raoultella genus Pathobionts Proteobacteria/Gammaproteob
acteria (Enterobacteriales)
yes Known pathobiont.







no Strict anaerobe, described as a common 
resident of animal and human guts.
Romboutsia genus BV Firmicutes/Clostridia 
(Clostridiales)
yes Strict anaerobe, described as a resident of the 
human gut.
Rothia dentocariosa BV Actinobacteria/Actinobacteria 
(Micrococcales)
yes Aerobe, described in periodontitis (and 
systemic infections in immunocompromised).
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Oxygen-producting environmental bacteria 
















































Strict anaerobes, associated with 
periodontitis.
Staphylococcus aureus Pathobionts Firmicutes/Bacilli (Bacillales) yes
Staphylococcus genus Pathobionts Firmicutes/Bacilli (Bacillales) no
Known pathobionts; cause a wide variety of 
diseases in animals and humans. Not all are 
equally pathogenic but none are completely 
harmless.
Staphylococcus haemolyticus Pathobionts Firmicutes/Bacilli (Bacillales) no

















Known pathobionts; cause a wide variety of 
diseases in animals and humans. Some 
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Table detailing all 276 ASVs that were identified through sequencing. Each ASV was 
allocated a classification which describes the assigned bacterial group, as descried in 
section 4.3.2.2. Classification was based on Bergey’s manual224 and available published 
literature. 
List of taxa (alphabetical 
order)



























Closely related to Campylobacter but not 




















































no Often described in molecular studies of BV.
